ISOXAZOLINE DERIVATIVES AS PESTICIDES.

Abstract

The present invention provides compounds of Formula (I): (I) that are useful for the long-lasting treatment and control of pests, for example, fleas and ticks, in pets and livestock, and pharmaceutical compositions and methods for using them.

Description

ISOXAZOLINE DERIVATIVES AS PESTICIDES CROSS REFERENCE TO RELATED REQUESTS The present application claims priority to U.S. Provisional Application No. 62 / 950,018, filed December 18, 2019, the contents of which are incorporated herein by reference in their entirety. FIELD OF THE INVENTION The present invention relates to medicinal chemistry, pharmacology and veterinary and human medicine. BACKGROUND OF THE INVENTION Aryl isoxazolines are used in the fields of agriculture, forestry, turf, household, wood products, seed crop protection, and veterinary medicine. The veterinary field includes pets and livestock, even fish. For example, such inhibitors are disclosed in WO 2005 / 085216, WO 2007 / 079162, US 2007 / 066617, US20130131017, WO 2009 / 002809, WO 2009 / 112275, WO 2010 / 003923, WO 2010 / 070 068, WO 2012 / 120399 and WO 2013 / 079407. In many applications, a long-lasting effect against pests is desirable. Long-lasting protection is particularly important in pets, such as dogs, cats and also mice, guinea pigs, ferrets and rabbits; and in farm animals, such as cows, sheep, pigs and fish, particularly salmon and sea bass. BRIEF DESCRIPTION OF THE INVENTION The present invention relates to a compound of Formula (I) having an extended half-life in pets and livestock, particularly warm-blooded animals, especially dogs, cats and cows, and to its use in the control of ectoparasites. In many cases, the compound of Formula (I) provides long-lasting action for months after a single oral administration or injection. The present invention also provides compounds of Formula (I) that effectively treat and / or control ectoparasites in pets and livestock. In one embodiment, the present invention provides a compound of Formula (I): where Ai is selected from the group consisting of CF3, CHF2, CH2F and CF2CF3; A2 is O or S; R1 is selected from the group consisting of hydrogen and halogen; R2 is selected from the group consisting of hydrogen, halogen, difluoromethyl and trifluoromethyl; R3 is selected from the group consisting of hydrogen, halogen and trifluoromethyl; R4 is selected from the group consisting of hydrogen, halogen, difluoromethyl and trifluoromethyl; Rs is selected from the group consisting of hydrogen and halogen; as long as: R1 can be hydrogen only when R2 is trifluoromethyl, difluoromethyl or bromine; Rs can be hydrogen only when R4 is trifluoromethyl or bromine; R3 can be hydrogen only when one of R2 or R4 is trifluoromethyl, difluoromethyl or bromo; R1, R3, and Rs cannot all be hydrogen when R2 and R4 are trifluoromethyl; and at most three of R1, R2, R3, R4, and Rs are hydrogen; Q is selected from the group consisting of where p is 0, 1 or 2; q is 0, 1,2 or 3; r is 0 or 1; s is 0, 1 or 2; t is 0 or 1; Re, in each case, is selected independently from the group consisting of halogen; cyan; nitro; hydroxyl; -NH2; -NH(Ci-C4 alkyl); -N(Ci-C4alkyl)2; C2-C5-alkoxycarbonyl; Ci-Ce-alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH (Ci-C4alkyl), -N(Ci-C4alkyl)2, -SCi-C4alkyl, -S(O)Ci-C4alkyl and -SO2C1-C4alkyl; Ci-Ce-alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-C6 cycloalkyl, Ci-C4alkoxy, -NH2, C1-C7 aminocarbonyl, -NH( Ci-C4alkyl), -N(Ci-C4alkyl)2, -SCi-C4alkyl, -S(O)CiC4alkyl and -SO2Ci-C4alkyl; -NRsC(O)(Ci-C4alkyl) optionally substituted on the Ci-C4alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, Cs-Ce cycloalkyl, Ci-C4alkoxy, -NH2, C1- C7 aminocarbonyl, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)2, where Re is independently selected from the group consisting of hydrogen and C1-C4 alkyl; -C(O)NR8(Ci-C4alkyl) optionally substituted on the Ci-C4alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, Ca-Ce cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)2, where Re is independently selected from the group consisting of hydrogen and Ci-C4alkyl; -SCi-Ce alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, Ca-Ce cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH (Ci-C4alkyl) and -N(Ci-C4alkyl)2; and -S(O)Ci-Cs alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, Ca-Ce cycloalkyl, Ci-C4alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl) and N(Ci-C4alkyl)2; R7, in each case, is independently selected from the group consisting of oxo, Ci-C4alkyl and Ca-Ce cycloalkyl; A3 is O or S; A4esCHoN; A5 is CH or N; Ae is CH or N; A7 is CH O, S, a bond or N; As is CH O, S, a bond or N; Ag is CH or N; A10 is CH or N; An is CH or N; A12 is CH or N; A13 is CH or N; Au is CH or N; A15 is CH or N; Ais is NR, O or S, where R is selected from the group consisting of hydrogen, C1-C4 alkyl and C3-C6 cycloalkyl; W1 is selected from the group consisting of -O-, -S-, -NR9-, -NC(O)Rw-, -CH2- and -C(O)-; W2 is selected from the group consisting of -O-, -S-, -NRg-, -NC(O)Rw-, -CH2- and -C(O)-; as long as: when W1 is -O-, -S-, -NR9- or -NC(0)Rio-, W2 is -CH2- or -C(O)-; and when W2 is -O-, -S-, -NR9- or -NC(0)Rio-, W1 is -CH2- or -C(O)-; W3 is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)2-, -NRg-, -CH-, -N-, -CH2, and -C(O )-; W4 is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)2-, -NRg-, -CH-, -N-, -CH2, and -0(0 )-; W5 is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)2-, -NRg-, -CH-, -N-, -CH2and -C( EITHER)-; We is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)2-, -NRg-, -CH-, -N-, -CH2, and -C( EITHER)-; where the links between W1, W2, W3 and W4 can be single or double links; as long as: (i) no more than two of W1, W2, W3 and W4 are void; (ii) no more than two of W1, W2, W3 and W4 are -O-, -S-, -S(O)-, -S(O)2-, -NRg- or -0(0)-; (iii) if two of W1, W2, W3 and W4 are -O- and / or -S-, at least one carbon atom is present between them; and (iv) when W1, W2, W3 or W4 is -CH- and / or -NRg-, a double bond is formed within the ring formed by W1, W2, W3 and W4; Rg, in each case, is independently selected from the group consisting of hydrogen and CiCe-alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-Ce cycloalkyl, C1 -C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SCi-C4alkyl, -S(O)Ci-C4alkyl and -SO2C1-C4 alkyl; R10, in each case, is independently selected from the group consisting of oxo, C1-C4 alkyl and Cs-Ce cycloalkyl; X is heteroaril of 5 to 10 members who has 1 or 2 selected heteroatomes of the O, Sy N group, where the heteroly carbons of 5 to 10 members are optionally replaced with 1, 2 or 3 selected substituents regardless of the group that consists in halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, - NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, - C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, Cs-Ce cycloalkyl, Ci-C4haloalkyl, Ci-C4alkoxy, -NH2, NH(Ci-C4alkyl), -N(Ci -C4alkyl), -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, where any N in the heteroaryl , if valency permits, is optionally substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, Ci-C4alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4alkyl, SO2Ci-C4alkyl, -C (O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, and Cs-Cs cycloalkyl; either X is selected from the group consisting of Rn O N w J-l, W • · and N where R11 is selected from the group consisting of hydrogen, C1-C4 alkyl, Ci-C4haloalkyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C2-C7 alkylcarbonyl, C2-C5 alkoxycarbonyl, C2-C6 alkenyl and C2-C6 alkynyl; W is selected from the group consisting of (i) hydrogen; (i) C1-C6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen; cyan; hydroxyl; oxo; C1-C4 alkoxy; C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group of halogen and cyano; acetylenyl; -NH2; C1-C7 aminocarbonyl; -NH(Ci-C4alkyl); -N(Ci-C4alkyl)2; -SC1-C4 alkyl; -S(O)Ci-C4alkyl; -SO2C1-C4 alkyl; -C(O)NH-C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano and Ci-C4alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, Ci-C4alkoxy, C3Ce cycloalkyl and -NH2; -C(O)NH-Ci-Ce alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, Ci-C4alkoxy, C3Ce cycloalkyl and -NH2; -C(O)NH-Ci-C6 cyanoalkyl optionally substituted with 1 to 3 halogens; C(O)NH-Ci-C6 haloalkyl; -C(O)-4- to 7-membered heterocycloalkyl linked by one nitrogen and optionally having 1 or 2 further heteroatoms selected from the group of O, S and N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with from 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, οχο, -NH2, C1-C7 aminocarbonyl, C1-C4 alkyl optionally substituted with from 1 to 5 substituents independently selected from the group consisting of halogen , cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O) Ci-C4alkyl, SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, and C3-C6 cycloalkyl, wherein any other N in the heterocycloalkyl from 4 to 7-membered, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1C4 alkyl, -SO2C1-C4 haloalkyl and C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1C4 alkoxy, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SCi-C4alkyl, -S(O)Ci -C4 alkyl, -SO2C1-C4 alkyl, C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl; 5 to 10 membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the carbons of the 5 to 10 membered heteroaryl are optionally substituted with 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH (Ci-C4 alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(Ci -C4 alkyl), -N(Ci-C4 alkyl)2, and -C(O)NH-C3-C6 cycloalkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consists of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl , -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3 -C6 cycloalkyl and -C(O)NHCi-Ce alkyl, and C3-C6 cycloalkyl, wherein any S in the heteroaryl is optionally substituted with 1 or 2 oxygen atoms; phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, Ci-C4alkyl, cyano and hydroxyl; C3-C6 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, C1-C4 alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C1-C4 haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl , -SO2Ci-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl, -C(O)NH-Ci-C6 haloalkyl, C2-C6 alkenyl and C2- C6 alkynyl;and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S, B and N, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the 4- to 7-membered heterocycloalkyl 7 members optionally benzofused are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo and C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen , cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, C3-C6 cycloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, wherein any B in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with hydroxyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -C (O)-NH2, Ci-C4alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1-C4 alkoxy, -NH(Ci-C4alkyl), -N(Ci- C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NHCi-Ce haloalkyl, C3- Ce cycloalkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; (iii) C3-C6 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, Ci-C4alkyl optionally substituted with 1 to 3 groups selected from the group consists of halogen and cyano, Ci-C4haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SCi-C4alkyl, S(O)Ci-C4alkyl, -SO2C1 -C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl, -C(O)NH-Ci-C6 haloalkyl, C2-C6 alkenyl optionally substituted with 1 to 3 halogens and C2-C6 alkynyl; (iv) 6-membered aryl or 5- to 10-membered heteroaryl having 1, 2 or 3 heteroatoms selected from the group of O, S and N, wherein the carbons of the 6-membered aryl and the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, Ci-C4alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, Ci-C4alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl , -C(O)NH-C3-Cs cycloalkyl and C(O)NH-Ci-C6 alkyl, C3-Ce cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(Ci-C4 alkyl) , -N(CiC4alkyl¡10)2 and -C(O)NH-C3-C6 cycloalkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen and C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl) , -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O) NH-Ci-C6 alkyl; (v) 4 to 7 membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4 to 7 membered heterocycloalkyl or the 4 to 7 membered heterocycloalkyl 7 optionally benzofused members are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C1-C4 alkoxy, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently of the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, Cs-Ce cycloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2 , -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-Ce cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C( O)NH-Ci-C6 haloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen , -NH2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -C(O)-NH2, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, Cs-Ce cycloalkyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci- C4 alkyl, -SO2C1-C4 alkyl, -SO2NH(Ci-C4 alkyl), -SO2N(Ci-C4 alkyl)2, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 haloalkyl, Cs-Ce cycloalkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4-heterocycloalkyl 7-membered or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; and (vi) -NR12R13 where R12 is selected from the group consisting of hydrogen, Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C1-C7 alkylcarbonyl, C1-C7 aminocarbonyl and C2-C5 alkoxycarbonyl; R13 is selected from the group consisting of hydrogen, Ci-Ce alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-Ce cycloalkyl, C1-C4 alkoxy, - NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl and -SO2C1-C4 alkyl, Cs-Ce cycloalkyl, -C(O)-Ci-Ce alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, Cs-Ce cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl and -SO2C1-C4 alkyl, heterocycloalkyl from 4 to 7 members having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen , cyano, nitro, hydroxyl, oxo, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl , -NH(CiC4alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, and C3-C6 cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the 4- to 7-membered heterocycloalkyl optionally benzofused, if valence permits, is substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1 -C4 alkoxy, -NH2, Ci-C? aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1C4alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, C3-C6 cycloalkyl, 5-6 membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; and 5 to 10 membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the carbons of the 5 to 10 membered heteroaryl are optionally substituted with 1, 2 or 3 substituents selected independently of the group consisting in halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, - NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and C(O)NH-Ci-C6 alkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, Ci-C4alkoxy, -NH2, -NH(Ci-C4 alkyl), -N(CiC4alkyl)2, -C(O) NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, wherein any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, Ci-C4alkoxy, NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci- C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl , and C3-C6 cycloalkyl; either R11 and W are taken together with the nitrogen to which they are attached to form a 4 to 7 membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S and O, wherein the ring carbons are optionally substituted with 1 to 4 substituents independently selected from cyano, hydroxyl, oxo, halogen, C1-C2 alkoxy, N,N-di-Ci-C4alkylaminocarboxyl, N-Ci-C4-alkylaminocarboxyl, C1-C7 aminocarboxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N( Ci-C4alkyl)2 and -C(O)NH-C3-C6 cycloalkyl, Cs-Cs cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, cyano, hydroxyl and C1-C4 alkoxy, C(O )NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl, -C(O)NH-Ci-Cs haloalkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 independently selected substituents of the group consisting of halogen, C1-C4 alkyl, cyano, hydroxyl, C1-C2 alkoxy, N,N-di-Ci-C4alkylaminocarboxyl, N-Ci-C4-alkylaminocarboxyl and C1-C7 aminocarboxyl, wherein any N in the 4 to 7 membered ring is substituted with one substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C3-Ce cycloalkyl , C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl^ and -C(O)NH-C3-C6 cycloalkyl, Cs-Ce cycloalkyl optionally substituted with de 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-CiCe alkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4 to 7 membered ring is optionally substituted with 1 or 2 oxygen atoms ; and Y is Ci-Ce alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, Cs-Ce cycloalkyl, Ci-C4alkoxy, acetylenyl, -NH2, C1-C7 aminocarbonyl, -NH (Ci-C4alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, S(O)Ci-C4alkyl, -SO2C1-C4alkyl, -SO2NH(Ci-C4alkyl), -SO2N(Ci-C4alkyl) 2, -SO2NH(Ci-C4haloalkyl), -C(O)NH-C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano and C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy and -NH2, -C(O)NH-Ci-C6 alkyl, -C(O)NH-Ci-C6 cyanoalkyl optionally substituted with 1 to 3 halogens, -C(O)NH-Ci-C6 haloalkyl, optionally substituted phenyl with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 optionally substituted alkyl with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, Cs-Ce cycloalkyl, Ci-C4haloalkyl, Ci-C4alkoxy, -NH2, -NH(Ci-C4alkyl), -N(Ci-C4alkyl) 2 and -C(O)NHCs-Ce cycloalkyl, and Cs-Ce cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, Ci-C4alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SCi-C4alkyl, -S(O)Ci-C4alkyl, -SO2Ci-C4alkyl, -C(O)NH-C3-Ce cycloalkyl, -C(O)NH-Ci-C6 alkyl, C2-C6 alkenyl and C2-Ce alkynyl, 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N, where the carbons of the heteroaryl 5 to 10 members are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen , cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O) Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-Ce cycloalkyl and -C(O)NH-Ci-C6 alkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl , wherein any N in the heteroaryl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano , hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O) Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl and Cs-Ce cycloalkyl, and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(CiC4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, - C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, and Cs-Cs cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the 4- to 7-membered heterocycloalkyl optionally benzofused, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1- C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(CiC4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl,C3-C6 cycloalkyl and 5- to 6-membered heteroaryl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms;, or one of these salt. In one embodiment, the present invention also provides compositions, comprising: a compound of Formula (I) or a salt thereof and at least one acceptable excipient, wherein the composition optionally further comprises at least one additional active compound. In one embodiment, the present invention also provides a method of treating pests, comprising: administering to a subject in need thereof an effective amount of a compound of Formula (I) or a salt thereof, wherein the method comprises further optionally an effective amount of at least one additional active compound. In one embodiment, the present invention also provides a method of controlling pests, comprising: administering to a subject in need thereof an effective amount of a compound of Formula (I) or a salt thereof, wherein the method comprises further optionally an effective amount of at least one additional active compound. In one embodiment, the present invention also provides a method of treating or controlling pests, comprising: bringing a subject's environment into contact with an effective amount of a compound of Formula (I) or a salt thereof, in wherein the method optionally further comprises an effective amount of at least one additional active compound. Therefore, the invention provides the use of the compounds of the invention as a medicament, including for the manufacture of a medicament. In one embodiment, the invention provides for the preparation of a medicament comprising a compound of Formula (I) or a salt thereof for treating parasites. In one embodiment, the invention provides for the manufacture of a medicament comprising a compound of Formula (I) or a salt thereof for controlling pests. The present invention also provides processes for making compounds of the invention and intermediates thereof. DETAILED DESCRIPTION OF THE INVENTION The term C1-C2 alkyl refers to an alkyl chain having one to two carbon atoms and includes methyl and ethyl. The term "C1-C4 alkyl" refers to a straight or branched alkyl chain having one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl and the like. Likewise, the term Ci-Ce alkyl refers to a straight or branched alkyl chain having one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl and the like. The terms C1-C4 haloalkyl and C1-C4 halogenoalkyl refer to a straight or branched alkyl chain having one to four carbon atoms and 1 to 5 halogens and include fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2- trifluoroethyl, 1,2,2-trifluoroethyl, 3,3,3-trifluoropropyl and the like. The terms Ci-Ce haloalkyl and Ci-Ce halogenoalkyl refer to a linear or branched alkyl chain having one to six carbon atoms and 1 to 5 halogens and include fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2- trifluoroethyl, 1,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4trifluorobutyl and the like. The term C2-C6 alkenyl refers to a straight or branched alkenyl chain having two to four carbon atoms and a carbon-carbon double bond and includes ethylene, propylene, isopropylene, butylene, iso-butylene, sec-butylene and Similar. The term "C2-C6 alkynyl" refers to a linear or branched alkynyl chain having two to four carbon atoms and a carbon-carbon triple bond and includes acetylene, propargyl and the like. The term C1-C2 alkoxy refers to a C1-C2 alkyl linked through an oxygen atom and includes methoxy and ethoxy. The term "C1-C4 alkoxy" refers to a C1-C4 alkyl linked through an oxygen atom and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term Ci-Ce alkoxy refers to a Ci-Ce alkyl linked through an oxygen atom and includes methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like. The term C3-C6 cycloalkyl refers to alkyl rings of three to six carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. It is understood that the cycloalkyl rings may be fused, bridged or spirofused. The term C4-C7 alkylcycloalkyl refers to a C1-C4 alkyl substituted with a Ca-Ce cycloalkyl so that the total number of carbons is four to seven and includes cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl and the like. The terms halo and halogen refer to chlorine, fluoro, bromine, or iodine atoms. The expressions 4 to 7 membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S, N, wherein the heterocycloalkyl is optionally benzofused and 4 to 7 membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S, B, N, where heterocycloalkyl is optionally benzofused refer to a saturated or partially (but not completely) unsaturated 4 to 7 membered ring having one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur or having one or two heteroatoms selected from the group consisting of nitrogen, oxygen, boron and sulfur and the ring optionally includes a carbonyl to form a lactam or lactone. It is understood that, when sulfur is included, the sulfur may be -S-, -SO- or -SO2-. The heterocyclic ring may be monocyclic or bicyclic and any bicyclic rings may be fused, bridged or spirofused. The 4 to 7 defined members are unique to any optional benzofused ring. Furthermore, as the person of average skill will fully appreciate, saturated or partially (but not completely) unsaturated 4- to 7-membered heterocycloalkyl ring applies to heterocycloalkyl ring and does not apply to any benzofused ring, which by its nature will be completely unsaturated. It is further understood that the group may be attached as a substituent through any of the ring heteroatoms, valence permitting, the heterocycloalkyl carbon atoms, or the carbon atoms of any benzofused ring. It is also understood that, when an optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted on carbon, the substituents may be on the carbon atoms of the heterocycle and / or the benzofused ring. For example, among others, the term includes azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl, thioxetanyl, dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuryl, hexahydropyrimidinyl, tetrahydropyrimidinyl, 2,6-diazaspiro[3.3]heptanyl , isoxazolidine, dihydroimidazolyl, indolyl, isoindolyl and the like. The term 5- or 6-membered heteroaryl refers to a six-membered monocyclic completely unsaturated ring with one to five carbon atoms and one or more, usually one to four, heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For example, among others, the term includes pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl and the like. It is understood that a 6-membered heteroaryl may be attached as a substituent through a ring carbon or a ring nitrogen atom where such a mode of attachment is available. When Rn and W are taken together with the nitrogen to which they are attached, the term 4 to 7 membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S and O refers to a fully saturated ring or partially (but not completely) unsaturated having four to seven members including the nitrogen to which Rn and W are attached, and includes azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxetanyl, dioxolanyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuryl, hexahydropyrimidinyl, tetrahydropyrimidinyl, dihydroimidazolyl and the like. The term "5 to 10 membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N" refers to a five to ten membered monocyclic or polycyclic completely unsaturated ring or ring system with one to nine carbon atoms. and one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. For example, among others, the term includes furyl, thienyl, pyrrolyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, thiazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, azepinyl, diazepinyl, benzofuryl, benzothienyl, indolyl, isoindolyl, benzimidazolyl , benzisothiazolyl, benzisoxazolyl, benzoxazolyl, benzopyrazinyl, benzopyrazolyl, quinazolyl, thienopyridyl, quinolyl, isoquinolyl benzothiazolyl and the like. It is understood that a 5 to 10 membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N may be attached as a substituent through a ring carbon or a ring nitrogen atom where such mode of attachment is available. The term oxo refers to an oxygen atom connected by a double bond to the carbon to which it is attached to form the carbonyl of an amide, ketone or aldehyde. For example, a pyridone radical is contemplated as an oxo-substituted 6-membered heteroaryl. The term carboxyl refers to the following group: The term N,N-di-Ci-C4-alkylaminocarboxyl refers to the group immediately below: O ^xnh2zcnocn / zznz / q / υιλι wherein the hydrogens on the nitrogen are substituted with two independently selected C1-C4 alkyl groups. Likewise, the expression N-Ci-Cvalkylaminocarboxyl refers to the group listed immediately below: Or ^xnh2en where one of the hydrogens on the nitrogen is substituted with a C1-C4 alkyl group. The term C2-C5 alkoxycarbonyl refers to the following group: O cr where R is a C1-C4 alkyl. The term C2-C7 alkylcarbonyl refers to the following group: EITHER TO. where R is a Ci-Ce alkyl. Likewise, the term C2-C7 haloalkylcarbonyl refers to the immediately preceding group, where R is a Ci-Ce haloalkyl. The expression C1-C7 aminocarbonyl refers to the following group: where R is a hydrogen or a C1-C4 alkyl. The term null, as used herein in reference to a group, substituent, moiety or the like, indicates that that group, substituent or moiety is not present. Wherein one group, substituent or portion is usually attached to two or more other groups, substituents or portions, wherein the others are attached to each other in place of the group, substituent or portion which is null. For example, with a compound that has the A-B-C structure; where B is null, A is linked directly to C and the compound is A-C. As another example, with a compound that has the A-B-C structure; where C is null, the compound is A-B. The terms salt and salts refer to salts of inorganic acids and bases or veterinary or pharmaceutically acceptable organic acids and bases. Such salts are known in the art and include those described in Journal of Pharmaceutical Science, 66, 2-19 (1977). An example is hydrochloride salt. The term substituted, even when used in optionally substituted, refers to the replacement of one or more hydrogen radicals of a group with non-hydrogen radicals (substituents). It is understood that the substituents can be the same or different in each substituted position. The combinations of groups and substituents contemplated by this invention are those that are stable or chemically feasible. In the case of the compounds described herein, the groups and substituents thereof can be selected according to the allowed valency of the atoms and substituents, so that the selections and substituents result in a stable compound, for example, which it does not transform spontaneously, such as by rearrangement, cyclization, elimination, etc. The term stable refers to compounds that do not substantially alter when subjected to conditions that allow their production. In a non-limiting example, a stable compound or chemically feasible compound is one that is not substantially altered when maintained at a temperature of 40°C or less, in the absence of humidity or other chemically reactive conditions, for about a week. It is understood that, when the terms defined herein mention a number of carbon atoms, the quantity mentioned refers to the group mentioned and does not include any carbon that may be present on any optional substituent found in the group or any carbon that may be present as part of a fused ring, including a benzofused ring. The average skilled person will appreciate that some of the compounds of the present invention exist as isomers. It is contemplated that all stereoisomers of the compounds of the invention, including enantiomers, diastereomers and geometric isomers, in any ratio, are within the scope of the present invention. As used herein, the term (RS) within chemical nomenclature refers to a racemic mixture at the indicated stereocenter. As used herein, the expression (R or S) or (S or R), within chemical nomenclature, refers to one of two possible configurations at the indicated stereocenter. The mid-level skilled person will also appreciate that some of the compounds of the present invention exist as tautomers. It is contemplated that all tautomeric forms of the compounds of the invention are within the scope of the present invention. Compounds of the invention also include all isotopic variations in which at least one atom of the predominant atomic mass is replaced by an atom having the same atomic number, but an atomic mass different from the predominant atomic mass. The use of isotopic variations (e.g., deuterium,2H) may provide greater metabolic stability. Additionally, certain isotopic variations of the compounds of the invention may incorporate a radioactive isotope (e.g., tritium,3H or14C), which may be useful in tissue distribution studies of drugs and / or substrates. Substitution with positron-emitting isotopes, such as 11C, 18F, 15O, and 13N, may be useful in positron emission topography (PET) studies. The terms compounds of the invention, a compound of the invention and compounds of the present invention and the like include the embodiment of Formula (I) and the other more particular embodiments encompassed by Formula (I) described herein and the exemplified compounds described herein and a salt of each of these embodiments. The compound of Formula (I) having various embodiments, as shown below: Formula (I): 7cnQcn / 77n7 / q / υιλι It is understood that, for A4, As, As, A?, Ag, A10, An, A12 A14, and / or A15, a substituent Re, when present, takes the place of the hydrogen of CH. It is further understood that, for the compound of Formula (Ig), the group of an NR- group. Additional embodiments of the compounds of the invention are provided below: (1) One embodiment relates to a compound of Formula (I) or a salt thereof. (a) One embodiment relates to the compounds of Formula (la) or a salt thereof. (b) One embodiment relates to the compounds of Formula (Ib) or a salt thereof. (c) One embodiment relates to the compounds of Formula (le) or a salt thereof. (d) One embodiment relates to the compounds of Formula (Id) or a salt thereof. (e) One embodiment relates to the compounds of Formula (le) or a salt thereof. (f) One embodiment relates to the compounds of Formula (If) or a salt thereof. (g) One embodiment relates to the compounds of Formula (Ig) or a salt thereof. (h) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f) and (g), where R1 is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is trifluoromethyl and Rs is halogen; or one of these salt. (i) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f) and (g), where R1 is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is halogen and Rs is halogen; or one of these salt. (j) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f) and (g), where R1 is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is chlorine and Rs is halogen; or one of these salt. (k) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f) and (g), where R1 is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is halogen and Rs is chlorine; or one of these salt. (I) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f) and (g), where Ri is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is halogen and Rs is fluoro; or one of these salt. (m) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f) and (g), where R1 is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is chloro and Rs is fluoro; or one of these salt. (n) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (I) and (m), where A2 is O; or one of these salt. (o) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (I), (m) and (n), where Ai is CF3; or one of these salt. (p) An embodiment refers to embodiments (1), (a), (b), (c), (d), (e), (f), (g), (h), (()), (j), (k), (I), (m) and (n), where Ai is CHF2; or one of these salt. (q) An embodiment refers to embodiments (1), (a), (h), (i), (j), (k), (I), (m), (n), (o) and (p), where A3 is S; or one of these salt. (r) One embodiment refers to embodiment (q), where p is 1 and Rs is Ci-Ce alkyl; or a salt of this. (s) An embodiment refers to embodiment (r), where Re is methyl; or a salt of this. (t) An embodiment refers to embodiments (1), (b), (h), (i), (j), (k), (I), (m), (n), (o) and (p), where A4, As and As are CH; or one of these salt. (u) An embodiment refers to embodiment (t), where p is 1 and Re is Ci-Ce alkyl; or a salt of this. (v) An embodiment refers to embodiment (u), where Re is methyl; or a salt of this. (w) An embodiment refers to embodiments (1), (c), (h), (i), (j), (k), (I), (m), (n), (o) and (p), where A?, As, A9, A10, Au and A12 are CH; or one of these salt. (x) An embodiment refers to embodiments (1), (d), (h), (i), (j), (k), (I), (m), (n), (o) and (p), where A13, Ai4 and A15 are CH; or one of these salt. (y) One embodiment refers to embodiment (x), where W1 is -CH2- and W2 is O; or a salt of this. (z) An embodiment refers to embodiments (1), (a), (b), (c), (g), (h), (i), (j), (k), (I), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w) and (x ), where X is EITHER Rn where Rn is hydrogen; or one of these salt. (aa) One embodiment refers to embodiment (z), wherein W is Ci-Ce alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen and cyano, acetylenyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl^, -SC1-C4 alkyl, -S(O)Ci-C4alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, C3-C6 cycloalkyl, and -NH2, -C(O)NH-Ci-C6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, C3-C6 cycloalkyl, and -NH2; -C(O)NH-Ci-C6 cyanoalkyl optionally substituted with 1 to 3 halogens, -C(O)NH-Ci-C6 haloalkyl, -C(O)-4- to 7-membered heterocycloalkyl linked by a nitrogen and optionally having 1 or 2 further heteroatoms selected from the group of O, S, N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, -NH2, C1-C7 aminocarbonyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, Ci-C4alkoxy, -nh2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SCi-C4alkyl, -S(O)Ci-C4alkyl, -SO2Ci-C4alkyl, -C(O)NH-C3-C6 cycloalkyl, and -C(O)NH-Ci-C6 alkyl, and Cs-Ce cycloalkyl; and any other N in the 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -nh2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1-C4 alkoxy, -NH(Ci-C4alkyl), -N(Ci-C4alkyl) 2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6alkyl, -C( O)NH-Ci-C6 haloalkyl; 5 to 10 membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N and wherein the carbons of the 5 to 10 membered heteroaryl are optionally substituted with 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, οχο, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl, and -C(O)NH-Ci-C6 haloalkyl; Cs-Cs cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, and -C(O)NH-C3-C6 cycloalkyl; and any N in the heteroaryl, valency permitting, is optionally substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, - SC1-C4 alkyl, -S(O)Ci-C4 alkyl, - SO2C1-C4 alkyl, - C(O)NH-C3-C6 cycloalkyl, and -C(O)NH-Ci-C6 alkyl; and Cs-Cs cycloalkyl; and any S in the heteroaryl is substituted with 1 or 2 oxygen atoms; phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-C4 alkyl, cyano, or hydroxyl; C3-C6 cycloalkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, C1-C4 alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C1-C4 haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl) 2, -SCi-C4alkyl, -S(O)Ci-C4alkyl, -SO2Ci-C4alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-Ce alkyl, -C(O) NH-Ci-C6 haloalkyl, C2-C6 alkenyl, and C2-C6 alkynyl; and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S, B, N, wherein the heterocycloalkyl is optionally benzofused and wherein the carbons of the 4- to 7-membered heterocycloalkyl or the 4- to 7-membered heterocycloalkyl 7 optionally benzofused members are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, Ca-Ce cycloalkyl, -NH2, C1-C7 aminocarbonyl, -NH( Ci-C4 alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, - C(O)NH-Ci-C6 alkyl, and -C(O)NH-Ci-C6 haloalkyl; and any B in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valence permits, is substituted with hydroxyl, and any N in the 4- to 7-membered heterocycloalkyl or the 4- to 7-membered heterocycloalkyl. 7-membered optionally benzofused, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -C(O)-NH2, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1-C4 alkoxy, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2 , -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, and -C(O)NH-Ci-C6 haloalkyl; C3-C6 cycloalkyl; 5-6 membered heteroaryl; and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, cyano, and hydroxyl; and any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is substituted with 1 or 2 oxygen atoms; or one of these salt. (ab) An embodiment related to embodiment (aa), wherein W is a C1Ce alkyl substituted with a substituent selected from the group consisting of -C(O)NH-Ci-C6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, Ca-Ce cycloalkyl, and -NH2; -C(O)NH-Ci-Ce cyanoalkyl optionally substituted with 1 to 3 halogens, -C(O)NH-Ci-C6 haloalkyl, and -C(O)-4- to 7-membered heterocycloalkyl linked by one nitrogen and optionally having 1 or 2 further heteroatoms selected from the group of O, S, N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with from 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, -NH2, C1-C7 aminocarbonyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl) , -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, and -C(O )NH-Ci-C6 alkyl, and C3-C6 cycloalkyl; and any other N in the 4- to 7-membered heterocycloalkyl, if valence permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, Ci-C4alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1-C4 alkoxy, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SC1 -C4 alkyl, -S(O)Ci-C4alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6alkyl, -C(O)NH-Ci -C6 haloalkyl; or one of these salt. (ac) An embodiment refers to embodiment (ab), where W is or a salt of this. (ad) One embodiment refers to embodiment (z), wherein W is Ci-Ce alkyl substituted with -C(O)NH-C3-Ce cycloalkyl optionally substituted with 1 to 3 substituents selected independently of the group consisting of halogen, hydroxyl, cyano and C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, Ci-C4alkoxy and -NH2; or a salt of this. (ae) One embodiment refers to embodiment (z), where W is Ci-Οθ alkyl substituted with -C(O)NH-Ci-C6 alkyl optionally substituted with 1 to 5 substituents selected independently of the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, C3-C6 cycloalkyl, and -NH2; or a salt of this. (ae1) An embodiment refers to embodiment (ae), where W is or a salt of this. (ae2) An embodiment refers to embodiment (ae), where W is or a salt of this. (af) One embodiment refers to embodiment (z), wherein W is Ο-Οβ alkyl substituted with a 5 to 10 membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S, B and N, and wherein the carbons of the 5 to 10 membered heteroaryl are optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SC1- C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl; Cs-Ce cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2 and -C(O)NH-C3-C6 cycloalkyl; and any B in the heteroaryl is substituted with hydroxyl and any N in the heteroaryl, if valency permits, is optionally substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected regardless of the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, Cs-Cs cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl) 2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl and any S in the heteroaryl is substituted with 1 or 2 oxygen atoms; or a salt of this. (af1) One embodiment refers to embodiment (z), wherein W is Ci-Ce alkyl substituted with a pyridine optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl ), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and C(O)NH -Ci-C6 alkyl; C3-Ce cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(Ci-C4 alkyl), -N(CiC4alkyl)2 and -C(O)NH-C3-C6 cycloalkyl; or a salt of this. (af2) One embodiment refers to embodiment (z), wherein W is Ci-Ce alkyl substituted with a thiazole optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl ), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and C(O)NH- Ci-C6 alkyl; C3-Ce cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(Ci-C4alkyl), -N(CiC4alkyl)2 and -C(O)NH-C3-C6 cycloalkyl; or a salt of this. (ag) One embodiment refers to embodiment (z), wherein W is a 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the heterocycloalkyl is optionally benzofused and wherein the carbons of the 4 to 7 membered heterocycloalkyl or the optionally benzofused 4 to 7 membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, Cs-Ce cycloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6alkyl, and -C(O)NH-Ci-C6 haloalkyl; and and any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, - SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -C(O)-NH2, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1-C4 alkoxy, C3-C6 cycloalkyl, -NH(Ci-C4 alkyl), -N(Ci -C4alkyl)2, -SCi-C4alkyl, -S(O)Ci-C4alkyl, -SO2Ci-C4alkyl, -C(O)NH-C3-C6 cycloalkyl, and -C(O)NH-Ci-C6 haloalkyl; Cs-Ce cycloalkyl; 5-6 membered heteroaryl; and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, Ci-C4alkyl, cyano, and hydroxyl; and any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is substituted with 1 or 2 oxygen atoms; or a salt of this. (agi) One embodiment refers to the embodiment (ag), wherein W is a 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S and N and is selected from the group consists of pyrrolyl, azetidinyl, 2-oxoazetidinyl, isoxazolidinyl, 2,6-diazaspiro[3.3]heptanyl and 1,6-diazaspiro[3.3]heptanyl, where the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, Ci- C4alkoxy, C3-C6 cycloalkyl, -nh2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, - SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-Ce alkyl, and -C(O)NH-Ci-C6 haloalkyl; and any N in the 4- to 7-membered heterocycloalkyl, valence permitting, is substituted with a substituent selected from the group consisting of hydrogen, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -C(O)-NH2, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1-C4 alkoxy, Cs-Ce cycloalkyl, -NH(Ci-C4 alkyl), -N(Ci-C4alkyl)2, - SC1-C4 alkyl, -S(O)Ci-C4 alkyl, - SO2C1-C4 alkyl, - C(O)NH-C3-C6 cycloalkyl, and -C(O)NH-Ci-C6 haloalkyl; and Cs-Cs cycloalkyl; or a salt of this. (ah) One embodiment refers to embodiments (ag) and (agi), wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 2 substituents independently selected from the group consisting of oxo and C1-C4 alkyl and any N in the 4- to 7-membered heterocycloalkyl, if valence permits, is substituted with hydrogen and C1-C4 alkyl optionally substituted with 1 to 3 halogen, cyano, acetylenyl or CsCe cycloalkyl; or one of these salt. (ai) One embodiment refers to embodiments (ag), (agi) and (ah), wherein the carbons of the 4- to 7-membered heterocycloalkyl are substituted with 1 oxo and any N in the 4-membered heterocycloalkyl. 7-membered, if valency permits, is substituted with C1-C4 alkyl substituted with 1 cyano; or one of these salt. (aj) One embodiment refers to embodiments (ag), (agi) and (ah), wherein the carbons of the 4- to 7-membered heterocycloalkyl are substituted with 1 oxo and any N in the 4-membered heterocycloalkyl. 7-membered, valence permitting, substituted with C1-C4 alkyl substituted with 1 to 3 halogens; or one of these salt. (ak) One embodiment refers to embodiments (ag), (agi) and (ah), wherein the carbons of the 4- to 7-membered heterocycloalkyl are substituted with 1 oxo and any N in the 4-membered heterocycloalkyl. 7-membered, valence permitting, is substituted with a C1-C4 alkyl substituted with a C3-C6 cycloalkyl; or one of these salt. (al) One embodiment refers to embodiments (ag), (agí) and (ah), wherein any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with C1- C4 alkyl substituted with 1 cyano; or one of these salt. (am) One embodiment refers to embodiments (ag), (agi) and (ah), wherein any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with C1- C4 alkyl substituted with 1 to 3 halogens; or one of these salt. (an) One embodiment refers to embodiments (ag), (agi) and (ah), wherein any N in the 4- to 7-membered heterocycloalkyl, valency permitting, is substituted with Ci- C4alkyl substituted with 1 C3-C6 cycloalkyl; or one of these salt. (an1) One embodiment refers to embodiment (z), wherein W is an optionally substituted Cs-Ce cycloalkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, Ci-C4alkoxy, C1-C4 alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C1-C4 haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4alkyl), -N(Ci-C4alkyl^, -SCi-C4alkyl, -S(O)Ci-C4alkyl, -SO2Ci-C4alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6alkyl, -C(O)NH-Ci-C6 haloalkyl, C2-C6 alkenyl optionally substituted with 1 to 3 halogens; and Cz-Ce alkynyl; or a salt of this. (ao) An embodiment refers to embodiments (1), (d), (e), (f), (h), (i), (j), (k), (I), (m), (n), (o), (p), (t), (x) and (y), where Y is Ci-Ce alkyl optionally substituted with 1 to 5 substituents selected independently of the group consisting in halogen, cyano, hydroxyl, oxo, Cs-Cs cycloalkyl, C1-C4 alkoxy, acetylenyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1 -C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, cyano, and C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of consists of halogen, cyano, hydroxyl, C1-C4 alkoxy, and -NH2, -C(O)NH-Ci-C6alkyl, -C(O)NH-Ci-C6 cyanoalkyl optionally substituted with 1 to 3 halogens, -C(O)NH-Ci-C6 haloalkyl; or one of these salt. (ap) One embodiment refers to embodiment (aq), wherein Y is Ci-Ce alkyl substituted with 1 -SO2C1-C4 alkyl; or a salt of this. (aq) One embodiment refers to embodiment (aq), wherein Y is Ci-Ce alkyl substituted with 1 -SO2CH3; or a salt of this. (xa) Another embodiment refers to each of the exemplified compounds or a salt thereof. (xb) Another embodiment refers to each stereoisomer of each exemplified, illustrated or named compound; or one of these salt. (xc) Another embodiment relates to a salt of each of the exemplified compounds. The compounds of the invention can be prepared with various procedures, many of which are already described in the art. For example, see WO 2005 / 085216, WO 2007 / 079162, US 2007 / 066617, US20130131017, WO 2009 / 002809, WO 2009 / 112275, WO 2010 / 003923, WO 2010 / 070068, W O 2012 / 120399 and WO 2013 / 079407 . The present disclosure relates to compounds of Formula (I) that have extended half-lives. Compounds of Formula (I) have a trifluoromethyl group in the meta position or a halogen in the para and / or ortho positions. Therefore, compounds of Formula (I) include the following features: a trifluoromethyl group at one or both meta positions; a halogen in the ortho position; a halogen in each of the ortho and para positions; or a halogen in each of the ortho positions and a trifluoromethyl in the para position. It is understood that compounds of Formula (I) may have other substituents, but the groups mentioned above are included. Without being limited to any particular theory, the applicant believes that inhibition of metabolism in both the ortho and para positions provides a longer duration after oral administration or an injection. The following examples are intended to be illustrative only and not limiting and represent specific embodiments of the present invention. 7cnQcn / 77n7 / q / υιλι 7cnQcn / 77n7 / q / υιλι 7cnQcn / 77n7 / q / υιλι 7cnQcn / 77n7 / q / υιλι 7cnQcn / 77n7 / q / υιλι 7cnQcn / 77n7 / q / υιλι In one embodiment, compounds of the Formula (Ha), or a salt thereof, are disclosed. where Ai, Cyi, Cy2and Ti are as defined above. In another embodiment, compounds of Formula (llb), or a salt thereof, are disclosed. where Ai, Cyi, Cy2and Ti are as defined above. In certain embodiments, Ai in Formula (II), (lia) or (llb) is -CF3. In certain embodiments, Cyi in Formula (II), (lia) or (llb) is In certain embodiments, Cys in Formula (II), (lia) or (llb) is In certain embodiments, Ti in Formula (II), (lia) or (llb) is EITHER In certain embodiments, compounds of Formulas (II), (lia) and (llb), or a salt thereof, are disclosed, wherein Ai is -CF3; Cyi is selected from: F F Cyz is You are 7cnQcn / 77n7 / q / υιλι In certain embodiments, compounds of Formulas (II), (lia) and (llb), or a salt thereof, are disclosed, wherein Ai is -CF3; Cy2is selected from: You are EITHER 7cnQcn / 77n7 / q / υιλι zcnacn / zznz / q / υιλι In certain embodiments, compounds of Formulas (II), (lia) and (llb), or a salt thereof, are disclosed, wherein Ai is -CFs; Cyi is 7cnQcn / 77n7 / q / υιλι γψ ci ; Cys is selected from: Ti is / H i? n^^n^cf3s In another aspect, compounds of Formula (III), or a salt thereof, are disclosed. where, Ai is -CF3 or -CHF2; Cys is selected from: F3' Br Cy4 is: T2 is selected from o o o θ ovo H. JJ V ' H o o oXN1y o o o N CF3 h In one embodiment, compounds of Formula (Illa), or a salt thereof, are disclosed. where Ai, Cy3, Cy4 and T2 are as defined above. In another embodiment, compounds of Formula (IIIb), or a salt thereof, are disclosed. T2where Ai, Cy3, Cy4 and T2 are as defined above. In certain embodiments, Ai in Formula (III), (Illa) or (lllb) is -CF3. In certain embodiments, Cy3 in Formula (III), (Illa) or (lllb) is F3C CL In certain embodiments, Ts in Formula (III), (Illa) or (Illb) is In certain embodiments, compounds of Formulas (III), (Illa) and (lllb), or a salt thereof, are disclosed, wherein Ai is -CF3; Cy4 is selected from: T3 is o 0 0 The following examples are intended to be illustrative only and not limiting and represent specific embodiments of the present invention. Analyzes were carried out with an Agilent 1200 Infinity series liquid chromatography (LC) system, consisting of a 1260 HiP degasser (G4225A), 1260 binary pump (G1312B), 1290 autosampler (G4226A), column compartment with 1290 thermostat (G1316C) and a 1260 diode array detector (G4212B), coupled to an Agilent 6150 single quadrupole mass spectrometry (MS) detector. The injection volume was set to 1 pL by default. UV acquisition (DAD) was carried out at 40 Hz, with a scan range of 190-400 nm (with steps of 5 nm). A 1:1 flow split was used before the MS detector. The MS was operated with an electrospray ionization (ESI) source in both positive ion mode and negative ion mode. The nebulizer pressure was set at 345 kPa, and the drying gas temperature and flow rate were set at 350°C and 12.0 L / min, respectively. The capillary voltages used were 4000V in positive mode and 3500V in negative mode. The MS acquisition range was set at 100–800 m / z with a jump size of 0.2 m / z in both polarity modes. The fragmentator voltage was set to 70 (ESI+) or 120 (ESI-), the gain was set to 0.40 (ESI+) or 1.00 (ESI-), and the ion count threshold was set to 4000 (ESI+) or 1000 ( ESI-). The total MS scan cycle time was 0.15 s / cycle. Data acquisition was carried out with Agilent Chemstation software. Method A: Analyzes were carried out on a Phenomenex Gemini-NX C18 column of 50 mm length, 2.1 mm internal diameter and 3 pm particle size. The mobile phase used was the following: A= water with 0.1% formic acid / B= CH3CN with 0.1% formic acid. Method B: Analyzes were carried out on a Waters XBridge C18 column of 50 mm length, 2.1 mm internal diameter and 3.5 pm particle size. The mobile phase used was the following: A=water with 10 mM ammonium bicarbonate, adjusted to pH 9 with ammonium hydroxide / B= CH3CN. Method I: Analyzes were carried out on a Waters XBridge BEH C18 of 50 mm length, 2.1 mm internal diameter and 2.5 pm particle size. The mobile phase used was the following: A= water with 10 mM ammonium acetate / B= CH3CN. Analyzes were carried out with a Waters Acquity LJPLC liquid chromatography (LC) system coupled to a Waters SQ Detector 2 single quadrupole mass spectrometry (MS) detector. UV acquisition (DAD) was carried out with a scanning range of 200-400 nm (with 1.2 nm resolution). The MS was operated with an electrospray ionization (ESI) source in both positive ion mode and negative ion mode. Capillary voltage of 3.50 (kV), cone voltage of 35 (V) and desolvation temperature of 550°C. Desolvation gas flow 1000 (L / h), cone gas flow 50 (L / h). The MS acquisition range was set at 100–1500 m / z. The MS scanning cycle time was 0.5 s. Data acquisition was carried out with Waters Masslynx software. Method C: Analyzes were carried out on an Acquity UPLC BEH C18 column of 50 mm length, 2.1 mm internal diameter and 1.7 pm particle size. The mobile phase used was the following: A= water with 0.1% formic acid / B= CH3CN with 0.1% formic acid. Method D: Analyzes were carried out on an Acquity UPLC BEH C18 column of 50 mm length, 2.1 mm internal diameter and 1.7 pm particle size. The mobile phase used was the following: A= water with 0.1% formic acid / B= CH3CN. Method E: Analyzes were carried out on an Acquity UPLC BEH C18 column of 50 mm length, 2.1 mm internal diameter and 1.7 pm particle size. The mobile phase used was the following: A- water with 10 mM ammonium acetate / B- CH3CN. Method H: Analyzes were carried out on a Luna Omega-PS C18 column of 50 mm length, 2.1 mm internal diameter and 1.6 pm particle size. The mobile phase used was the following: A= water with 10 mM ammonium acetate in water / B= CH3CN. Analyzes were carried out with an ultra-high-performance liquid chromatography (UHPLC) system (brand Thermo Scientific), coupled with an ion trap mace analyzer. UV acquisition was carried out with a scanning range of 200–400 nm (with 1 nm resolution). The MS was operated with an electrospray ionization (ESI) source in both positive ion mode and negative ion mode, with drive gas flow rate (arb): 40, aux gas flow rate (arb ): 20, sweep gas flow rate (arb): 1, spray voltage (kv): 5, capillary temperature (°C): 350, capillary voltage (V): 30, tube lens (V): positive mode 30 and negative mode -30. The MS acquisition range was set at 100–2000 m / z. The MS scan cycle time was 3 microscans. Data acquisition was carried out with Xcal i bu r software. Method F: Analyzes were carried out on an Ascentis Express C18 of 5 cm length, 2.1 mm internal diameter and 2.7 pm particle size. The mobile phase used was the following: A= water with 0.1% formic acid / B= 100% CH3CN. Method G: Analyzes were carried out on an Ascentis Express C18 of 5 cm length, 2.1 mm internal diameter and 2.7 pm particle size. The mobile phase used was the following: A= 10 mM ammonium acetate in water / B= 100% CH3CN. As used herein: ac. refers to aqueous, br refers to broad, CH3CN refers to acetonitrile, d refers to doublet, dd refers to doublet doublet, DCM refers to dichloromethane, DCE refers to dichloroethane, DIPEA refers to N-diisopropylethylamine , DMF refers to N,Ndimethylformamide, DMSO refers to dimethyl sulfoxide, ee: refers to enantiomeric excess, ES refers to electrospray ionization, EtOAc refers to ethyl acetate, h refers to hours, HATU refers to 1 -[bis(dimethylamino)methylene]-1 Λ7-1,2,3-triazolo[4,5-¿>]pyridinium 3-oxide hexafluorophosphate, HPLC refers to high performance liquid chromatography, ProOH refers to isopropanol , J refers to coupling constant, LCMS refers to liquid chromatography - mass spectrometry, m / z: refers to mass to charge ratio, M refers to molarity, m refers to multiplet, MeOH refers to refers to methanol, min refers to minutes, NaHCOs refers to sodium bicarbonate, NazCOs refers to sodium carbonate, NEts refers to triethylamine, NMR refers to nuclear magnetic resonance, q refers to quartet, quint refers to quintet, rt refers to room temperature, Rt refers to retention time, s refers to singlet, sat. refers to saturated, T refers to temperature, t refers to triplet, td refers to triplet of doublets, THF refers to tetrahydrofuran, wt refers to weight and δ refers to chemical shift. Examples 1.1 and 1.2 2-methylsulfonyl-1 -[6-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol3-yl]spiro[1 H-isobenzofuran-3,3'-azetidin]-r-yl]ethanone and 2-methylsulfonyl-1-[6-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H -¡soxazol3-¡l]spiro[1 H-isobenzofuran-3,3'-azetidin]-1'-¡l]ethanone To a pressure vessel containing a solution of tert-butyl 6-bromospiro[1H-isobenzofuran3,3'-azetidine]-1'-carboxylate (8.86 g, 24.7 mmol) and Ν,Ν,Ν',Ν'-tetramethylethyldiamine (2.8 mL, 18 mmol) in toluene (50 mL) palladium (II) acetate (286 mg, 1.21 mmol) and butyldi-1-adamantylphosphine (1.42 g, 3.76 mmol) were added. The vessel was sealed, purged with Nz gas three times, and then purged with CO gas and hydrogen three times to a pressure of 310 kPa. The reaction was warmed to 90°C and stirred overnight. The reaction was allowed to cool to rt and then purged with Nz gas three times. The reaction mixture was filtered through Celite® (while washing with EtOAc). The filtrate was concentrated in vacuo and the crude product was purified by silica gel column chromatography (020% EtOAc in cyclohexane) to obtain tert-butyl 6-formylspiro[1H-isobenzofuran-3,3'-azetidine. ]-1'carboxylate. LC-MS (method A) Rt= 1.10 min, m / z= 234.2 [M-tBu+H]+. To a flask containing a stirred solution of tert-butyl 6-formyl spiro[1 H-isobenzofuran-3,3'azetidine]-1'-carboxylate (6.57 g, 21.6 mmol) in MeOH (110 mL) was added NHzOH solution (50% in water, 3 mL, 49.0 mmol) slowly. The reaction was stirred at rt for 2 h. The reaction was concentrated in vacuo and the resulting solid was left in the vacuum oven to dry overnight to obtain tert-butyl 6-(hydroxyim¡nomethyl)spiro[1 H-isobenzofuran-3,3'- azetidine]-r-carboxylate. LC-MS (method A) Rt= .00 min and 1.02 min, m / z= 303.0 [M-H]· (mixture of E / Z isomers). To a flask containing a stirred solution of tert-butyl 6-(hydroxyaminomethyl)spiro[1 Hisobenzofuran-3,3'-azetidine]-1'-carboxylate (3.05 g, 9.52 mmol) in DMF (10 mL ) Nchlorosuccinimide (1.54 g, 11.3 mmol) was added. The reaction was stirred for 30 min. The reaction was cooled to 0°C and 1-chloro-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene (2.96 g, 8.61 mmol) was added, followed by slow addition of NEts (1.9 mL, 13 mmol). The reaction was allowed to warm to rt and stirred overnight. The reaction was partitioned into EtOAc and brine (50 mL each) and the layers were separated. The aqueous layer was extracted with EtOAc (2x 25 mL) and the combined organic layers were concentrated in vacuo. The crude product was purified by silica gel column chromatography (0-15% EtOAc in cyclohexane) to obtain the title compound tert-butyl 6-[(rac)-5-[3-chloro-2-fluoro5- (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-íl]spiro[1 H-isobenzofuran-3,3'-azetidine]-1'carboxylate. LC-MS (method A) Rt= 1.57 min, m / z= 539.0 [M-tBu+H]+. To a flask containing a stirred solution of tert-butyl 6-[(rac)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazole -3-yl]spiro[1 H-isobenzofuran-3,3'-azetidin]-1'-carboxylate (4 g, 6.38 mmol) in DCM (60 mL) at 0°C TFA was added ( 5 mL) slowly. The reaction was allowed to warm to rt and stirred at rt overnight. The reaction mixture was concentrated in vacuo and the residue was partitioned into a solution of saturated aqueous NaHCOs and 10% MeOH in DCM (50 mL of each). The layers were separated and the aqueous layer was extracted with 10% MeOH in DCM (2 x 50 mL). The combined organic layers were concentrated in vacuo to obtain 6-[(rac)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazole. -3-yl]spiro[1H-isobenzofuran-3,3'-azetidine]. LC-MS (method A) Rt= 1.35 min, m / z= 495.0 [M+H]+. To a flask containing a stirred solution of 6-[(rac)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]5-(trifluoromethyl)-4H-isoxazol-3-yl]spiro[ 1H-isobenzofuran-3,3'-azetidine] (3.94 g, 7.57 mmol) and 2methylsulfonylacetic acid (1.49 g, 10.3 mmol) in EtOAc (25 mL) were added NEts (1.5 mL, 11 mmol) slowly. The reaction was cooled to 0°C and 2,4,6-tripropyl-1,3,5,2,4,6trioxatríphosphorinan-2,4,6-trioxide (50% in wt in EtOAc) (9.1 mL, 15 mmol) over 10 min. The reaction was allowed to warm to rt and stirred overnight. The reaction mixture was diluted with EtOAc (50 mL), washed with aqueous NaHCOs solution (50 mL) and brine (100 mL), and concentrated in vacuo. The crude product was purified by silica gel column chromatography (20-70% EtOAc in cyclohexane) to obtain the title compound. LC-MS (method A) Rt= 1.36 min, m / z= 615.0 [M+H]+.1H NMR (CDCb, 400 MHz) δ 8.03 (dd, J= 2, 6 Hz, 1 H), 7.81 ( dd, 1.6, 6 Hz, 1 H), 7.59-7.71 (m, 3 H), 5.17 (s, 2 H), 4.64-4.70 (m, 2 H), 4.1-4.47 (m, 3 H), 3.87 (m, 3 H) 3.20 (s, 3 H). The two enantiomers were separated by SFC. The separation was performed in Chiralpak® OJ-H with column dimensions of 250 mm x 30 mm (5 pm), a flow rate of 175 mL / min and a CO2-based mobile phase with 12% ¡PrOH containing 0.2% Ν,Ν-dimethylethylamine as additive to obtain Example 1.1: 2-methylsulfonyl-1-[6-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl] -5(trifluoromethyl)-4H-¡soxazol-3-yl]spiro[1H-¡sobenzofuran-3,3'-azet¡din]-1'-¡l]ethanone and Example 1.2: 2-methylsulfonyl-1 -[6-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-¡soxazol-3yl]spiro [1 H-isobenzofuran-3,3'-azetidin]-1 '-íl]ethanone. Examples 2.1 and 2.2 N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl] -5(thfluoromethyl)-4H-¡soxazol-3-¡l]naphthalen-1-carboxamide and N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen l]-5(trifluoromethyl)-4H-isoxazol-3-yl]naphthalen-1-carboxamide zcnacn / zznz / q / υιλι A solution of 4-bromo-1-naphthaldehyde (3.04 g, 12.31 mmol) in 1,4-dioxane (30 mL) and MeOH (30 mL) in a round-bottom pressure flask was treated with NEts (36.6 mmol, 5.10 mL) and [1,Tbis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.95 g, 1.23 mmol) before stirring at 90°C in a CO atmosphere (380 kPa) overnight . The reaction mixture was directly diluted in silica gel and subjected to column chromatography on silica gel (0-15% EtOAc in cyclohexane) to obtain methyl 4-formylnaphthalen-1-carboxylate. LC-MS (method A) Rt= 1.06 min, m / z= 215.0 [M+H]+. A solution of methyl 4-formylnaphthalen-1-carboxylate (2.52 g, 11.2 mmol) in THF (50 mL) in a flask was treated with NaOH in water (2 M, 52.0 g, 100 mmol) and stirred for 4 h at rt. . The reaction mixture was acidified to pH~1 with conc. HCl. and extracted with DCM (3x 40 mL). The combined organic layers were passed through Celite® and concentrated in vacuo to obtain 4-formylnaphthalen-1-carboxylic acid. LC-MS (method A) Rt= 0.36 min, m / z= 199.0 [M-H]·. A suspension of 4-formylnaphthalene-1-carboxylic acid (2.54 g, 10.8 mmol, 85%) in DCM (55 mL) was placed in an N2 atmosphere and treated with DMF (0.02 mL). The resulting mixture was then slowly treated with oxalyl chloride (13.8 mmol, 1.20 mL) and further stirred at rt for 30 min. The reaction mixture was concentrated in vacuo and used directly in the next step. A mixture of 4-formylnaphthalen-1-carbonyl chloride (2.36 g, 10.8 mmol) and 2-amino-N-(2,2,2-trifluoroethyl)acetamide-HCI (2.14 g, 10.9 mmol) was placed in an atmosphere of N2y was treated with DCM (55 mL) and DIPEA (29 mmol, 5.0 mL). The reaction mixture was diluted with HCl solution (2 M, 40 mL) and the two layers were separated. The aqueous layer was extracted with DCM (2x 30 mL) and the combined organic layers were passed through Celite®, concentrated in vacuo, and then subjected to column chromatography on silica gel (60-80% EtOAc in cyclohexane ) to obtain 4-formyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]naphthalen-1-carboxamide. LC-MS (method A) Rt= 0.86 min, m / z= 339.0 [M+H]+. A suspension of 4-formyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide (3.05 g, 8.55 mmol) in EtOH ( 45 mL) was placed in a N2 atmosphere, treated with NH2OH solution (50% in water, 3 mL, 49.0 mmol) and stirred for 4 h at rt. The reaction mixture was concentrated in vacuo to obtain 4-(hydroxyiminomethyl)-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalen-1-carboxamide. LC-MS (method A) Rt= 0.77 min, m / z= 354.0 [M+H]+. [3-chloro-2-fluoro-5(trifluoromethyl)phenyl]boronic acid (6.1 g, 24.41 mmol) and XPhos Pd(crotyl)CI (Pd-170) (537 mg, 0.76 mmol). Then, to the flask purged with N2 gas, THF (50 mL) was added, followed by a degassed solution of tribasic potassium phosphate (10.9 g, 49.8 mmol) in water (100 mL). 2-Bromo3,3,3-trifluoro-prop-1-ene (4.0 mL, 37 mmol) was added and the reaction was heated to 70°C and stirred for 1 h. The reaction was allowed to cool to rt and the layers were separated. The aqueous layer was extracted with Et2O (2x 50 mL), the combined organic layers were filtered through Celite® and the solvent was removed in vacuo. The crude product was purified by silica gel column chromatography (isocratic isohexane) to obtain 1-chloro-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene. LC-MS (method A) Rt- 1.45 min (no ionization). A mixture of 4-(hydrox¡minomethyl)-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1carboxamide (1.54 g , 3.71 mmol) and N-chlorosuccinimide (0.63 g, 4.59 mmol) was placed in an N2 atmosphere and treated with DMF (7.5 mL). The resulting solution was heated to 40°C and stirred for 10 min. LC-MS (method A) Rt= 0.88 min, m / z= 350.0 [M-H]'. The reaction mixture was cooled on ice and treated with 1-chloro-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene (1.29 g, 3.76 mmol) and NEts (5.7 mmol, 0.80 mL). The ice bath was then removed and the reaction mixture was stirred for 4 h. The reaction mixture was diluted with a saturated aqueous NaHCOs solution (60 mL) and extracted with tert-butylmethyl ether (3x 30 mL). The combined organic layers were dried over anhydrous MgSCU, filtered and concentrated in vacuo. The residues were purified by silica gel column chromatography (40-75% EtOAc in cyclohexane) to obtain the title compounds. LC-MS (method A) Rt= 1.39 min, m / z= 644.0 [M+H]+.1H-NMR (DMSO-d6, 400 MHz) δ 8.95 (t, J= 6 Hz, 1 H), 8.79 (d, J= 8 Hz, 1 H) 8.71 (t, J= 6.4 Hz, 1 H), 8.39 (d, J= 7.6 Hz, 2 H), 7.94-8.01 (m, 2 H), 7.64-7.74 (m, 3 H), 4.70 (m, 2 H), 4.43.95 (m, 4 H). The two enantiomers were separated by SFC. The separation was performed in Chiralpak® OJ-H with column dimensions of 250 mm χ 30 mm (5 pm), a flow rate of 120 mL / min and a CO2-based mobile phase with 10% MeOH containing 0.2 % Ν,Ν-dimethylethylamine as additive to obtain Example 2.1: N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3- chloro-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]naphthalen-1-carboxamide and Example 2.2: N-[2-oxo-2(2,2, 2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5-( trifluoromethyl)-4Hisoxazol-3-yl]naphthalen-1-carboxamide. Examples 3.1 and 3.2 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl) phenyl]60 5-(trifluoromethyl)-4H-¡soxazol-3-¡l]benzamide and 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-chloro-2-fluoro-5 -(trifluoromethyl)phenyl]5-(trifluoromethyl)-4H-soxazol-3-yl]benzamide A mixture of methyl 4-bromo-2-methyl-benzoate (10.0 g, 42.3 mmol), Ν,Ν,Ν',Ν'-tertramethylethylene diamine (3.96 mL, 26.3 mmol), palladium (II) acetate (0.5 g , 2.12 mmol), butyldi-1-adamantylphosphine (2 g, 5.29 mmol) and toluene (65 mL) were loaded into a pressure vessel. The reaction was pressurized with CO gas (-414 kPa) and heated to 85°C overnight. The reaction was cooled to rt. The reaction mixture was filtered through Celite®, while washing with toluene, and the solvent was removed under reduced pressure. The resulting residue was purified by silica gel column chromatography (0-10% EtOAc in cyclohexane) to obtain methyl 4-formyl-2-methyl-benzoate. LC-MS (method A) Rt= 0.95 min (no ionization). A mixture of methyl 4-formyl-2-methyl-benzoate (2.05 g, 11.2 mmol) in MeOH (65 mL) and NaOH in water (2 M, 65 mL) was stirred at rt for 5 h. The reaction mixture was acidified with conc. HCl. up to pH -1. The reaction was diluted with EtOAc, the organic layer was separated and the aqueous layer was washed with EtOAc. The organic layers were then combined, dried over anhydrous MgSO4, filtered and concentrated in vacuo to obtain 4-formyl-2-methyl-benzoic acid. LC-MS (method B) Rt= 0.71 min, m / z= 163.0 [M-H]-. At rt, DMF (25 pL) was added to a suspension of 4-formyl-2-methyl-benzoic acid (1.8 g, 10.4 mmol) and oxalyl chloride (995 pL, 11.5 mmol) in DCM (35 mL). in an N2 atmosphere. The reaction was stirred at rt for 3 h. The reaction mixture was concentrated to obtain crude acid chloride. A solution of 2-amino-N-(2,2,2-trifluoroethyl)acetamide-HCI (2.25 g, 11.5 mmol) and NEts (3.2 mL, 23 mmol) in DCM (35 mL) was added to the crude acid chloride at 0°C and the reaction was then warmed to rt and stirred for 30 min. The reaction was diluted with DCM / water, the organic layer was collected, and the solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography (010% MeOH in DCM) to obtain 4-formyl-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamine). )et¡l]benzam¡da. LC-MS (method A) Rt= 0.69 min, m / z= 303.0 [M+H]+. A solution of NH2OH (32.6 M in water, 385 pL, 6.28 mmol) was added to 4-formyl-2-methyl-N-[2oxo-2-(2,2,2-trifluoroethylamino)ethyl]benzamide (1.00 g, 3.14 mmol) in MeOH (15 mL) and the reaction was stirred at rt for 6 h. The solvent was removed under reduced pressure to obtain 4-[(E and Z)-hydroxyim¡nomethyl]-2methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl ]benzam¡da. LC-MS (method B) Rt= 0.68 min and 0.70 min, m / z= 318.0 [M+H]+. To a solution of 4-[(E and Z)-hydroxyim¡nomethyl]-2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]benzamide ( 1.08 g, 3.16 mmol,) in DMF (3.34 mL) N-chlorosuccinimide (548 mg, 4.10 mmol) was added and the reaction was heated to 40°C for 15 min. The reaction was cooled to 0°C and 1-chloro-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene (1.03 g, 3.15 mmol) was added, followed by NEts (484 pL , 3.47 mmol). The reaction was stirred at rt. The reaction was diluted with EtOAc and brine. The organic layer was separated and washed with more brine, dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (060% EtOAc in cyclohexane) to obtain the title compound. LC-MS (method A) Rt= 1.38 min, m / z= 608.0 [M+H]±1H NMR (CDCh, 400MHz) δ 8.04 (dd, J= 2, 6 Hz, 1 H), 7.81 (dd, J= 2, 6 Hz, 1 H), 7.47-7.56 (m, 3 H), 6.90 (br s, 1 H), 6.71 (br s, 1 H), 4.18-4.23 (m, 3 H), 3.84 -4.00 (m, 3 H), 2.48 (s, 3 H). The two enantiomers were separated by SFC in Chiralpak® AS-H with column dimensions of 250 mm χ 30 mm (5 pm), a flow rate of 152 mL / min and a CO2-based mobile phase with 10% MeOH. containing 0.2% Ν,Ν-dimethylethylamine as additive to obtain Example 3.1: 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl] -4-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-soxazol-3-l]benzam gives and Example 3.2: 2-methyl-N-[2-oxo-2-(2,2,2trlfluoroethylamino)ethyl]-4-[(5R or S)-5-[3-chloro-2-fluoro -5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-soxazol-3yl]benzamide. The following compounds were prepared in an analogous manner with the methodology of Examples 3.1 and 3.2: Ex- Name Structure 3.3 4-[(5S 0 R)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3-yl]-2methyl-N -[(4R)-3-oxo-2-(2,2,2trifluoroethyl)isoxazolidin-4yl]benzamide F3C 0---N 3.4 4-[(5S 0 R)-5-[3-chloro-2-fluoro -5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2methyl-N-[(4S)-3-oxo-2-(2,2,2trifluoroethyl)isoxazolidine -4yl]benzamide 3.5 4-[(5RS)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-¡soxazol-3-¡l]-2methyl-N-[ (3S)-2-oxo-1 -(2,2,2trifluoroethyl)pyrrolidin-3yl]benzamide f3c 0---N 3.6 4-[(5RS)-5-[3-chloro-2-fluoro-5- ( trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-¡soxazol-3-¡l]-2methyl-N-[(3R)-2-oxo-1 -(2,2,2trifluoroethyl)p¡ rrolidin-3yl]benzamide F3C 0---N WJ^RR 3.7 4-[(5RS)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5- (tr¡ fluoromethyl)-4H-¡soxazol-3-¡l]-2methyl-N-[(4S)-3-oxo-2-(2,2,2trifluoroethyl)isoxazolidín-4yl]benzamide 3.8 N-[2-( cycloprop¡lmethylamino)-2oxo-ethyl]-2-methyl-4-[(5RS)-5-[3chloro-2-fluoro-5(trifluoromethyl)phen¡l]-5(trifluoromethyl)-4H- isoxazol-3yl]benzamide FaC F,r 0--N 0 3.14 [2-methyl-4-[(5RS)-5-[3-chloro-2fluoro-5-(trifIuoromethyl)phenyl]-5(trifluoromethyl)-4H -isoxazol-3yl]phenyl]-[(3RS)-3-hydroxypyrrolídin1-yl]methanone F3Ck c r 0---N 3.15 2-methyl-4-[(5RS)-5-[3- chloro-2fluoro-5-(trif[uoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3-yl]-N[(3RS)-1 -cyclopropyl-2-oxopyrrolidin-3-íl] benzamide F3c^ c n 0---N 7cnQcn / 77n7 / q / υιλι 3.16 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)pheníl]-5- (trifluoromethyl)-4H-ísoxazol-3-íl]-N(trans -3-cyanocyclobutyl)-2-methylbenzamide F3C 0---N - 3.17 4-[(5S or R)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (tr ¡fluoromethyl)-4H-¡soxazol-3-¡l]-N(trans-3-cyanocyclobutyl)-2-methylbenzamide F3C 0---N 3.18 2-methyl-4-[(5RS)-5-[3- chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3-yl]-N[[4-(trifluoromethyl)thiazol-2¡l]methyl]benzamide F3C 0-- -N \f3 3.19 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazol-3-yl]-N( cis-3-cyanocyclobutyl)-2-methylbenzamide F3C 0---N - 3.20 4-[(5S or R)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl] -5- (trifluoromethyl)-4H-ísoxazol-3-íl]-N(cis-3-cyanocyclobutíl)-2-methylbenzamide F3c 0---N 3.21 4-[(5RS)-5- [3-chloro-2-fluoro-5- (trifluoromethyl)pheníl]-5- (trifluoromethyl)-4H-ísoxazol-3-íl]-2methyl-N-[(3R)-2-oxopyrrolidin-3yl ]benzamide 3.22 4-[(5RS)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-¡soxazol-3-¡l]-2methyl- N-[(3S)-2-oxopírrolídin-3yl]benzamide 7cnQcn / 77n7 / q / υιλι 3.23 N-[(4-cyanothiazol-2-¡l)methyl]-2methyl-4-[(5RS)-5-[3-chloro-2-fluoro5-(trifluoromethyl)phenyl]-5(trifluoromethyl )-4H-isoxazol-3yl]benzamide F3C 0---N 3.24 2-methyl-N'-(2-methylsulfon¡lacet¡l)-4[(5RS)-5-[3-chloro-2-fluoro- 5(trifluoromethyl)pheníl]-5(trifluoromethyl)-4H-isoxazol-3íl]benzohydrazide f3c. p r 0---N o 3.25 2-methyl-N-(2-oxoim¡dazol¡din-1-yl)4-[(5RS)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phen ¡l]-5(trifluoromethyl)-4H-¡soxazol-3yl]benzamide p r 0---N 0 3.26 2-methyl-N-[2-oxo-3-(2,2,2- trifluoroethyl)¡ m¡dazol¡din-1 -yl]-4[(5RS)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3yl ]benzamide YoY 3.27 4-[(5S or R)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazol-3-yl]-N[( 33)-1 -(cyanomethyl)-2-oxopyrrolídin-3-¡l]-2-methyl-benzamide f3C 0---N 0 3.28 4-[(5S or R)-5-[ 3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazol-3-íl]-N[(3R)-1 -(cyanomethyl)-2-oxopyrrolidin-3- ¡l]-2-methyl¡l-benzamide 3.29 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-¡soxazol- 3-¡l]-N[(3S)-1 -(cyanomethyl)-2-oxo- 7cnQcn / 77n7 / q / υιλι pyrrolidin-3-¡l]-2-methyl-benzamide 3.30 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl) -4H-isoxazol-3-¡l]-N[(3R)-1 -(cyanomethyl)-2-oxopyrrolidin-3-¡l]-2-methyl-benzamide ρ3θ p r 0---N o 3.33 2 -methyl-4-[(5RS)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3-¡l]-N[(3RS)-1 -ethyl-2-oxo-pyrrolidin-3yl]benzamide .......- 3.34 2-methyl-N-(1 -methylsulfonylazetidin- 3-yl)-4-[(5R or S)-5-[3 -chloro-2- fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3yl]benzamide F3C 0---N 3.35 2-methyl-N-(1-methylsulfonílazetidine3- ¡l)-4-[(5S or R)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3yl]benzamide F?c o--- N 3.36 N-[1-(cyclopropancarbonyl)azetidin-3-yl]2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl) -4H-¡soxazol-3yl]benzamide f3c. P _ 0---N 3.37 N-[1- (cyclopropancarbonyl)azetidin-3-¡l]2-methyl-4-[(5S or R)-5-[3-chloro-2fluoro-5-(trifluoromethyl) phenyl]-5(trifluoromethyl)-4H-¡soxazol-3yl]benzamide 7cnQcn / 77n7 / q / υιλι 3.38 2-methyl-4-[(5R or S)-5-[3-chloro-2- fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-¡soxazol-3-yl]-N - [3- (trifluoromethyl)cyclobutyl]benzamide F3C Cl p r 0---N -CF3 3.39 2-methyl-4-[(5S or R)-5-[3-chloro-2 - fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazol-3-yl]-N- [3- (trifluoromethyl)cyclobutíl]benzamid a f3c ~-cf3 3.40 2- methyl-4-[(5S or R)-5-[3-chloro-2- fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-¡soxazol-3-¡l]-N [1-(2,2,2-trifluoroethyl)azetidin-3yl]benzamide f3c RR 'Y v- cf3 3.41 2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro -5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-¡soxazol-3-yl]-N[1-(2,2,2-trifluoroethyl)azetidin-3yl]benzamide f3c > cf3 3.42 2-methyl -4-[(5RS)-5-[3-chloro-2- fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3-yl]-N[1 -(2,2 ,2-trifluoroethyl)pyrazol-4yl]benzamide f3c o---N / O' 3.43 2-methyl-N-(oxetan-3-íl)-4-[(5S or R)-5-[3-chloro -2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3yl]benzamide f3c P „ 0---N 0 3.44 2-methyl-N-(oxetan-3-yl)-4 -[(5R or S)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazole-3- f3c R2 0 7cnQcn / 77n7 / q / υιλι yl]benzamide 3.45 2-methyl-4-[(5S or R)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-íl]-N [1 -(1,3,4-thiadiazol-2-yl)azetidin-3yl]benzamide F3C 0---N 3.46 2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro- 5-(trifluoromethyl)pheníl]-5(trifluoromethyl)-4H-ísoxazol-3-íl]-N[1 -(1,3,4-thiadíazol-2-yl)azetidin-3yl]benzamide Ύ c „ 0--N 3.47 4-[(5RS)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3-íl ]-N(cis-3-methoxycyclobutyl)-2-methylbenzamide F3C 0---N 3.48 N-(3-cyano-1- bicyclo[1.1.1]pentanyl)-2-methyl-4[(5RS)-5 -[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazol-3yl]benzamide 3.49 4-[(5R or S)-5-[3-chloro- 2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2methyl-N-((cis)3-methylsulfonylcyclobutyl)benzamide f3c o—n - 3.50 N-( 3-fluorocyclobutyl)-2-methyl-4[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3yl]benzamide F3C O ---N 3.51 2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]-N (tietan-3-yl)benzamide F3C O--N 7cnQcn / 77n7 / q / υιλι 3.52 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-soxazol-3-yl]-N(1, 1-dioxothietan-3-yl)-2-methylbenzamide F3C 0---N 3.53 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl )-4H-¡soxazol-3-yl]-2methyl-N-[(3R)-2-oxoazetidin-3yl]benzamide f3c. p r 0---N - 3.54 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazol-3-yl] -2methyl-N-[(3S)-2-oxoazet¡din-3yl]benzamide 3.55 N-cyclobut¡l-2-methyl-4-[(5R or S)-5[3-chloro-2 -fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3yl]benzamide F3C 0---N 3.59 2-methyl-4-[(5RS)-5-[3-chloro-2fluoro-5 -(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]-N[5-(trifluoromethyl)-1,3,4-oxadiazol2-¡l]benzamide f \ / F Γ F\l H 0 ¿_F Y / Y y « f I Y \\ N--N \ 0 Cl 3.60 2-methyl-4-[(5RS)-5-[3-chloro-2- fluoro-5-(trifluoromethyl)phenyl]- 5- (trifluoromethyl)-4H-ísoxazol-3-yl]-N[1 -(2,2,2-trifluoroethyl)-1,2,4-triazol3-yl]benzamide F Γ —N p F^ 9 \ \ \>__ / / Λ H I ll n= / / \ Y- \ 0 F \ Cl 3.61 2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro-5-(trifIuoromethyl)phenyl ]-5(trifluoromethyl)-4H-¡soxazol-3-yl]-N[1 -(trifluoromethi Isulfonyl) azetidin-3yl]benzamide F F4 p^N F Ίγ il h F Ύ YF 1 Π Vli 0 Cl 0 ^F 0 F 7cnQcn / 77n7 / q / υιλι 3.62 2-methyl-N-(2-oxaspiro[3.3]heptan-6-yl)-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5 (trifluoromethyl)-4H-¡soxazol-3yl]benzamide η Τ' .π A ^71 — 'A'v r~ ή ή Ao \ 1 )=^ ° \ ZI 3.63 N-(1-cyanocycloprop¡l)-2 -methyl-4[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3yl]benzamide F F4 p-n f f / 4 JI Cl ° 3.64 N-(azetidin-3-yl)-2-methyl-4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazole -3yl]benzamide Cl 3.65 2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl ]-N[trans-3- (trifluoromet¡l)cyclobutyl]benzamid a F \ 0---N F \\ F f^—y y—f \\ \ F / \_ / \ ° F F '----- \ Cl 3.66 N-[1-(dimethylsulfamo¡l)azetidin-3yl]-2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro-5-(trifIuoromethyl)phenyl]-5( trifluoromethyl)-4H-isoxazol-3yl]benzamide Q t / o Ή I / / O / Ζ'^Ό o 7cnQcn / 77n7 / q / υιλι 3.71 3-[[2-methyl-4-[(5S or R)-5-[3-chloro2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3¡ l ]benzoyl]am i no]azetid i n -1 carboxamide F-X..........I) X ti--\ y. P F / '----\ N---< N---V ' NH, F' / F Cl 3.72 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl )pheníl]-5- (trifluoromethyl)-4H-ísoxazol-3-íl]-2methyl-N-[(3S)-2-oxo-1 -(2,2,2trifluoroethyl)azetidin-3yl ]benzamide F θ__N 0 4- / · Cl 3.73 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazole -3-¡l]-2methyl-N-[(3R)-2-oxo-1 -(2,2,2trifluoroethyl)azetidin-3yl]benzamide F θ__N 0 Cl 3.74 2-methyl-4-[(5R or S )-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3-yl]-N[cis-3-(trifluoromethyl)cyclobut¡l]benzam ¡d a Cl 3.75 N-[1-(cyanomethyl)pyrazol-4-yl]-2methyl-4-[(5S or R)-5-[3-chloro-2fluoro-5-(trifIuoromethyl)phenyl]-5 (trifluoromethyl)-4H-¡soxazol-3yl]benzamide f 0--N 1 \\ z~—N 1 \_ / / y-F F'7\—7 ξ H \ 1 Cl 7cnQcn / 77n7 / q / υιλι 3.76 4-[(5S or R)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3-yl]-N[(3R)-1 -(cyanomethyl)pyrrolidin-3-yl]2-methyl-benzamide; F\ o—N. M i \\ \ J / \---F Ni...... / '''X N 3.77 N-[(1-clanocyclopropyl)methyl]-2methyl-4-[(5R or S)-5- [3-chloro-2fluoro-5-(trifIuoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3yl]benzamide F M PN f F^ / KJL h v F Y^Z^F I Π Cl 0 3.78 2-methyl-4- [(5S or R)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3-¡l]-N[(4R or S)-2- methylsulfonylisoxazolidin-4yl]benzamide \ ° z-O mT b—......u. O pu_ 3.79 2-methyl-4-[(5S or R)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3-yl]-N[ (4S or R)-2- methylsulfonylisoxazolidin-4yl]benzamide \ ° z-O °<sxz:i: Z / / b—í......u. χΧO pu_ 3.80 4-[(5S or R)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3-yl]-2methyl-N-[ (3R)-1 -(2,2,2trifluoroethyl)pyrrolidin-3yl]benzamide ?\\ J\ / / \Νω,,. / Ύ / '--N Cl / F^ / / ^F F 7cnQcn / 77n7 / q / υιλι 3.81 N-(3-cyanophenyl)-2-methyl-4-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H -isoxazol-3yl]benzamide c F\ 0—N >...... / \\ F \\ \ 0 ~CI W N 3.82 2-methyl-4-[(5R or S)-5-[3-chloro -2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]-N[[1- (trifluoromethyl)c¡cloprop¡l]methyl]ben zamida F Μ O-N f Cl 1 0 F 3.83 2-methyl-N-[(1-methylsulfonylcyclopropyl)methyl]-4[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H- ¡soxazol-3yl]benzamide F F\L θ-Ν f / / O yl y \ Cl 1 0 0 3.84 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phen¡ l]-5- (trifluoromethyl)-4H-¡soxazol-3-¡l]-2methyl-N-[(3S)-5-oxopírrol¡n-3yl]benzamide J?_\\ F F“^ \ / F \ F Cl 3.85 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-¡soxazol-3-yl]- 2methyl-N-[(3R)-5-oxopyrrolidin-3yl]benzamide F4^?_\\ — F F^“A_YF \ F \ / Vbs and Cl '—N 3.86 4-[(5R or S)-5-[3-chloro-2-fluoro-5(triyluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazol-3-yl]-N[(3S)- 1-ethyl-5-oxo-pyrrolidin-3-yl]-2methyl-benzamide \\ __ F Cl '—___ 3.87 4-[(5R or S)-5-[3-chloro-2-fluoro-5 (triyluoromethyl)phenyl]-5-(trifluoromethyl)-4H-ísoxazol-3-yl]-N[(3R)-1-ethyl-5-oxo-pyrrolídin-3-yl]-2methyl-benzamide F- Jl JTtt __ F^ \ 5(trifluoromethyl)-4H-¡soxazol-3-¡l]-N[(4S or R)-2-ethylisoxazol¡din-4yl]benzamide c F\ O-N f ΑΧΥΜ 9 \=< ' n... ...O Cl ____ 3.89 2-methyl-4-[(5R or S)-5-[3-chloro-2fluoro-5-(trifIuoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3-¡ l]-N[(4R or S)-2-ethylisoxazolidin-4yl]benzamide p F\ O-N V F Cl __ 3.90 4-[(5S or R)-5-[3-chloro-2-fluoro-5( trifluoromethyl)phen¡l]-5- (trifluoromethyl)-4H-¡soxazol-3-¡l]-N[cis-3-cyanoc¡cloperit¡l]-2-methylbenzamide F F\ °-Nx F \\ 'VF \ o F Cl 3.91 N-(cis-4-cyanocyclohexíl)-2-methyl4-[(5R o S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5( trifluoromethyl)-4H-ísoxazol-3yl]benzamide F F\ °-N. F \\ T“F \ or F ^=\ Cl 7cnQcn / 77n7 / q / υιλι 3.92 N-(trans-4-cyanocyclohexyl)-2methyl-4-[(5R or S)-5-[3-chloro-2fluoro-5-(trifIuoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3yl] benzamide c F\ 0—N V F / K / Γ \\ N^Z1 F y----¿ &2\ Vf F ' Cl 3.93 2-methyl-N-(3-methylothiethan-3-yl)-4[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-soxazol-3yl]benzamide Cl 3.94 2-methyl-4-[(5S or R )-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-¡soxazol-3-yl]-N[(5S or R)-3-ethoxy¡-4, 5- dihydroisoxazol-5-¡l]benzamide Cl F N / P n / TljV / N^or21 F-t( FTF F F 3.95 2-methyl-4-[(5S or R)-5-[3-chloro-2fluoro- 5-(trif[uoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]-N[(5R or S)-3-ethoxy¡-4,5-dihydro¡soxazol-5-¡ l]benzamide 0-N Λ—» / \ / / or2 η F F 3.96 N-(trans-3-cyano-3-fluorocyclobutyl)-2-methyl-4-[(5R or S)-5[3- chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3yl]benzamide F 'i 0-N F ' '^N Cl r 3.97 4-[(5R or S)-5- [3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2methyl-N-[(3SR)-5-oxo-1 -(2,2 ,2trifluoroethyl)pyrrolidin-3yl]benzamide Mixad c f 0—N F f ' h ^2 jr Cl Tf F 7cnQcn / 77n7 / q / υιλι 4-[(5R or S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]-N[(3SR)-1-( cyclopropylmethyl)-5-oxopyrrolídin-3-yl]-2-methyl-benzamide Example 3.9 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5RS)-5-(trifluoromethyl)-5-(2,4,6 -trifluorophenyl)-4Hisoxazol-3-yl]thiophen-2-carboxamide 2,4,6-Trifluorobromobenzene (1.00 g, 4.76 mmol) was dissolved in dry Et20 (5 mL) and cooled to 78°C. A solution of n-BuLI in THF (3.25 mL, 5.2 mmol, 1.6 M) was added dropwise over 30 min and the resulting solution was stirred for 1 h at −78°C. Then, a solution of trifluoroethyl acetate (675 mg, 4.76 mmol) in Et2O (5 mL) was added all at once and the reaction was stirred for 20 min at 78°C and for an additional 40 min at −40°C. Then, a ready-made cooled (-78°C) solution of 2,2,2-trifluoro-1-(2,4,6-trifluorophenyl)ethan-1-one (866 mg, 3.8 mmol) and LiHMDS (6.6 mL, 6.6 mmol) in dry Et20 (5 mL) and the resulting reaction mixture was stirred for 4 h, at which time it was allowed to warm to rt. The reaction mixture was quenched by the addition of saturated aqueous NH4Cl solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SÜ4, filtered and concentrated in vacuo. 1 -(5-Bromo-4-methyl-2-thienyl)4,4,4-trlfluoro-3-hydroxy-3-(2,4,6-trifluorophenyl)butan-1-one was obtained as a yellowish liquid and It was used in the next step without additional purification. LC-MS (method E) Rt= 2.88 min, m / z= 447.2 / 449.1 [M+H]+. A mixture of 1 -(5-bromo-4-methyl-2-thienyl)-4,4,4-trifluoro-3-hydroxy-3-(2,4,6-trifluorophenyl)butan-1one (800 mg, 1.79 mmol) and pyridine (0.578 mL, 7.16 mmol) in DCM (10 mL) was cooled to 0°C in an ice bath. Then, SOCI2 (0.43 mL, 3.58 mmol) was added dropwise at 0°C. The ice bath was removed and the reaction mixture was stirred at rt for 4 h. After this point, a saturated aqueous NH4Cl solution was slowly added. The aqueous layer was separated and extracted with DCM (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The desired product was obtained as a yellowish liquid and used in the next step without further purification. LC-MS (method C) Rt= 2.52 and 2.56 min (mixture of E / Z isomers), m / z= 429.1 / 431.1 [M+H]+. To a solution of 1-(5-bromo-4-methylophen-2-l)-4,4,4-trifluoro-3-(2,4,6-trifluorophenl)but -2-in-1 one above (450 mg, 1.05 mmol) in DCE (10 mL) a solution of NH2OH (50% in water, 52 mg, 1.57 mmol) and DBU (0.319 mg, 2.10 mmol) were added to rt. The mixture was stirred at rt for 3 h. After this point, water was added, and the aqueous layer was separated and extracted with DCM (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 3-(5-Bromo-4-methylothiophen-2-yl)-5-(2,4,6-trifluorophenyl)-5-(trifluoromethyl)isoxazole was obtained as a yellowish solid and used in the next stage without further purification. LC-MS (method C) Rt= 2.53 min, m / z= 444.1 / 449.1 [M+H]+. 3-(5-bromo-4-methylophen-2-l)-5-(2,4,6-tnfluorophenl)-5-(trifluoromethyl)-isoxazole (220 mg, 485 pmol) was dissolved in THF (5 mL) in an N2 atmosphere at 0°C. A solution of ¡PrMgCl in THF (0.77 mL, 1.49 mmol, 2 M) was added dropwise and the mixture was stirred for 30 min at 0°C in an ice bath. CO2 gas was then bubbled through the solution for 1 h at 0°C. The reaction was quenched by the addition of aqueous HCl solution (1 M). The aqueous layer was separated and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The desired product was obtained as a yellow liquid and was used immediately in the next step without further purification. LC-MS (method C) Rt= 2.53 min, m / z= 410.1 [M+H]+. 3-Methyl-5-(5-(trifluoromethyl)-5-(2,4,6-trifluorophenyl)-4,5-dihydroisoxazol-3-l)t acid ofen-2carboxylic above (200 mg, 0.49 mmol), PyBOP (307 mg, 0.59 mmol), and NEts (144 mg, 1.47 mmol) were mixed in DMF (10 mL) and cooled to 0 °C in an ice bath. Then, 2-amino-N(2,2,2-trifluoroethyl)acetamide (92 mg, 0.59 mmol) was added at 0°C. The ice bath was removed and the reaction mixture was stirred for 4 h at rt. After this point, cold water was added. The aqueous layer was separated and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (5-14% EtOAc in petroleum ether) to obtain Example 3.9: 3-methyl-N-[2-oxo-2-(2,2,2 -trifluoroethylamino)ethyl]-5-[(5RS)-5-(trifluoromethyl)-5-(2,4,6-trifluorophenyl)-4H¡soxazol-3-yl]thiophen-2 -carboxamide as a colorless solid. LC-MS (method D) Rt=2.07 min, m / z= 546.1 [M-H]-.1H-NMR (DMSO-d6, 400 MHz) δ 8.61 (br s, 1 H), 8.38 (br s, 1 H ), 7.53 (s, 1 H), 7.41 (t, J= 9.6 Hz, 2 H), 4.42 (q, J= 18 Hz, 2 H), 3.98-3.87 (m, 4 H), 2.43 (s, 3H). Example 3.56 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamine)ethyl]-5-[(5RS)-5-[2,4-difluoro-5 -(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-soxazol-3-l]thiophen-2-carboxamide Π zcnacn / zznz / q / υιλι k a solution of 5-bromo-4-methyl-thiophen-2-carbaldehyde (4.74 g, 22.7 mmol) in MeOH (113 mL) was added dropwise with a solution of NH2OH (50% in water, 2.7 mL, 44 mmol). The reaction was stirred at rt for 4.5 h. After this point, the reaction was concentrated in vacuo and the resulting solid was dried in the vacuum oven to obtain 5-bromo-4-methyl-thiophen-2-carbaldehyde oxime as a creamy solid. LC-MS (method A) Rt= 0.99 and 1.02 min, m / z= 217.6 / 219.6 [M+H]+(mixture of E / Z isomers). A mixture of 2-[2,4-difluoro-5-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.75 g, 5.80 mmol), methanesulfonate(2-dicyclohexylphosph ino-2',4',6'-tri-i-propyl-1,1 '-biphenyl)(2'-methylamino-1,1 '-biphenyl-2yl)palladium(ll) (256 mg, 292 pmol) and 2-bromo-3,3,3-trifluoropropene (2.53 g, 14.5 mmol) was placed in an N2 atmosphere and treated with potassium phosphate (0.5 M in water, 11.0 mmol, 22 mL) and THF (11 mL ). The resulting reaction mixture was stirred at 70°C for 30 min. The reaction mixture was allowed to cool to rt, diluted with water (30 mL) and extracted with DCM (3x 25 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (100% / so-hexane) to obtain 1,5difluoro-2-(trifluoromethyl)-4-[1-(trifluoromethyl)vinyl] benzene as a colorless oil. LC-MS (method A) Rt= 1.37 min (no significant mass ion observed). A mixture of the above 5-bromo-4-methyl-thiophen-2-carbaldehyde oxime (950 mg, 4.10 mmol) and N-chlorosuccinimide (0.73 g, 5.36 mmol) was placed in a N2 atmosphere, treated with DMF ( 3.0 mL) and stirred for 5 min at 40°C, during which period a bright yellow precipitate formed. The reaction mixture was cooled to 0°C in an ice bath and treated with the above 1,5-difluoro-2-(trifluoromethyl)-4-[1(thfluoromethyl)vinyl]benzene (1.34 g, 4.12 mmol). NEts (0.47 g, 4.6 mmol) was then slowly added and the resulting mixture was stirred at 0°C for 10 min and then for an additional 30 min at rt. The reaction mixture was diluted with a saturated aqueous NaHCOs solution (40 mL) and extracted with DCM (3 x 25 mL). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0-10% fer-butylmethyl ether in cyclohexane) to obtain 3-(5-bromo-4-methyl-2-thienyl)-5-[2,4-difluoro -5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazole as a yellowish semisolid. LC-MS (method A) Rt= 1.64 min, m / z= 493.8 / 495.8 [M+H]+. A solution of 3-(5-bromo-4-methyl-2-thienyl)-5-[2,4-difluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)4H-isoxazole (851 mg, 1.29 mmol) in THF (6.5 mL) was placed in an N2 atmosphere, cooled to 0°C in an ice bath, and treated with a solution of / PrMgCl in THF (1.3 mL, 2.6 mmol, 2.0 M ). The resulting mixture was stirred for 30 min at 0sC. CO2 gas was then bubbled through the reaction mixture for 15 min. After this point, the reaction mixture was acidified to pH ~2 with a 2 M HCl solution and then extracted with DCM (3x 15 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was dissolved in MeOH, filtered and purified by preparative HPLC (C-18 Phenomenex Gemini-NX 10 microns and 5 50*150 mm) (CH3CN, water, both with 0.1% formic acid, 30-100% of CH3CN over 11 min at 120 mL / min) (2 injections). 5-[5-[2,4-difluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)4H-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic acid was obtained of a main peak as a creamy solid. LC-MS (method A) Rt= 1.02 min, m / z= 458.0 [M-H]'. A mixture of 5-[5-[2,4-difluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-3methyl-thiophen-2-carboxylic acid (154 mg, 318 pmol), 2-amino-N-(2,2,2-tñfluoroethyl)acetamide-HCI (96.0 mg, 473 pmol) and PYBOP (254 mg, 488 pmol) were placed in a N2 atmosphere and treated with THF ( 1.6 mL) and NEts (94.4 mg, 933 pmol, 0.13 mL) before shaking for 30 min at rt. The reaction mixture was diluted with saturated aqueous NaHCO3 solution (20 mL) and extracted with DCM (3x10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was dissolved in MeOH (plus ~1 mL DMF), filtered and purified by preparative HPLC (10 micron 50*150 mm C-18 Phenomenex Gemini-NX) (CH3CN, water with 10 mM ammonium bicarbonate adjusted to pH 9 with ammonium hydroxide, 30-100% CHsCN for 10 min at 120 mL / min) (1 injection). Example 3.56: 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[rac-(5R)-5-[2, 4difluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-soxazol-3-yl]thiophen-2-carboxamide from a main peak as a colorless solid. LC-MS (method A) Rt= 1.33 min, m / z= 598.0 [M+H]+. 1H-NMR (DMSO-d6, 400 MHz) δ 8.62 (t, J= 6 Hz, 1 H), 8.38 (t, J= 5.6 Hz, 1 H), 7.92-7.97 (m, 2 H), 7.49 ( s, 1 H), 4.30-4.55 (m, 2 H), 3.89-3.97 (m, 4 H), 2.43 (s, 3 H). Examples 4.1 and 4.2 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl) phenyl]5-(trifluoromethyl)-4H-soxazol-3-yl]thiophen-2-carboxamide and 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5R or S)-5-[3-chloro-2-fluoro-5 -(trifluoromethyl)phenyl]5-(trifluoromethyl)-4H-soxazol-3-yl]thiophen-2-carboxamide zcnacn / zznz / q / υιλι A mixture of 5-bromo-4-methyl-thiophen-2-carbaldehyde oxime (3.36 g, 14.5 mmol) and N-chlorosuccinimide (2.74 g, 20.1 mmol) was combined in DMF (11 mL) in an N2 atmosphere. The resulting solution was heated to 40°C and stirred for 5 min, during which period a bright yellow precipitate was observed. The mixture was cooled to 0°C in an ice bath and treated with l-chloro-279 fluoro-5-(tnfluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene (4.35 g, 11.2 mmol). before the slow addition of NEt3 (2.40 mL, 17.0 mmol). Once the addition of NEt3 was complete, the ice bath was removed and the reaction mixture was stirred for 15 min at rt. The reaction mixture was stirred for an additional 30 min at rt and then diluted with aqueous NaOH solution (1 M, 60 mL) and extracted with tert-butylmethyl ether (3x 40 5 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (0-10% DCM in cyclohexane) to obtain 3-(5-bromo-4-methyl-2-thienyl)-5-[3-chloro- 2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazole as a colorless solid. LC-MS (method B): Rt= 1.65 min, m / z= 509.8 [M+H]+. A solution of 3-(5-bromo-4-methyl-2-thien¡l)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5( trifluoromethyl)-4H-isoxazole (2.84 g, 5.28 mmol) in THF (26 mL) was placed in an N2 atmosphere, cooled to 0°C in an ice bath, and treated with / PrMgCl in THF (2.0 M, 5.50 mL, 11 mmol) before shaking for 30 min. Then, carbon dioxide (232 mg, 5.28 mmol) was bubbled through the reaction mixture for 15 min. The reaction mixture was then treated with HCl solution (2 M, 40 mL) and extracted with DCM (3 x 30 mL). The combined organic layers were washed with a saturated aqueous NaHCOs solution (20 mL) and the aqueous layer was back extracted with DCM (2x 20 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated in vacuo to obtain 3-methyl-5-[rac-(5R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl) acid. )pheníl]-5-(trifluoromethyl)-4H-ísoxazol-3yl]thiophen-2-carboxylic acid as a pale yellow solid. LC-MS (method B) Rt= 1.06 min, m / z= 473.8 [M-H]'. A mixture of 5-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]3-methyl-thiophen-2-carboxylic acid ( 2.48 g, 4.17 mmol), 2-amino-N-(2,2,2-trifluoroethyl)acetamideHCI and PYBOP (3.26 g, 6.27 mmol) was placed in a N2 atmosphere and treated with THF (20 mL) and NEt3 (1.31 g, 12.9 mmol). The resulting mixture was stirred at rt for 30 min. The reaction mixture was then diluted with saturated aqueous NaHCO3 solution (40 mL) and extracted with DCM (3x 40 mL). The combined organic layers were dried over anhydrous MgSCL, filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (0-50% EtOAc in cyclohexane) to obtain the desired product. LC-MS (method B) Rt= 1.40 min, m / z= 614.0 [M+H]+.1H-NMR (DMSO-d6, 400 MHz) δ 8.62 (t, J= 6 Hz, 1 H), 8.35 (m, 2 H), 7.87-7.87 (m, 1 H), 7.50 (s, 1 H), 4.38-4.59 (m, 2 H), 3.89-3.97 (m, 4 H), 2.43 (s, 3 H). The two enantiomers were separated by SFC. The separation was performed in Chiralpak® OJ-H with column dimensions of 250 mm χ 30 mm (5 pm), a flow rate of 160 mL / min and a CO2-based mobile phase with 6% MeOH containing 0.2% of W. / V-dimethylethylamine as additive to obtain Example 4.1: 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5S or R) -5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5-(tñfluoromethyl)-4H-isoxazol-3-l]thiophen-2-carboxamide and Example 4.2: 3-methyl-N-[2oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5R or S)-5-[3-chloro-2-fluoro -5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)4H-isoxazol-3-yl]thiophen-2-carboxamide The following compounds were prepared in an analogous manner with the methodology of Examples 4.1 and 4.2: zcnacn / zznz / q / υιλι Ex. Name Structure 3.10 (2R)-1 -[5-[(5RS)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-ísoxazole-3 -yl]-3methyl-thiophen-2-carbonyl]-N-(2,2,2trifluoroethyl)pyrrolidine-2carboxamide F3C. p p 0---N o °A Cl 3.11 (2S)-1 -[5-[(5RS)-5-[3-chloro-2- fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H -soxazol-3-yl]-3methyl-thiophen-2-carbon¡l]-N-(2,2,2trifluoroethyl)pyrrolidine-2carboxamide F3C p r 0---N o °\\ Cl 3.12 3-methyl-5 -[(5RS)-5-[3-chloro-2- fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3-íl]-N[(3RS)-2 -oxo-1 -(2,2,2-trifluoroethyl)pyrrolidin-3-¡l]thiophen-2carboxamide ..... Cl 3.13 3-methyl-N-(4-pyrid¡l)-5 -[(5RS)-5-[3chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3yl]thiophen-2-carboxamide F3C O---N or Cl 3.31 3-methyl-5-[(5RS)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3-yl]-N[[4- (trifluoromethyl)thiazol-2¡l]methyl]thiophen-2-carboxamide f3c. p p 0---N o Cl 3.32 N-[(4-cyanothiazol-2-yl)methyl]-3methyl-5-[(5RS)-5-[3-chloro-2-fluoro5-(trifluoromethyl)phen ¡l]-5(trifluoromethyl)-4H-isoxazol-3¡l]thiophen-2-carboxamide FsC 0---N 0 7cnQcn / 77n7 / q / υιλι 4.3 N-(cis-3-c¡anoc¡clobutíl)-3-methyl-5[(5R 0 S)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl )-4H-isoxazol-3yl]thiophen-2-carboxamide 'V0 ω I ) 4.4 N-(cis-3-cyanocyclobutyl)-3-methyl-5[(5S 0 R)-5-[3- chloro-2-fluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3yl]thiophen-2-carboxamide F Γ \ / FR / O—N f YAX K s v-R 'R# 0 / F \ Cl\ Example 5.1 (RS)-4-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(difluoromethyl)-4H-¡soxazol-3-yl]- 2-methyl-N-[2-oxo2-(2,2,2-trifluoroethylamino)ethyl]benzamide To a stirred solution of 2-chloro-1-fluoro-4-(trifluoromethyl)benzene (5.0 g, 25.1 mmol) in anhydrous THF (40 mL) was added LDA in THF (2M, 18.8 mL, 37.78 mmol) at - 78°C. The reaction mixture was stirred at -78°C for 2.5 h. A solution of ethyl 2,2-difluoroacetate (3.75 g, 30.2 mmol) in THF (10 mL) was added and the reaction mixture was stirred at −10°C for 1 h. The reaction was quenched with HCl solution (1M) at -10°C and extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 1-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-2, 2-difluoro-ethanone, which was used in the next step without further purification. To a stirred solution of 1-(4-bromo-3-methyl-phenyl)ethanone (3.0 g, 14 mmol) in dry THF (10 mL) was added dropwise LiHMDS in THF (1M, 28 mL) at -78 °C and the resulting mixture was stirred for 2.5 h. A solution of 1-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-2,2-difluoro-ethanone (5.84 g, 21.1 mmol) in THF (5) was added dropwise. mL) to the reaction mixture at -78°C and kept for 1 h. The reaction mixture was allowed to warm to rt over 16 h. The reaction was quenched with a saturated aqueous NH4CI solution (20 mL) at -10°C and extracted with EtOAc (2x 80 mL). The combined organic layers were washed with brine (70 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 1 -(4-bromo-3-methyl-phenyl)-3-[3-chloro-2-fluoro- Crude 5-(trifluoromethyl)phenyl]-4,4difluoro-3-hydroxyl-butan-1-one, which was purified by silica gel column chromatography (5% EtOAc in petroleum ether). To a stirred solution of 1 -(4-bromo-3-methyl-phenyl)-3-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-4,4difluoro-3- hydroxy-butan-1-one (1.0 g, 2.04 mmol) in dry DCM (10 mL) was added to pyridine (0.64 g, 8.16 mmol), followed by dropwise addition of SOCI2 (0.3 mL, 4 mmol) to 0 °C. The reaction mixture was stirred at 0°C for 1 h. The reaction was quenched with water (25 mL) and extracted with EtOAc (2x 20 mL). The combined organic layers were washed with brine (35 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain (Z)-1-(4-bromo-3-methyl-phenyl)-3-[3-chloro- 2-fluoro-5(trifluoromethyl)phenyl]-4,4-difluoro-but-2-en-1 -one, which was used in the next step without further purification. LC-MS (method B) Rt= 3.06 and 3.13 min, m / z= 469.0 [M-H]\ To a stirred solution of (Z)-1-(4-bromo-3-methyl-phenyl)-3-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-4,4difluoro-but-2- en-1-one (1.0 g, 2.12 mmol) in dry DCE (10 mL) was added with a solution of NH2OH (50% in water, 0.58 g, 8.48 mmol), followed by dropwise addition of DBU (0.645 g , 4.20 mmol) at 0°C. The reaction mixture was heated to rt over a period of 1 h. The reaction was quenched with water (30 mL) and extracted with EtOAc (2x 20 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude mixture was purified by silica gel column chromatography (2% EtOAc in petroleum ether) to obtain 3-(4-bromo-3-methyl-phenyl)-5-[3-chloro- 2-fluoro-5-(trifluoromethyl)phenyl]-5-(difluoromethyl)-4H-soxazole. LC-MS (method B) Rt= 2.66 min, m / z= 487.9 [M+H]+. A stirred solution of 3-(4-bromo-3-methyl-phenyl)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(difluoromethyl)-4H- isoxazole (0.80 g, 1.64 mmol) and NaOAc (0.27 g, 3.28 mmol) in anhydrous MeOH (10 mL) was degassed with N2 gas for 5 min and Pd(dppf)Cl2 (0.24 g, 0.32 mmol) was added. The reaction mixture was transferred to an autoclave and stirred at 100°C in an atmosphere of CO gas at 500 psi pressure for 20 h. The reaction mixture was filtered through a plug of Celite® and washed with MeOH (10 mL). The filtrate was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (50-90% EtOAc in petroleum ether) to obtain methyl 4-[5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl ]-5-(difluoromethyl)-4H-¡soxazol-3-¡l]-2-methyl-benzoate. LC-MS (method B) Rt= 2.56 min, m / z= 466.4 [M+H]+. To a solution of methyl 4-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(difluoromethyl)-4H-isoxazol-3yl]-2-methyl- benzoate (0.8 g, 1.71 mmol) in THF:water (1:1, 10 mL) was added to LYOH-H2O (0.288 g, 6.87 mmol) and the resulting mixture was stirred at 70°C for 6 h. The reaction mixture was concentrated under reduced pressure and the residue was diluted with 2.5 mL of water and acidified with HCl solution (1 M) to pH ~6. The aqueous layer was extracted with EtOAc (2x 50 mL) and the combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 4-[5-[3-chloro-2 acid. -fluoro-5-(trifluoromethyl)phenyl]-5-(difluoromethyl)-4H-soxazol-3-l]-2-methyl-benzoic. LCMS (method B) Rt= 2.30 min, m / z- 452.3 [M+H]+. To a solution of acid 4-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(difluoromethyl)-4H-soxazol3-yl]-2-methyl- Benzoic acid (0.2 g, 0.44 mmol) in dry DMF (3 mL) was added to DIPEA (0.193 mL, zcnacn / zznz / q / υιλι 1.10 mmol) and HATU (0.2 g, 0.53 mmol) and the resulting mixture was stirred at rt for 10 min. A solution of 2-amino-N-(2,2,2-trifluoroethyl)acetamide (0.083 g, 0.53 mmol) in dry DMF (1 mL) was added and the resulting reaction mixture was stirred for 4 p.m. to rt. The reaction mixture was quenched with cold water (10 mL) and extracted with EtOAc (2x 15 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude mixture was purified by silica gel column chromatography (30-70% EtOAc in petroleum ether) to obtain Example 5.1: (RS)-4-[5[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5-(difluoromethyl)-4H-soxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino) et¡l]benzam¡da. LC-MS (method B) Rt= 2.19 min, m / z= 590.2 [M+H]+. 1H-NMR (DMSOd6, 400 MHz) δ 8.65-8.58 (m, 2 H), 8.27 (dd, J= 6, 2 Hz, 1 H), 7.84 (dd, J= 6, 2 Hz, 1 H), 7.64-7.59 (m, 2 H), 7.49 (d, J= 8 Hz, 1 H), 6.54 (t, J= 54 Hz, 1 H), 4.18 (q, J= 18 Hz, 2 H), 4.0 -3.89 (m, 4 H), 2.40 (s, 3 H). Examples 6.1 and 6.2 4-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-6-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl) phenyl]5-(trifluoromethyl)-4H-isoxazol-3-yl]pyridazine-3-carboxamide 4-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-6-[(5S or R)-5-[3-chloro-2-fluoro -5-(trifluoromethyl)phen¡I]5-(trifluoromethyl)-4H-¡soxazol-3-¡l]pyr¡dazín-3-carboxamide In a 100 mL steel pump, a mixture of 3,6-dibromo-4-methylpyridazine (4.00 g, 15.9 mmol) and EtaN (6.69 mL, 47.6 mmol) in MeOH (40 mL) was degassed with N2gas for 10 min before adding Pd(dppf)CI2(1.16 g, 1.59 mmol). The reaction mixture was then heated to 65°C with CO gas pressure (~60 psi) for 16 h. The reaction mixture was passed through Celite®, while washing with EtOAc (2x 30 mL). The combined filtrates were concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (20% EtOAc in petroleum ether) to obtain methyl 6-bromo-5-methylpyridazin-3-carboxylate as a yellow solid. To a solution of methyl 6-bromo-5-methylpyridazin-3-carboxylate (3.30 g, 14.3 mmol) in MeOH (28 mL) and DCM (7 mL) was added NaBH4 (1.08 g, 28.6 mmol) in portions at 0°C and the resulting reaction mixture was stirred at rt for 3 h. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in EtOAc (50 mL). The organic layer was washed with aqueous HCl solution (0.1 M, 30 mL), brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-100% EtOAc in petroleum ether) to obtain (6-bromo-5-methylpyridazn-3-¡l)methanol as a yellow solid. LC-MS (method C) Rt= 0.99 min, m / z= 203.1 [M+H]+. To a stirred solution of (6-bromo-5-methylpyridazin-3-¡l)methanol (1.70 g, 8.37 mmol) in chloroform (30 mL) was added MnO2 (7.30 g, 83.7 mmol) in portions at 0°C. The reaction mixture was then allowed to warm to rt and stirred for 2 h. The reaction mixture was filtered through a Celite® pad, while washing with EtOAc (2 x 20 mL). The combined filtrates were concentrated under reduced pressure to obtain 6-bromo-5-methylpyridazin-3-carbaldehyde, which was used immediately in the next step without purification. LC-MS (method E) Rt= 1.08 min, m / z= 202.9 [M+H]+. To a stirred solution of 6-bromo-5-methylpyridazin-3-carbaldehyde (1.30 g, 6.47 mmol) in MeOH (6 mL) was added a solution of NH2OH (50% in water, 6 mL) and The resulting mixture was stirred at rt for 16 h. After this point, the reaction mixture was concentrated under reduced pressure. A saturated aqueous NaHCOs solution (2x 20 mL) was added and the mixture was extracted with EtOAc (3x 25 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SÜ4 and concentrated under reduced pressure. The crude compound was purified by silica gel column chromatography (10% EtOAc in petroleum ether) to obtain 6-bromo-5-methylpyridazin-3-carbaldehyde oxime as a brownish semisolid. LC-MS (method D) Rt= 1.12 min, m / z= 216.1 [M+H]+. To a stirred solution of 6-bromo-5-methylpyridazin-3-carbaldehyde oxime (315 mg, 1.46 mmol) in DMF (4 mL) was added NCS (253 mg, 1.90 mmol) at 0°C in an ice bath and the mixture was then stirred at 40°C for 30 min. The reaction was then cooled to 0°C in an ice bath and NEta (0.22 mL, 1.60 mmol) and 1-chloro-2-fluoro-5-(trifluoromethyl)-3-(3,3,3-trifluoroprop) were added. -1-en-2-yl)benzene (512 mg, 1.75 mmol) drip. The mixture was allowed to warm slowly to rt and stirred for 3 h. The reaction mixture was quenched by adding water (15 mL) and then extracted with EtOAc (3x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and then concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to obtain 3-(6-bromo-5-methyl-pyridazin-3-yl)-5-[3-chloro- 2fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazole as a brownish semisolid. LC-MS (method D) Rt= 2.66 min, m / z= 506.1 [M+H]+. In a 100 mL steel pump, a mixture of 3-(6-bromo-5-methyl-pyridazín-3-íl)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]- 5-(trifluoromethyl)-4H-isoxazole (200 mg, 395 mmol) in MeOH (10 mL) and EtsN (0.16 mL, 1.18 mmol) was degassed with N2 gas for 10 min before adding Pd(dppf)Cl2 (29.0 mg , 39.4 mmol). The reaction mixture was then heated to 70°C with CO gas pressure (−120 psi) in a pressure vessel for 16 h. The reaction mixture was filtered through Celite®, while washing with EtOAc (2x 20 mL). The combined filtrates were concentrated under reduced pressure. The crude compound was purified by silica gel column chromatography (20% EtOAc in petroleum ether) to obtain methyl 6-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4H-isoxazol-3yl]-4-methyl-pyridazine-3-carboxylate as a yellowish solid. LC-MS (method D) Rt= 2.52 min, m / z= 486.6 [M+H]+. To a stirred solution of methyl 6-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hísoxazol-3-yl]-4-methyl -pyridazine-3-carboxylate (67.0 mg, 138 mmol) in THF (1 mL) and water (1 mL), LiOH-HaO (17.3 mg, 414 mmol) was added and the resulting reaction mixture was stirred for 1 h to rt. Water (5 mL) was added and the reaction mixture was extracted with EtOAc (3x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 6-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-acid. 5-(trifluoromethyl)-4H-isoxazol-3-yl]4-methyl-pyridazín-3-carboxylic acid, which was used in the next step without further purification. LC-MS (5 G method) Rt= 2.00 min, m / z= 472.2 [M+H]+. To a stirred solution of 6-[5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-4-methyl-pyridazin acid -3-carboxylic acid (67 mg, 142 mmol) in DMF (2 mL) was added to HATL) (64.8 mg, 170 mmol) and the resulting reaction mixture was stirred for 10 min at rt. Then, 2amino-A / -(2,2,2-trifluoroethyl)acetamide-HCI (33.0 mg, 170 mmol) was added, followed by DIPEA (0.70 mL, 426 mmol), and the resulting mixture was stirred. for 2 h at rt. The reaction mixture was quenched by the addition of ice water (10 mL) and extracted with EtOAc (3x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-10% EtOAc in petroleum ether) to obtain the title compound. LC-MS (method D) Rt- 2.41 min, m / z- 610.5 [M+H]+.1H-NMR (DMSO-d6, 400 MHz) or 9.36 (s, 1 H), 8.36-8.34 (m, 1 H), 7.92-7.89 (m, 1 H), 7.69-7.62 (m, 2 H), 7.58 (d, J= 8.0 Hz, 1 H), 4.51 (d, J= 18 Hz, 1 H), 4.36 (d, J= 18 Hz, 1 H), 3.50-3.40 (m, 1 H), 3.20-3.09 (m, 1 H), 2.60-2.50 (m, 2 H), 2.35-2.22 (m, 2 H), 2.25 (s, 3 H). The two enantiomers were separated by SFC. The separation was performed in Chiralpak® AS-H with column dimensions of 250 mm x 30 mm (5 pm), a flow rate of 95.0 g / min and a CO2-based mobile phase with 15% MeOH containing 0.2 % A / ,A / -dimethylethylamine as additive to obtain Example 6.1: 4-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-6-[( 5R or S)-5-[3-chloro-2fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]pyridazin-3- carboxamide and Example 6.2: 4methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-6-[(5S or R)-5-[3-chloro-2-fluoro-5 -(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3-yl]pyridazine-3-carboxamide. Examples 7.1 and 7.2 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5R or S)-5-[3-chloro-2-fluoro-5-( trifluoromethyl)phenyl]5-(trifluoromethyl)-4H-isoxazol-3-yl]pyrazin-2-carboxamide and 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5S or R)-5-[3-chloro-2-fluoro -5-(trifluoromethyl)phen¡l]5-(trifluoromethyl)-4H-¡soxazol-3-¡l]pyrazín-2-carboxamide To a stirred solution of methyl 3-methylopyrazin-2-carboxylate (15 g, 98.6 mmol) in chloroform (300 mL) was added meta-chloroperbenzoic acid (34 g, 197 mmol) and the mixture was stirred at 80°C for 4 h. The mixture was allowed to cool to rt, diluted with DCM (200 mL) and washed with aqueous NaHCOs solution (2x 150 mL). The organic layer was washed with brine (150 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-100% EtOAc in petroleum ether) to obtain methyl 3-methyl-4-oxo-pyrazine-2-carboxylate. LCMS (method D) Rt= 0.81 min, m / z= 169.4 [M+H]+. To a stirred solution of methyl 3-methyl-4-oxo-pyrazine-2-carboxylate (11 g, 65.4 mmol) in DMF (110 mL) was added dropwise phosphoryl chloride (22 mL, 235 mmol) to 0°C, before heating the mixture to 120°C for 15 min. The reaction mixture was then cooled to rt, poured into ice water, and extracted with EtOAc (300 mL). The organic layer was washed with brine (4 x 100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-100% EtOAc in petroleum ether) to obtain a mixture of methyl 5-chloro-3-methyl-pyrazine-2-carboxylate and methyl 6-chloro-3- methyl-pyrazine-2-carboxylate. LC-MS (method D) Rt= 1.43 min, m / z= 186.9 [M+H]+. To a stirred solution of the isomer mixture (8.12 g, 43.5 mmol) in 1,4-dioxane (80 mL) was added 5 M NaOH (13.1 g) at rt and the mixture was stirred for 2 h and then concentrated to reduced pressure. The resulting residue was diluted with water (15 mL), acidified to pH ~2-3 with a 2 N aqueous HCl solution and extracted with EtOAc (2x100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a mixture of 5chloro-3-methyl-pyrazine-2-carboxylic acid and 6-chloro-3-methyl-pyrazine-2 acid. -carboxylic acid, which was used immediately in the next step without further purification. A stirred solution of mixture of carboxylic acid isomers (7.0 g, 40.6 mmol) and 2-aminoN-(2,2,2-trifluoroethyl)acetamide-HCI (8.40 g, 44.0 mmol) in DMF (70 mL) was added HATU (18.2 g, 48.0 mmol), followed by DIPEA (21.0 mL, 120 mmol) at rt. After 1 h, the reaction mixture was quenched by adding water (5 mL) and then extracted with EtOAc (100 mL). The organic layer was washed with brine (3 x 75 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-100% EtOAc in petroleum ether) to obtain a mixture of isomers: 5-chloro-3-methyl-N-[2-oxo-2-( 2,2,2trifluoroethylamino)ethyl]pyrazin-2-carboxamide and 6-chloro-3-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]pyrazin-2-carboxamide gives. LC-MS (method D) Rt= 1.40 / 1.44 min, m / z= 311.1 [M+H]+. To a stirred solution of 5-chloro-3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]pyrazin-2carboxamide (8.00 g, 26.0 mmol) in MeOH (160 mL) in an autoclave vessel, NEts (11.0 mL, 78.0 mmol) was added and the mixture was degassed with N2 gas for 15 min before adding 1,1'-bis(diphenylphosphino)ferrocene dichloride. ]palladium(ll) (1.88 g, 2.57 mmol). The reaction mixture was then heated at 80°C for 16 h in 150 psi CO gas. The mixture was allowed to cool to rt and filtered. The solids were washed with diethyl ether to obtain methyl 6-methyl-5-[[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]carbamoyl]pyrazine-2-carboxylate. LC-MS (method D) Rt= 1.99 min, m / z= 333.1 [M-H]. To a stirred solution of methyl 6-methyl-5-[[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]carbamoyl]pyrazin-287 carboxylate (1.30 g, 3.90 mmol) in THF (65 mL) in a N2 atmosphere, sodium borohydride (0.44 g, 12.0 mmol) was added portionwise at 0°C and the resulting mixture was stirred at rt for 3 h. The reaction was quenched by the addition of ice and extracted with EtOAc (2x 50 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ΟΙ 00% EtOAc in petroleum ether) to obtain 5-(hydroxymethyl)-3-methyl-N-[2-oxo-2-(2,2, 2trifluoroethylamino)ethyl]pyrazín-2-carboxamide. LC-MS (method D) Rt= 1.41 min, m / z= 307.1 [M+H]+. To a stirred solution of 5-(hydroxymethyl)-3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]pyrazine-2carboxamide (370 mg, 1.20 mmol) in DCM (20 mL ) Dess-Martin periodinane (750 mg, 1.80 mmol) was added and the mixture was stirred for 6 h at rt. The reaction mixture was diluted with DCM (30 mL) and washed with a saturated aqueous NaHCOs solution (2x 40 mL). The organic layer was concentrated under reduced pressure to obtain 5-formíl-3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]pyrazin- 2-carboxamide, which was used immediately in the next step without further purification. To a stirred solution of 5-formíl-3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]pyrazín-2carboxamide (500 mg, 1.63 mmol) in EtOH (10 mL) and water (5 mL), hydroxyammonium chloride (0.17 g, 2.40 mmol) and sodium acetate (200 mg, 2.44 mmol) were added at rt and the resulting mixture was stirred for 3 hrs. The mixture was concentrated under reduced pressure and the residue was diluted with water (10 mL) and extracted with EtOAc (2x 25 mL). The combined organic layers were washed with aqueous NaHCOs solution (30 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain 5-(hydroxyiminomethyl)-3-methyl-N-[2- oxo-2-(2,2,2-trifluoroethylamino)ethyl]pyrazin-2-carboxamide. LCMS (method D) Rt= 1.18 min, m / z= 318.2 [M-H]\ To a stirred solution of 5-(hydroxyiminomethyl)-3-methyl-N-[2-oxo-2-(2,2,210 trifluoroethylamino)ethyl]pyrazin-2-carboxamide (0.28 g , 0.88 mmol) in DMF (3 mL), N-chlorosuccinimide (152 mg, 1.14 mmol) was added at rt and the mixture was then heated to 40°C for 10 min. Then, the mixture was cooled to 0°C and 1-chloro-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene (0.29 g, 0.99 mmol) was added, followed by NEts (0.13 mL, 0.92 mmol): The reaction was stirred at rt for 16 h. Then, the reaction mixture was quenched by adding water (5 mL) and extracted with EtOAc (25 mL). The organic layer was washed with brine (3x10 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-100% EtOAc in petroleum ether) to obtain the title compound. LC-MS (method D) Rt= 2.51 min, m / z= 610.4 [M+H]+. 1H-NMR (DMSO-d6, 400 MHz) or 9.10-9.03 (m, 2 H), 8.65 (t, J= 6.0 Hz, 1 H), 8.40-8.35 (m, 1 H), 7.96-7.92 (m , 1 H), 4.49 (s, 2 H), 4.00-3.87 (m, 4 H), 2.82 (s, 3 H). The two enantiomers were separated by SFC. The separation was performed in DCPAK P4VP with column dimensions of 250 mm x 21 mm (5 pm), a flow rate of 60.0 g / min and a CO2-based mobile phase with 10% MeOH to obtain Example 7.1: 3-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]-5-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl] -5-(trifluoromethyl)-4H-isoxazol-3yl]pyrazine-2-carboxamide and Example 7.2: 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5- [(5S or R)-5-[3 zcnacn / zznz / q / υιλι chloro-2-fluoro-5-(trifluoromethyl)pheníl]-5-(trifluoromethyl)-4H-ísoxazol-3-yl ]pyrazin-2-carboxamide. Examples 8.1 and 8.2 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-bromo-2-fluoro-5 (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide and 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3-bromo-2-fluoro-5(trifluoromet ¡l)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide To a stirred solution of 2-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2dioxaborolane (1.3 g, 3.5 mmol) in THF (15 mL) and water (7.5 mL), dipotassium carbonate (1.02 g, 7.38 mmol) was added and the mixture was degassed with N2 gas for 10 min. 2-Bromo-3,3,3trifluoro-prop-1-ene (0.76 g, 4.3 mmol) and bis(triphenylphosphine)palladium(ll) dichloride (0.25 g, 0.36 mmol) were added and the Reaction mixture was heated at 80°C for 3 h. The mixture was then allowed to cool to rt and extracted with diethyl ether (2x10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 1-bromo-2-fluoro-5-(trifluoromethyl)3-[1-(trifluoromethyl)vin. ¡l]benzene as a brown liquid, which was used immediately in the next step without further purification. To a stirred solution of methyl 4-(hydroxyl iminomethyl)-2-methylbenzoate (500 mg, 2.59 mmol) in DMF (5 mL) was added N-chlorosuccinimide (0.45 g, 3.4 mmol) at rt and the mixture was heated at 40°C for 10 min. Then, the mixture was cooled to 0°C and 1-bromo-2-fluoro-5-(trifluoromethyl)-3-[1(thfluoromethyl)vinyl]benzene (1.05 g, 3.12 mmol) was added, followed by NEts (0.40 mL, 2.85 mmol), and the reaction was stirred at rt for 3 h. The reaction mixture was quenched by adding water (10 mL) and extracted with EtOAc (30 mL). The organic layer was washed with brine (3x15 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-20% EtOAc in petroleum ether) to obtain methyl 4-[5-[3-bromo-2-fluoro-5(thfluoromethyl)phen. l]-5-(trifluoromethyl)-4H-¡soxazol-3-¡l]-2-methyl-benzoate as a beige semisolid. LC-MS (method C) Rt= 2.78 min, m / z= 528.1 [M+H]+. To a stirred solution of methyl 4-[5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoate (500 mg, 0.9 mmol) in THF (5 mL) and water (5 mL), lithium hydroxide monohydrate (0.12 g, 2.9 mmol) was added at rt and the mixture was heated at 60°C for 16 h. The mixture was then allowed to cool to rt and the solvent was evaporated under reduced pressure. The residue was dissolved in water (5 mL), acidified to pH ~2-3 with HCl solution (1M) and extracted with EtOAc (2 x 25 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain 4-[5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5 acid. (trifluoromethyl)-4H-soxazol-3-yl]-2-methyl-benzoic acid as a beige solid. LC-MS (method F) Rt= 2.74 min, m / z= 514.3 [M+H]+. To a stirred solution of 4-[5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzoic acid (0.31 g, 0.60 mmol) and 2-amino-N-(2,2,2-trifluoroethyl)acetamide-HCI (0.14 g, 0.73 mmol) in DMF (5 mL) HATU (0.28 g, 0.74 mmol) was added, followed of DIPEA (0.32 mL, 1.8 mmol), at rt and the mixture was stirred for 2 h. The reaction mixture was quenched by the addition of water (5 mL) and extracted with EtOAc (3x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-50% EtOAc in petroleum ether) to obtain the title compound. LC-MS (method F) Rt= 2.66 min, m / z= 652.0 [M+H]+. 1H-NMR (DMSOde, 400 MHz) 5 8.65-8.58 (m, 2 H), 8.45-8.41 (m, 1 H), 7.96-7.91 (m, 1 H), 7.69-7.63 (m, 2 H), 7.49 (d, J7.6 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.39 (d, J= 18 Hz, 1 H), 4.00-3.89 (m, 4 H), 2.40 (s, 3 H). The two enantiomers were separated by SFC. The separation was performed in Chiralcel-OJ-H with column dimensions of 250 mm χ 30 mm (5 pm), a flow rate of 95.0 g / min and a CO2-based mobile phase with 10% / PrOH containing 0.2% Ν,Ν-isopropylamine as additive to obtain Example 8.1: 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamine)ethyl]-4-[(5R or S)-5-[3-bromo-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide and Example 8.2: 2-methyl-N-[2 -oxo-2(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5- (trifluoromethyl)-4Hisoxazol-3-yl]benzamide. zcnacn / zznz / q / υιλι The following compounds were prepared in an analogous manner with the methodology of Examples 8.1 and 8.2: Ex- Name Structure 8.3 2-methyl-N-[2-oxo-2-(2,2,2trlfluoroethylamino)ethyl]-4-[(5S 0 R)-5-[2,3-difluoro-5( trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-¡soxazol-3yl]benzamide F 8.4 2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]-4-[ (5R 0 S)-5-[2,3-difluoro-5(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3yl]benzamide F f f / C JL f yCuy \ II I f F 1 0 F 8.5 2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]-4-[(5R 0 S)-5-[3-bromo-5(trifluoromethyl)phenyl]-5 (trifluoromethyl)-4H-soxazol-3yljbenzamide fJ F F^v^'N f-L zVvL J lX h 0 - O H 8.6 2-methyl-N-[2-oxo-2-(2,2,2- trifluoroethylamino)et l]-4-[(5S 0 R)-5-[3-bromo-5- (trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-ísoxazol-3yljbenzamide LL LL ZI A rz )=o θχ . Λ m LL LL ( Γ LL Examples 9.1 and 9.2 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-(difluoromethyl)-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-soxazol-3-yl]benzamide and 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or (trifluoromethyl)phenyl]-5-(trifluoromethyl) l)-4H-isoxazol-3-¡l]benzamide R)-5-[3-(difluoromethyl)-2-fluoro-5- zcnacn / zznz / q / υιλι In a sealed tube, -bromo-3-(difluoromethyl)-2-fluoro-5-(trifluoromethyl)benzene (500 mg, 1.71 mmol), trifluoro-potassium-[1 -(trifluoromethyl)vinyl]boron (515 mg, 2.55 mmol), palladium(ll) acetate (0.020 g, 0.089 mmol), triphenylphosphine (0.053 g, 0.20 mmol ) and cesium carbonate (1.65 g, 5.08 mmol) were dissolved in THF (4 mL) and water (2 mL) in an N2 atmosphere. The sealed tube was closed and shaken at 80°C for 6 h. The reaction mixture was allowed to cool to rt and EtzO and water were added. The organic layer was separated and the solvent was evaporated under reduced pressure. The crude product (1-(difluoromethyl)-2 fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl)vinyl]benzene) was used in the next step without further purification. In an N2 atmosphere, methyl 4-[(E)-hydrox¡m¡nomethyl]-2-methyl-benzoate (200 mg, 1.03 mmol) and 1chloropyrro¡din-2,5-d¡one (0.413 g, 3.09 mmol) were mixed in dry DMF (5 mL). The reaction mixture was stirred at 40°C for 1 h. Then, the reaction mixture was cooled to 0°C in an ice bath and 1-(difluoromethyl)-2-fluoro-5-(trifluoromethyl)-3-[1-(trifluoromethyl) was added. crude vinyl]benzene (350 mg, 1.14 mmol) and NEts (0.15 mL). The resulting reaction mixture was stirred at rt for 12 h. Once the reaction was complete, ice was added and the mixture was extracted with Et20. The organic layer was separated and concentrated in vacuo. The crude product was purified by silica gel column chromatography (1% EtOAc in petroleum ether) to obtain methyl 4-[5-[3-(difluoromethyl)-2-fluoro-5-(tnfluoromethyl) )pheníl]-5(trifluoromethyl)-4H-isoxazol-3-íl]-2-methyl-benzoate. LC-MS (method D) Rt= 2.53 min, m / z= 500.2 [M+H]+. To a solution of methyl 4-[5-[3-(difluoromethyl)-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hísoxazol-3-yl]-2-methyl-benzoate ( 100 mg, 0.20 mmol) in THF (2 mL) and water (2 mL) was added to lithium hydroxide monohydrate (0.025 g, 0.60 mmol). The resulting mixture was stirred at 60°C for 6 h. After completion of the reaction, the solvents were evaporated under reduced pressure, and the aqueous layer was acidified to pH~ 3 by using an aqueous HCl solution (1 M). The precipitate was filtered and dried under vacuum to obtain 4-[5-[3-(d¡f]uoromethyl)-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazole3- acid. l]-2-methyl-benzoic acid. LC-MS (method D) Rt= 2.29 min, m / z= 484.2 [M-H]'. To a solution of 4-[5-[3-(difluoromethyl)-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-2-methyl-benzo acid co (0.085 g, 0.18 mmol) and HATU (100 mg, 263 pmol) in dry DMF (1 mL) at 0°C, a solution of 2-amino-N-(2,2,2-trifluoroeth ¡l)acetam¡de (0.050 g, 0.32 mmol) in dry DMF (1 mL). Then, DIPEA (0.1 mL, 0.6 mmol) was added and the resulting reaction mixture was stirred at rt for 4 h. The reaction mixture was quenched by the addition of ice water and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-100% EtOAc in petroleum ether) to obtain the title compound. LC-MS (method D) Rt= 2.23 min, m / z- 624.3 [M+H]+. 1H-NMR (DMSO-d6, 400 MHz) or 8.66-8.57 (m, 2 H), 8.26-8.23 (m, 1 H), 8.17-8.11 (m, 1 H), 7.69-7.64 (m, 2 H ), 7.49 (d, J= 7.6 Hz, 1 H), 7.36 (t, J= 53 Hz, 1 H), 4.59 (d, J= 18 Hz, 1 H), 4.37 (d, J= 18 Hz, 1 H), 4.00-3.88 (m, 4 H), 2.40 (s, 3 H). The two enantiomers were separated by SFC. The separation was carried out in Chiralcel OJ-H with column dimensions of 250 mm χ 21 mm (5 pm), a flow rate of 90.0 g / min and a CO2-based mobile phase with 8% MeOH to obtain the Example 9.1: 2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-(difluoromethyl)-2-fluoro-5 -(tnfluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]benzamide and Example 9.2: 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylam ¡no)ethyl]-4-[(5S or R)-5-[3(difluoromethyl)-2-fluoro-5-(trifluoromethyl)phen¡l]-5-( trifluoromethyl)-4H-soxazol-3-l]benzamide. zcnocn / zznz / q / υιλι The following compounds were prepared in an analogous manner with the methodology of the Examples 9.1 and 9.2: Ex. Name Structure 9.3 2-methyl-N-(1-methylsulfonylazetidin3-¡l)-4-[(5R or S)-5-[3- (difluoromethyl)-2-fluoro-5(trifluoromethyl)phenyl]-5 (trifluoromethyl)-4H-isoxazol-3yljbenzamide F F\ / O—N \ TI / F Z \ 7—F í T F 7=< ' ν^λ 0 )-F VN-sl F~ / '° 9.4 2-methyl-N -(1-methylsulfonylazetidin-3-íl)-4-[(5S or R)-5-[3- (difluoromethyl)-2-fluoro-5(trifluoromethyl)phenyl]-5(tnfluoromethyl)-4H-ísoxazole -3yljbenzamide O / / / z o / y-—2 I 5 LL l i 9.5 2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]-4-[(5R o S)-5 -[3,5-bls(difluoromethyl)-2fluoro-phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]benzamide F f f / 4 JL V Y A O \ II I F \ lo F Z~F F 9.6 2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3,5-bis(difluoromethyl)-2fluoro-phenyl] -5-(trifluoromethyl)-4Hisoxazol-3-yl]benzamide f4 / °^n Examples 10.1 and 10.2 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3,5-bis(difluoromethyl)phenyl]-5(trifluoromethyl)-4H-soxazol-3-yl]benzamide and 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3,5-bis(difluoromethyl)phenyl]-5( trifluoromethyl)-4H-isoxazol-3-yl]benzamide To a stirred solution of 5-bromobenzene-1,3-dicarbaldehyde (2.00 g, 9.4 mmol) in DCM (40 mL) was added dropwise DAST (6.2 g, 38 mmol) at 0°C, and the resulting mixture was stirred for 3 h at rt. The mixture was quenched by the addition of water at 0°C, and the aqueous layer was separated and extracted with DCM (3x). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (100% petroleum ether) to obtain 1-bromo-3,5-bis(difluoromethyl)benzene. A mixture of 1-bromo-3,5-bis(difluoromethyl)benzene (1.2 g, 4.7 mmol) and trifluoro-potassium-[1(trifluoromethyl)vinyl]boron (1.44 g, 7.09 mmol) in THF (6 mL ) and water (3 mL) was degassed in a Na atmosphere for 10 min. Then, palladium acetate (168 mg, 1.02 mmol), triphenylphosphine (156 mg, 595 pmol), and CS2CO3 (3.72 g, 11.4 mmol) were added, and the reaction mixture was stirred for 24 h at 80 °C. The mixture was inactivated by adding water. The aqueous layer was separated and extracted with diethyl ether, and the solvent was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (100% petroleum ether) to obtain 1,3-bis(difluoromethyl)-5-[1(tnfluoromethyl)vinyl] benzene. To a stirred solution of methyl 4-[(E)-hydrox¡minomethyl]benzoate (465 mg, 2.60 mmol) in DMF (2.0 mL) was added NCS (0.36 g, 2.7 mmol) and the mixture was heated at 40°C for 10 min. Then, the reaction mixture was cooled to 0°C and a solution of 1,3-bis(difluoromethyl)-5-[1(trifluoromethyl)vinyl]benzene (0.75 g, 2.8 mmol) and NEts (0.3 mL) in DMF (1 mL). The resulting mixture was stirred for 3 h at rt. The reaction was quenched by the addition of water, and the aqueous layer was separated and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (0-100% EtOAc in petroleum ether) to obtain methyl 4-[5[3,5-bis(difluoromethyl)phenyl]- 5-(trifluoromethyl)-4H-soxazol-3-l]-2-methylbenzoate. LC-MS (method D) Rt= 2.37 min, m / z= 464.18 [M+H]+. A mixture of ethyl 4-[5-[3,5-bis(difluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methylbenzoate (0.3 g, 0.6 mmol) and LiOH (81.0 mg, 3.4 mmol) in 1,4-dioxane (5.0 mL) and water (5.0 mL) was heated overnight at 90°C. Then, the reaction mixture was reduced under reduced pressure and acidified by adding HCl solution (1 M). The aqueous layer was extracted with 5% MeOH-DCM solution (3x). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was used in the next step without further purification. LC-MS (method D) Rt= 2.47 min, m / z= 450.29 [M+H]+. A mixture of 4-[5-[3,5-bis(difluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methylbenzoic acid (246 mg, 548 pmol), 1-amino -3-(trifluoromethylamino)propan-2-one-HCI (164 mg, 1.05 mmol), HATU (317 mg, 834 pmol) and DIPEA (351 pL, 2.0 mmol) in DMF (4.0 mL) were stirred at rt for 2 h. Once the reaction was complete, the mixture was quenched with water and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by silica gel column chromatography (0-10% EtOAc in petroleum ether) to obtain the title compound. LC-MS (method D) Rt= 2.08 min, m / z= 588.28 [M+H]+. 1H-NMR (DMSO-d6, 400 MHz) or 8.64-8.57 (m, 2 H), 7.98 (s, 2 H), 7.93 (s, 1 H), 7.66-7.60 (m, 2 H), 7.49 ( d, J= 8.4 Hz, 1 H), 7.23 (t, J= 55 Hz, 2 H), 4.50 (d, J= 18 Hz, 1 H), 4.29 (d, J= 18 Hz, 1 H), 3.99-3.88 (m, 4 H), 2.40 (s, 3 H). The two enantiomers were separated by SFC. The separation was carried out in Chiralcel OJ-H with column dimensions of 250 mm χ 21 mm (5 pm), a flow rate of 60.0 g / min and a mobile phase based on CO2 with 10% MeOH to obtain Example 10.1 : 2-methyl-N-[2-oxo-2-(2,2,2trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3,5-b¡s(d¡ fluoromethyl)phenyl]-5-(trifluoromethyl)-4H-soxazol-3-l]benzamide and Example 10.2: 2-methyl-N-[2-oxo-2-(2 ,2,2-trifluoroethilano)ethyl]-4-[(5S or R)-5-[3,5-bis(difluoromethyl)phen¡I]5-(trifluoromethyl)- 4H-¡soxazol-3-¡l]benzamide. zcnocn / zznz / q / υιλι Experimental details for the compounds in the tables: Ex. HPLC NMR 3.3 Rt= 1.44 min, m / z= 634.0 [Μ- Η]' / method A 1H-NMR (CDCh, 400 MHz) or 8.03 (dd, J= 1.6, 6 Hz, 1 H), 7.81 (dd, J= 2, 6 Hz, 1 H), 7.49-7.57 (m, 3 H), 6.38 (d, J= 4.4 Hz, 1 H), 4.92-5.05 (m, 2 H), 4.07-4.30 (m, 4 H), 3.84-3.88 (m, 1 H), 2.50 (s, 3 H) 3.4 Rt= 1.44 min, m / z= 634.0 [ΜΗ]' / method A 1H-NMR (CDCh, 400 MHz ) or 8.03 (dd, J= 1.6, 6 Hz, 1 H), 7.81 (dd, J= 2, 6 Hz, 1 H), 7.49-7.57 (m, 3 H), 6.38 (d, J= 4.4 Hz , 1 H), 4.92-5.05 (m, 2 H), 4.07-4.30 (m, 4 H), 3.84-3.88 (m, 1 H), 2.50 (s, 3 H) 3.5 Rt= 1.41 min, m / z= 634.1 [M+H]+ / method A 1H-NMR (CDCI3, 400 MHz) or 8.04 (dd, J= 1.6, 5.6 Hz, 1 H), 7.80 (dd, J= 2, 6 Hz, 1 H ), 7.49-7.56 (m, 3 H), 6.33 (d, J= 5.2 Hz, 1 H), 4.56-4.63 (m, 1 H), 4.02-4.23 (m, 2 H), 3.80-3.90 (m , 2 H), 3.54-3.64 (m, 2 H), 2.90-2.99 (m, 1 H), 2.51 (s, 3 H) 3.6 Rt= 1.41 min, m / z= 634.1 [M+H]+ / method A 1H-NMR (CDCI3, 400 MHz) 5 8.04 (dd, J= 1.6, 5.6 Hz, 1 H), 7.80 (dd, J= 2, 6 Hz, 1 H), 7.49-7.56 (m, 3 H ), 6.33 (d, J= 5.2 Hz, 1 H), 4.56-4.63 (m, 1 H), 4.02-4.23 (m, 2 H), 3.80-3.90 (m, 2 H), 3.54-3.64 (m , 2 H), 2.90-2.99 (m, 1 H), 2.51 (s, 3 H) 3.7 Rt= 1.43 min, m / z= 636.0 1H-NMR (CDCIs, 400 MHz) 5 8.04 (dd, J= 2 , 6 Hz, 1 H), 8.04 (dd, J= 2, 6 Hz, 1 H), 7.50-7.57 (m, 3 H), 6.37 (d, J= 4 Hz, 1 H), [M+H]+ / method A 5.03 (t, J= 8 Hz, 1 H), 4.92-4.98 (m, 1 H), 4.07-4.31 (m, 4 H), 3.84-3.89 (m, 1 H ), 2.5 (s, 3 H) 3.8 Rt= 2.30 min, m / z= 578.1 [ΜΗ]' / method C 1H-NMR (DMSO-d6, 400 MHz) 5 8.51 (d, J= 8.52 Hz, 1 H ), 8.36 (dd, J= 6.0, 1.6 Hz, 1 H), 7.96 (t, J= 5.6 Hz, 1 H), 7.92-7.90 (m, 1 H), 7.68-7.62 (m, 3 H), 7.50 (d, J= 7.6 Hz, 1 H), 4.57 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 3.84 (d, J= 6.0 Hz, 2 H ), 2.99 (t, J= 6.0 Hz, 1 H), 2.40 (s, 3 H), 0.96-0.85 (m, 1 H), 0.44-0.38 (m, 2 H), 0.20-0.14 (m, 2 H) 3.10 Rt= 2.87 min, m / z= 654.2 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.75-8.49 (m, 1 H), 8.39-8.32 (m, 1 H), 7.91-7.85 (m, 1 H), 7.51-7.37 (m, 1 H), 4.63-4.32 (m, 3 H), 4.10-3.39 (m, 4 H), 2.34-2.08 (m, 4 H), 1.96-1.70 (m, 3 H) 3.11 Rt= 2.87 min, m / z= 654.3 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.75-8.48 (m , 1 H), 8.39-8.33 (m, 1 H), 7.91-7.84 (m, 1 H), 7.52-7.37 (m, 1 H), 4.65-4.30 (m, 3 H), 4.10-3.39 (m , 4 H), 2.35-2.08 (m, 4 H), 1.95-1.70 (m, 3 H) 3.12 Rt= 2.37 min, m / z= 638.1 [ΜΗ]- / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.55 (d, J= 8.4 Hz, 1 H), 8.398.33 (m, 1 H), 7.91-7.85 (m, 1 H), 7.50 (s, 1 H), 4.65-4.52 (m , 3 H), 4.41 (d, J= 18 Hz, 1 H), 4.17-3.98 (m, 2 H), 3.51-3.42 (m, 1 H), 2.42 (s, 3 H), 2.42-2.30 ( m, 1 H), 2.11-2.00 (m, 1 H) 3.13 Rt= 2.83 min, m / z= 552.2 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 10.5 (s , 1 H), 8.48 (dd, J= 4.8, 1.2 Hz, 2 H), 8.41-8.35 (m, 1 H), 7.92-7.87 (m, 1 H), 7.69 (dd, J= 4.8, 1.6 Hz , 2 H), 7.59 (s, 1 H), 4.60 (dd, J= 18, 4.8 Hz, 1 H), 4.45 (d, J= 17 Hz, 1 H), 2.46 (s, 3 H) 3.14 Rt = 2.66 min, m / z= 539.2 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 8.38-8.32 (m, 1 H), 7.93-7.88 (m, 1 H), 7.69 (s, 1 H), 7.67-7.61 (m, 1 H), 7.34-7.27 (m, 1 H), 4.98 (dd, J= 18, 3.6 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.43-4.18 (m, 2 H), 3.59-3.38 (m, 2 H), 3.24-3.15 (m, 1 H), 3.11-2.82 (m, 1 H), 2.26 (s, 3 H), 1.99-1.70 (m, 2 H) 3.15 Rt= 2.70 min, m / z= 592.4 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.59 (d, J = 8.8 Hz, 1 H), 8.388.34 (m, 1 H), 7.93-7.88 (m, 1 H), 7.68-7.61 (m, 2 H), 7.41 (d, J= 7.6 Hz, 1 H) , 4.62-4.52 (m, 2 H), 4.40 (d, J= 18 Hz, 1 H), 3.263.18 (m, 2 H), 2.72-2.65 (m, 1 H), 2.40 (s, 3 H ), 2.32-2.26 (m, 1 H), 1.93-1.79 (m, 1 H), 0.72-0.63 (m, 4 H) 3.16 Rt= 2.78 min, m / z= 548.23 1H-NMR (DMSO-d6, 400 MHz) δ 8.78 (d, J= 7.2 Hz, 1 H), 8.38- 8.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.44 (d , J= 7cnQcn / 77n7 / q / υιλι [M+H]+ / method E 8.0 Hz, 1 H), 4.65-4.51 (m, 2 H), 4.40 (d, J= 18 Hz, 1 H), 3.403.30 (m, 1 H), 2.67 -2.54 (m, 2 H), 2.48-2.38 (m, 2 H), 2.36 (s, 3 H) 3.17 Rt= 2.78 min, m / z= 548.3 [M+H]+ / method E 1H-NMR ( DMSO-d6, 400 MHz) δ 8.77 (d, J= 7.2 Hz, 1 H), 8.388.34 (m, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H) , 7.44 (d, J= 8.0 Hz, 1 H), 4.65-4.52 (m, 2 H), 4.40 (d, J= 18 Hz, 1 H), 3.393.30 (m, 1 H), 2.68-2.54 (m, 2 H), 2.49-2.39 (m, 2 H), 2.36 (s, 3 H) 3.18 Rt= 2.52 min, m / z= 632.2 [M+H]+ / method C 1H-NMR (DMSO- d6, 400 MHz) 5 9.38 (t, J= 6.0 Hz, 1 H), 8.468.43 (m, 1 H), 8.38-8.34 (m, 1 H), 7.93-7.88 (m, 1 H), 7.72 -7.66 (m, 2 H), 7.50 (d, J= 8.0 Hz, 1 H), 4.76 (d, J= 6.0 Hz, 2 H), 4.58 (dd, J= 18, 2.0 Hz, 1 H), 4.41 (d, J= 18 Hz, 1 H), 2.41 (s, 3 H) 3.19 Rt= 2.80 min, m / z= 548.3 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz ) δ 8.72 (d, J= 8.0 Hz, 1 H), 8.398.33 (m, 1 H), 7.94-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.44 (d, J = 8.0 Hz, 1 H), 4.57 (dd, J= 19, 2.4 Hz, 1 H), 4.46-4.35 (m, 2 H), 3.14-3.03 (m, 1 H), 2.73-2.62 (m, 2 H), 2.41-2.30 (m, 5 H) 3.20 Rt= 2.80 min, m / z= 548.2 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.72 (d, J= 7.6 Hz, 1 H), 8.398.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.44 (d, J= 7.6 Hz, 1 H), 4.57 (dd, J= 18, 2.4 Hz, 1 H), 4.47-4.35 (m, 2 H), 3.14-3.04 (m, 1 H), 2.74-2.63 (m, 2 H), 2.42-2.28 (m , 5 H) 3.21 Rt= 2.54 min, m / z= 552.3 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.55 (d, J= 8.4 Hz, 1 H), 8.398 .33 (m, 1 H), 7.94-7.88 (m, 1 H), 7.85 (s, 1 H), 7.68-7.63 (m, 2 H), 7.42 (d, J= 7.6 Hz, 1 H), 4.62-4.45 (m, 2 H), 4.40 (d, J= 18 Hz, 1 H), 3.27-3.18 (m, 2 H), 2.40 (s, 3 H), 2.39-2.30 (m, 1 H) , 2.03-1.90 (m, 1 H) 3.22 Rt= 2.54 min, m / z= 552.3 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.55 (d, J= 8.4 Hz , 1 H), 8.388.34 (m, 1 H), 7.94-7.88 (m, 1 H), 7.84 (s, 1 H), 7.68-7.63 (m, 2 H), 7.42 (d, J= 7.6 Hz, 1 H), 4.60-4.46 (m, 2 H), 4.40 (d, J= 18 Hz, 1 H), 3.26-3.19 (m, 2 H), 2.40 (s, 3 H), 2.39-2.30 (m, 1 H), 2.04-1.90 (m, 1 H) 3.23 Rt= 2.38 min, m / z= 591.1 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 9.38 ( t, J= 5.6 Hz, 1 H), 8.81 (s, 1 H), 8.39-8.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.73-7.65 (m, 2 H), 7.50 (m, 1 H), 4.75 (d, J= 6.0 Hz, 2 H), 4.58 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 2.41 (s, 3 H) 3.24 Rt= 2.15 min, m / z= 602.0 1H-NMR (DMSO-d6, 400 MHz) δ 10.50 (d, J= 10 Hz, 2 H), 8.36 (d, J= 4.4 Hz, 1 H), 7.91 (d, J= 3.6 Hz, 1 H), 7.67-7.71 8M, 2 h), 7cnQcn / 77n7 / q / υιλι [M+H]+ / method D 7.48 (d, J= 8 Hz, 1 H), 4.39-4.61 (m, 2 H), 4.23 (s, 2 H), 3.17 (s, 3 H), 2.42 ( s, 3H) 3.25 Rt= 2.58 min, m / z= 551.1 [M+H? / method D 1H-NMR (DMSO-d6, 400 MHz) δ 10.13 (s, 1 H), 8.36 (d, J= 4 Hz, 1 H), 7.91 (d, J= 3.6 Hz, 1 H), 7.66 -7.69 (m, 2 H), 7.45 (d, J= 8 Hz, 1 H), 6.88 (s, 1 H), 4.38-4.60 (m, 2 H), 3.61 (t, J= 7.6 Hz, 1 H), 3.31 (m, 2 H), 2.41 (s, 3 H) 3.26 Rt= 2.32 min, m / z= 635.1 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 10.38 (s, 1 H), 8.36 (d, J= 4 Hz, 1 H), 7.91 (d, J= 4 Hz, 1 H), 7.65-7.73 (m, 2 H), 7.47 (d, J= 8 Hz, 1 H), 4.57 (d, J= 19 Hz, 1 H), 4.41 (d, J= 18 Hz, 1 H), 4.00 (q, J= 9.6 Hz, 2 H), 3.61-3.68 ( m, 2 H), 3.55-3.61 (m, 2 H), 2.42 (s, 3 H) 3.27 Rt= 2.69 min, m / z= 591.3 [M+H]+ / method E 1H-NMR (DMSO-d6 , 400 MHz) δ 8.71 (d, J= 8.4 Hz, 1 H), 8.398.33 (m, 1 H), 7.94-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.43 ( d, J= 8.0 Hz, 1 H), 4.66-4.52 (m, 2 H), 4.49-4.37 (m, 3 H), 3.49-3.35 (m, 2 H), 2.47-2.32 (m, 4 H) , 2.09-1.83 (m, 1 H) 3.28 Rt= 3.09 min, m / z= 590.9 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.71 (d, J= 8.4 Hz , 1 H), 8.36 (dd, J= 2, 6 Hz, 1 H), 7.91 (dd, J= 1.6, 4 Hz, 1 H), 7.65-7.67 (m, 2 H), 7.42 (d, J = 7.6 Hz, 1 H), 4.54-4.64 (m, 2 H), 4.37-4.47 (m, 3 H), 3.39-3.48 (m, 2 H), 2.4 (m, 4 H), 1.96-2.07 ( m, 1 H) 3.29 Rt= 2.69 min, m / z= 591.3 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.70 (d, J= 8.4 Hz, 1 H), 8.398.33 (m, 1 H), 7.94-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.42 (d, J= 8.0 Hz, 1 H), 4.66-4.52 (m, 2 H), 4.49-4.37 (m, 3 H), 3.49-3.35 (m, 2 H), 2.48-2.32 (m, 4 H), 2.09-1.83 (m, 1 H) 3.30 Rt= 3.11 min, m / z= 591.0 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) δ 8.71 (d, J= 8.8 Hz, 1 H), 8.36 (dd, J= 2, 6 Hz, 1 H ), 7.91 (dd, J= 1.6, 4 Hz, 1 H), 7.65-7.67 (m, 2 H), 7.42 (d, J= 7.6 Hz, 1 H), 4.54-4.64 (m, 2 H), 4.37-4.47 (m, 3 H), 3.39-3.48 (m, 2 H), 2.4 (m, 4 H), 1.96-2.07 (m, 1 H) 3.31 Rt= 2.53 min, m / z= 640.2 [M +H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 9.18 (t, J= 6.0 Hz, 1 H), 8.42 (s, 1 H), 8.39-8.33 (m, 1 H), 7.91-7.86 (m, 1 H), 7.53 (s, 1 H), 4.74 (d, J= 6.0 Hz, 2 H), 4.57 (d, J= 18 Hz, 1 H), 4.41 (d, J= 18 Hz, 1 H), 2.45 (s, 3 H) 3.32 Rt= 2.42 min, m / z= 595.2 [ΜΗ]' / method C 1H-NMR (DMSO-d6, 400 MHz) δ 9.17 (t, J= 6.0 Hz, 1 H), 8.79 (s, 1 H), 8.39-8.33 (m, 1 H), 7.91-7.86 (m, 1 H), 7.53 (s, 1 H), 4.72 (d, J= 5.6 Hz, 2 H), 4.57 (d, J= 18 Hz, 1 H), 4.41 (d, J= 18 Hz, 1 H), 2.44 (s, 3 H) 3.33 Rt= 2.25 min, 1H-NMR (DMSO -d6, 400 MHz) δ 8.60 (d, J= 8.8 H, 1 H), 8.39- 7cnQcn / 77n7 / q / υιλι m / z= 578.1 [ΜΗ]' / method C 8.32 (m, 1 H), 7.93-7.88 (m, 1 H), 7.68-7.61 (m, 2 H), 7.42 (d, J= 7.6 Hz, 1 H), 4.62-4.52 (m, 2 H), 4.40 (d, J= 18 Hz, 1 H), 3.353.15 (m, 4 H), 2.40 (s, 3 H), 2.39-2.30 (m, 1 H), 1.96-1.86 (m, 1 H), 1.05 (t, J= 7.2 Hz, 3H) 3.34 Rt= 2.29 min, m / z= 602.1 [M+H]+ / method B 1H-NMR (DMSO -d6, 400 MHz) δ 9.03 (d, J= 6.8Hz, 1 H), 8.37 (dd, J= 1.6, 6 Hz, 1 H), 7.90 (d, J= 3.6 Hz, 1 H), 7.66- 7.68 (m, 2 H), 7.49 (d, J= 8 Hz, 1 H), 4.38-4.69 (m, 3 H), 4.13 (t, J= 8 Hz, 2 H), 3.87-3.91 (m, 2 H), 3.03 (s, 3 H), 2.38 (s, 3 H) 3.35 Rt= 2.29 min, m / z= 602.1 [M+H]+ / method B 1H-NMR (DMSO-d6, 400 MHz) δ 9.03 (d, J= 6.8Hz, 1 H), 8.37 (dd, J= 1.6, 6 Hz, 1 H), 7.90 (d, J= 3.6 Hz, 1 H), 7.66-7.68 (m, 2 H ), 7.49 (d, J= 8 Hz, 1 H), 4.38-4.69 (m, 3 H), 4.13 (t, J= 8 Hz, 2 H), 3.87-3.91 (m, 2 H), 3.03 ( s, 3 H), 2.38 (s, 3 H) 3.36 Rt= 2.28 min, m / z= 592.2 [M+H]+ / method B 1H-NMR (DMSO-d6, 400 MHz) δ 9.02 (d, J = 6.8Hz, 1 H), 8.37 (dd, J= 2, 6 Hz, 1 H), 7.90 (d, J= 4.4 Hz, 1 H), 7.65-7.68 (m, 2 H), 7.50 (d, J= 7.6 Hz, 1 H), 4.68-4.71 (m, 1 H), 4.53-4.61 (m, 2 H), 4.39-4.53 (m, 1 H), 4.16-4.34 (m, 2 H), 3.84 -3.86 (m, 1 H), 2.39 (s, 3 H), 1.53-1.57 (m, 1 H), 0.69-0.77 (m, 4 H) 3.37 Rt= 2.28 min, m / z= 592.2 [M+ H]+ / method B 1H-NMR (DMSO-d6, 400 MHz) δ 9.02 (d, J= 6.8Hz, 1 H), 8.37 (dd, J= 2, 6 Hz, 1 H), 7.90 (d, J= 4.4 Hz, 1 H), 7.65-7.68 (m, 2 H), 7.50 (d, J= 7.6 Hz, 1 H), 4.68-4.71 (m, 1 H), 4.53-4.61 (m, 2 H) ), 4.39-4.53 (m, 1 H), 4.16-4.34 (m, 2 H), 3.84-3.86 (m, 1 H), 2.39 (s, 3 H), 1.53-1.57 (m, 1 H), 0.69-0.77 (m, 4 H) 3.38 Rt= 5.45 min, m / z= 591.3 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.78 (d, J= 7 Hz, 1 H), 8.36 (dd, J= 6, 2 Hz, 1 H), 7.91 (d, 6 Hz, 1 H), 7.68-7.63 (m, 2 H), 7.44 (d, J= 7 Hz, 1 H), 4.52 (d, J= 18 Hz, 1 H), 4.52-4.45 (m, 1 H), 4.40 (d, J= 18 Hz, 1 H), 3.18-3.05 (m, 1 H), 2.48 -2.31 (m, 7 H) 3.39 Rt= 2.51 min, m / z= 591.3 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 8.78 (d, J= 7 Hz, 1 H), 8.36 (dd, J= 6, 2 Hz, 1 H), 7.91 (d, 6 Hz, 1 H), 7.68-7.62 (m, 2 H), 7.44 (d, J= 7 Hz, 1 H ), 4.52 (d, J= 18 Hz, 1 H), 4.52-4.45 (m, 1 H), 4.40 (d, J= 18 Hz, 1 H), 3.17-3.05 (m, 1 H), 2.48- 2.31 (m, 7 H) 3.40 Rt= 2.49 min, m / z= 607.7 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 8.84 (d, J= 6.8 Hz, 1 H ), 8.36 (dd, J= 1.6, 6.8 Hz, 1 H), 7.91 (dd, J= 2, 5.6 Hz, 1 H), 7.64-7.67 (m, 2 H), 7.44 (d, J= 8 Hz , 1 H), 4.37-4.54 (m, 3 H), 3.73 (t, J= 12 Hz, 2 H), 3.17-3.26 (m, 4 H), 2.36 (s, 3 H) 7cnQcn / 77n7 / q / υιλι 3.41 Rt= 2.49 min, m / z= 607.7 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 8.84 (d, J= 6.8 Hz, 1 H), 8.36 (dd, J = 1.6, 6.8 Hz, 1 H), 7.91 (dd, J= 2, 5.6 Hz, 1 H), 7.64-7.67 (m, 2 H), 7.44 (d, J= 8 Hz, 1 H), 4.37- 4.54 (m, 3 H), 3.73 (t, J= 7.2 Hz, 2 H), 3.17-3.26 (m, 4 H), 2.36 (s, 3 H) 3.42 Rt= 2.49 min, m / z= 617.4 [ M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) <5 10.56 (s, 1 H), 8.36-8.37 (m, 1 H), 8.22 (s, 1 H), 7.91-7.92 (m, 1 H), 7.69-7.72 (m, 2 H), 7.64 (s, 1 H), 7.57 (d, J= 8 Hz, 1 H), 5.13 (q, J= 8.8 Hz, 2 H) , 4.58 (d, J= 18 Hz, 1 H), 4.42 (d, J= 18 Hz, 1 H), 2.42 (s, 3 H) 3.43 Rt= 2.66 min, m / z= 525.3 [M+H] + / method C 1H-NMR (DMSO-d6, 400 MHz) δ 9.09 (d, J= 6.4 Hz, 1 H), 8.36 (d, J= 4.8 Hz, 1 H), 7.91 (d, J= 4.4 Hz , 1 H), 7.65-7.68 (m, 2 H), 7.47 (d, J= 8 Hz, 1 H), 4.95-5.01 (sextuplet, J)=6.8 Hz, 1 H), 4.78 (t, J= Hz, 2 H), 4.53-4.59 (m, 3 H), 4.38-4.42 (d, J= 18 Hz, 1 H), 2.37 (s, 3 H) 3.44 Rt= 2.66 min, m / z= 525.3 [ M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 9.09 (d, J= 6.4 Hz, 1 H), 8.36 (d, J= 4.8 Hz, 1 H), 7.91 (d, J= 4.4 Hz, 1 H), 7.65-7.68 (m, 2 H), 7.47 (d, J= 8 Hz, 1 H), 4.95-5.01 (sextuplet, J= 6.8 Hz, 1 H), 4.78 (t , J= Hz, 2 H), 4.53-4.59 (m, 3 H), 4.38-4.42 (d, J= 18 Hz, 1 H), 2.37 (s, 3 H) 3.45 Rt= 2.62 min, m / z = 608.4 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 9.08 (d, J=6.8 Hz, 1 H), 8.82 (s, 1 H), 8.39-8.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.70-7.63 (m, 2 H), 7.50 (d, J= 7.6 Hz, 1 H), 4.94-4.88 (m, 1 H), 4.57 (dd , J= 18, 2.0 Hz, 1 H), 4.45-4.35 (m, 3 H), 4.10-4.02 (m, 2 H), 2.39 (s, 3 H) 3.46 Rt= 2.62 min, m / z= 608.4 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 9.08 (d, J= 7.0 Hz, 1 H), 8.82 (s, 1 H), 8.39-8.33 (m, 1 H ), 7.93-7.88 (m, 1 H), 7.70-7.63 (m, 2 H), 7.50 (d, J= 7.8 Hz, 1 H), 4.94-4.88 (m, 1 H), 4.57 (dd, J = 18 Hz, 1 H), 4.45-4.35 (m, 3 H), 4.10-4.02 (m, 2 H), 2.39 (s, 3 H) 3.47 Rt= 3.22 min, m / z= 553.5 [M+H ]+ / method F 1H-NMR (DMSO-d6, 400 MHz) δ 8.57 (d, J= 7.2 Hz, 1 H), 8.37 (dd, J=6.0, 2.0 Hz, 1 H), 7.91 (dd, J = 5.6, 1.6 Hz, 1 H), 7.68-7.61 (m, 2 H), 7.41 (d, J= 8.0 Hz, 1 H), 4.56 (dd, J= 18, 2.0 Hz, 1 H), 4.38 ( d, J=18Hz, 1 H), 4.44-3.91 (m, 1 H), 3.61 (quint., J= 7.2 Hz, 1 H), 3.13 (s, 3 H), 2.65-2.55 (m, 2 H ), 2.36 (s, 3 H), 1.93-1.81 (m, 2 H) 3.48 Rt= 3.79 min, m / z- 560.4 [M+H]+ / 1H-NMR (DMSO-d6, 400 MHz) δ 9.14 (s, 1 H), 8.36 (dd, J= 6.0, 2.0 Hz, 1 H), 7.90 (dd, J= 5.6, 2.0 Hz, 1 H), 7.66 (s, 1 H), 7.63 (d, J = 8.4 Hz, 1 H), 7.41 (d, J= 8.0 Hz, 1 H), 4.56 (dd, 7cnQcn / 77n7 / q / υιλι 100 method F J= 18, 2.0 Hz, 1 H), 4.38 (J= 18 Hz, 1 H), 2.565 (s, 6 H), 2.36 (s, 3 H) 3.49 Rt= 3.55 min, m / z= 601.2 [ M+H? / method F 1H-NMR (DMSO-d6, 400 MHz) δ 8.82 (d, J= 7.2 Hz, 1 H), 8.398.34 (m, 1 H), 7.94-7.89 (m, 1 H), 7.66 ( s, 1 H), 7.64 (d, J= 8.4 Hz, 1 H), 7.43 (d, J= 8.0 Hz, 1 H), 4.56 (dd, J= 18, 2.0 Hz, 1 H), 4.44-4.32 (m, 2 H), 3.76 (quint., J= 8.0 Hz, 1 H), 2.90 (s, 3 H), 2.65-2.55 (m, 2 H), 2.39-2.30 (m, 5 H) 3.50 Rt = 3.27 min, m / z= 541.3 [M+H]+ / method F 1H-NMR (DMSO-d6, 400 MHz) δ 8.65 (d, J= 7.6 Hz, 1 H), 8.398.33 (m, 1 H), 7.94-7.88 (m, 1 H), 7.68-7.62 (m, 2 H), 7.43 (d, J= 7.6 Hz, 1 H), 4.95-4.75 (m, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 3.95 (q, J= 7.6 Hz, 1 H), 2.80-2.65 (m, 2 H), 2.36 (s, 3 H), 2.25-2.12 (m, 2 H) 3.51 Rt= 3.67 min, m / z= 541.4 [M+H]+ / method F 1H-NMR (DMSO-d6, 400 MHz) δ 8.99 (d, J= 7.6 Hz, 1 H), 8.398.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.44 (d, J= 8.0 Hz, 1 H), 5.25-5.10 (m, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.40 (d, J=18Hz, 1 H), 3.51-3.38 (m, 2 H), 3.29-3.22 (m , 2 H), 2.36 (s, 3 H) 3.52 Rt= 3.17 min, m / z= 573.2 [M+H]+ / method F 1H-NMR (DMSO-d6, 400 MHz) δ 9.13 (d, J= 4.8 Hz, 1 H), 8.36 (dd, J= 6.0, 2.0 Hz, 1 H), 7.91 (dd, J= 5.6, 1.6 Hz, 1 H), 7.717.64 (m, 2 H), 7.50 (d , J= 7.6 Hz, 1 H), 4.63-4.45 (m, 4 H), 4.40 (d, J= 18 Hz, 1 H), 4.28-4.19 (m, 2 H), 2.39 (s, 3 H) 3.53 Rt= 3.02 min, m / z= 538.5 [M+H]- / method F 1H-NMR (DMSO-d6, 400 MHz) δ 8.99 (d, J= 8.4 Hz, 1 H), 8.398.33 (m , 1 H), 8.04 (s, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.45 (d, J= 8.0 Hz, 1 H), 5.07-4.89 ( m, 1 H), 4.57 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 3.52-3.45 (m, 1 H), 3.243.18 (m, 1 H ), 2.39 (s, 3 H) 3.54 Rt= 2.78 min, m / z= 538.5 [M+H]+ / G method 1H-NMR (DMSO-d6, 400 MHz) δ 9.00 (d, J= 8.8 Hz, 1 H), 8.398.33 (m, 1 H), 8.05 (s, 1 H), 7.94-7.88 (m, 1 H), 7.70-7.64 (m, 2 H), 7.45 (d, J= 8.0 Hz , 1 H), 5.08-5.00 (m, 1 H), 4.58 (d, J= 18 Hz, 1 H), 4.41 (d, J= 18 Hz, 1 H), 3.52-3.46 (m, 1 H) , 3.253.19 (m, 1 H), 2.39 (s, 3 H) 3.55 Rt= 2.28 min, m / z= 557.2 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 8.95 (d, J= 7.6 Hz, 1 H), 8.398.33 (m, 1 H), 7.94-7.88 (m, 1 H), 7.69-7.63 (m, 2 H), 7.48 (d, J= 7.6 Hz, 1 H), 4.58 (d, J= 18 Hz, 1 H), 4.45-4.35 (m, 2 H), 4.13-4.04 (m, 2 H), 3.29-3.19 (m, 2 H), 2.38 (s, 3 H) 3.59 Rt= 5.47 min, m / z= 605.2 1 H-NMR (DMSO-d6, 400 MHz) δ 12.81 (br s, 1 H), 8.38-8.34 (m, 1 H), 7.95 -7.88 (m, 1 H), 7.76-7.66 (m, 3 H), 4.60 (d, J= 18 7cnQcn / 77n7 / q / υιλι 101 [M+H]+ / method C Hz, 1 H), 4,.42 (d, J= 18 Hz, 1 H), 2.47 (s, 3H). 3.60 Rt= 2.45 min, m / z= 618.2 [M+H]+ / method C 1H-NMR (DMSO-d6, 400 MHz) δ 10.95 (br s, 1 H), 8.57 (s, 1 H), 8.37 (d, J= 4.0 Hz, 1 H), 7.91 (d, J= 3.8 Hz, 1 H), 7.73-7.63 (m, 2 H), 7.57-7.51 (m, 1 H), 5.25 (q, J = 9.2 Hz, 2 H), 4.58 (d, J= 18 Hz, 1 H), 4. 41 (d, J= 18 Hz, 1 H), 2.42 (s, 3H). 3.61 Rt= 2.64 min, m / z= 656.3 [M+H]+ / method C 1 H-NMR (DMSO-d6, 400 MHz) δ 9.16 (d, J= 6.8 Hz, 1 H), 8, 37 (d, J= 4.0 Hz, 1 H), 7.91 (d, J= 3.8 Hz, 1 H), 7.93-7.65 (m, 2 H), 7.52 (d, J= 8.0 Hz, 1 H), 4.83 (quint., J= 6.8 Hz, 1 H), 4.62-4.48 (m, 3 H), 4.40 (d, J= 18 Hz, 1 H), 4.292 (t, J= 6.4 Hz, 2 H), 2.39 (s, 3 H). 3.62 Rt= 2.43 min, m / z= 565.2 [M+H]+ / method C 1 H-NMR (DMSO-d6, 400 MHz) 5 8.55 (d, J= 7.6 Hz, 1 H), 8.388.33 ( m, 1 H), 7.93-7.87 (m, 1 H), 7.68-7.60 (m, 2 H), 7.39 (d, J= 8.0 Hz, 1 H), 4.62 (s, 2 H), 4.56 (d , J= 18 Hz, 1 H), 4.49 (s, 2 H), 4.39 (d, J= 18 Hz, 1 H), 4.21-4.12 (m, 1 H), 2.60-2.55 (m, 2 H) , 2.35 (s, 3 H), 2.20-2.14 (m, 2 H). 3.63 Rt= 3.21 min, m / z= 534.4 [M+H]+ / method F 1 H-NMR (DMSO-d6, 400 MHz) 5 9.29 (s, 1 H), 8.38-8.34 (m, 1 H) , 7.93-7.88 (m, 1 H), 7.69-7.64 (m, 2 H), 7.45 (d, J= 8.0 Hz, 1 H), 4.57 (d, J= 18 Hz, 1 H), 4.40 (d , J= 18 Hz, 1 H), 2.37 (s, 3 H), 1.60-1.53 ​​(m, 2 H), 1.33-1.25 (m, 2 H). 3.64 Rt= 4.03 min, m / z= 524.2 [M+H]+ / method C 1 H-NMR (DMSO-d6, 400 MHz) 5 9.02 (d, J= 6.8 Hz, 1 H), 8.388.35 ( m, 1 H), 7.92-7.88 (m, 1 H), 7.70-7.65 (m, 2 H), 7.50 (d, J= 8.0 Hz, 1 H), 4.78-4.71 (m, 1 H), 4.57 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 4.13-4.04 (m, 2 H), 3.99-3.93 (m, 2 H), 2.29 ( s, 3 H). 3.65 Rt= 2.63 min, m / z= 591.1 [M+H]+ / method E 1 H-NMR (DMSO-d6, 400 MHz) 5 8.78 (d, J= 7.2 Hz, 1 H), 8.388.34 ( m, 1 H), 7.92-7.89 (m, 1 H), 7.68-7.62 (m, 2 H), 7.61 (d, J= 7.6 Hz, 1 H), 4.57 (d, J= 18 Hz, 1 H ), 4.54-4.44 (m, 1 H), 4.40 (d, J= 18 Hz, 1 H), 3.16-3.06 (m, 1 H), 2.50-2.30 (m, 7 H). 3.66 Rt= 2.49 min, m / z= 631.1 [M+H]+ / method E 1 H-NMR (DMSO-d6, 400 MHz) 5 9.06 (d, J= 6.8 Hz, 1 H), 8.388.34 ( m, 1 H), 7.92-7.89 (m, 1 H), 7.68-7.63 (m, 2 H), 7.48 (d, J= 8.0 Hz, 1 H), 4.70-4.52 (m, 2 H), 4.40 (d, J= 18 Hz, 1 H), 4.04 (t, J= 7.6 Hz, 2 H), 3.87 (t, J= 7.2 Hz, 2 H), 2.75 (s, 6 H), 2.38 (s, 3H). 3.71 Rt= 2.21 min, m / z= 567.2 [M+H]+ / 1 H-NMR (DMSO-d6, 400 MHz) 5 8.95 (d, J= 6.4 Hz, 1 H), 8.398.34 (m, 1 H), 7.92-7.89 (m, 1 H), 7.69-7.63 (m, 2 H), 7.47 (d, J= 8.0 Hz, 1 H), 5.89 (s, 2 H), 4.61-4.52 (m , 2 H), 4.40 (m, 1 H), 7cnQcn / 77n7 / q / υιλι 102 method E 4.09-4.02 (m, 2 H), 3.75 (dd, J= 6.4, 5.6 Hz, 2 H), 2.37 (s, 3 H). 3.72 Rt= 2.71 min, m / z= 620.4 [M+H]+ / method F 1H-NMR (DMSO-d6, 400 MHz) 5 9.10 (d, J= 8.4 Hz, 1 H), 8.388.34 (m , 1 H), 7.92-7.88 (m, 1 H), 7.70-7.63 (m, 2 H), 7.47 (d, J= 8.0 Hz, 1 H), 5.15-5.07 (m, 1 H), 4.57 ( d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 4.23-4.01 (m, 2 H), 3.74-3.67 (m, 1 H), 3.53-3.49 (m, 1 H), 2.39 (s, 3 H). 3.73 Rt= 2.71 min, m / z= 620.3 [M+H]+ / method F 1 H-NMR (DMSO-d6, 400 MHz) 5 9.10 (d, J= 8.0 Hz, 1 H), 8.388.34 ( m, 1 H), 7.92-7.88 (m, 1 H), 7.69-7.63 (m, 2 H), 7.47 (d, J= 7.6 Hz, 1 H), 5.15-5.07 (m, 1 H), 4.57 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 4.23-4.00 (m, 2 H), 3.74-3.68 (m, 1 H), 3.53-3.49 (m , 1 H), 2.39 (s, 3 H). 3.74 Rt= 2.57 min, m / z= 591.04 [M+H]+ / method E 1 H-NMR (DMSO-d6, 400 MHz) 5 8.73 (d, J= 7.6 Hz, 1 H), 8,388.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.43 (d, J= 7.6 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.44-4.33 (m, 2 H), 2.992.88 (m, 1 H), 2.47-2.42 (m, 2 H), 2.36 (s, 3 H), 2.18-2.10 (m, 2 H). 3.75 Rt= 2.34 min, m / z= 574.17 [M+H]+ / method D 1 H-NMR (DMSO-d6, 400 MHz) 5 10.6 (s, 1 H), 8.39-8.34 (m, 1 H) , 8.23 ​​(s, 1 H), 7.94-7.89 (m, 1 H), 7.75-7.67 (m, 2 H), 7.65 (s, 1 H), 7.57 (d, J= 8.0 Hz, 1 H), 5.48 (s, 2 H), 4.59 (d, J= 17 Hz, 1 H), 4.42 (d, J= 18 Hz, 1 H), 2.42 (s, 3 H). 3.76 Rt= 2.29 min, m / z= 577.72 [M+H]+ / method D 1 H-NMR (DMSO-d6, 400 MHz) 5 8.58 (d, J= 6.8 Hz, 1 H), 8.388.33 ( m, 1 H), 7.93-7.88 (m, 1 H), 7.67-7.60 (m, 2 H), 7.40 (d, J= 7.6 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H ), 4.43-4.32 (m, 2 H), 3.83 (s, 2 H), 2.94-2.88 (m, 1 H), 2.74-2.67 (m, 1 H), 2.61-2.52 (m, 2 H), 2.36 (s, 3 H), 2.24-2.15 (m, 1 H), 1.81 -1.73 (m, 1 H). 3.77 Rt= 2.34 min, m / z= 548.23 [M+H]+ / method D 1 H-NMR (DMSO-d6, 400 MHz) 5 8.83 (t, J= 6.0 Hz, 1 H), 8.388.33 ( m, 1 H), 7.93-7.88 (m, 1 H), 7.70-7.64 (m, 2 H), 7.42 (d, J= 7.6 Hz, 1 H), 4.57 (d, J= 18 Hz, 1 H ), 4.40 (d, J= 18 Hz, 1 H), 3.40 (d, J= 3.0 Hz, 2 H), 2.41 (s, 3 H), 1.26-1.20 (m, 2 H), 1.151.07 ( m, 2H). 3.78 Rt= 2.33 min, m / z= 618.22 [M+H]+ / method D 1 H-NMR (DMSO-d6, 400 MHz) 5 8.91 (d, J= 6.0 Hz, 1 H), 8.388.33 ( m, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.47 (d, J= 7.6 Hz, 1 H), 4.94-4.84 (m, 1 H), 4.57 (d, J= 18 Hz, 1 H), 4.444.30 (m, 2 H), 4.08-4.00 (m, 2 H), 3.47 (dd, J= 12, 4.8 Hz, 1 H), 3.20 (s , 3 H), 2.38 (s, 3 H). 3.79 Rt= 2.32 min, 1 H-NMR (DMSO-d6, 400 MHz) 5 8.91 (d, J= 6.0 Hz, 1 H), 8.38- 7cnQcn / 77n7 / q / υιλι 103 m / z= 618.17 [M+H]+ / method D 8.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.47 (d, J= 7.6 Hz , 1 H), 4.94-4.84 (m, 1 H), 4.57 (d, J= 18 Hz, 1 H), 4.44- 4.30 (m, 2 H), 4.08-4.00 (m, 2 H), 3.47 ( dd, J= 12, 4.8 Hz, 1 H), 3.20 (s, 3 H), 2.38 (s, 3 H). 3.80 Rt= 2.44 min, m / z = 620.23 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.53 (d, J= 6.8 Hz, 1 H), 8.388.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.67-7.60 (m, 2 H), 7.39 (d, J= 8.0 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H) , 4.39 (d, J= 18 Hz, 1 H), 4.37-4.31 (m, 1 H), 3.40-3.22 (m, 2 H), 3.02 (t, J=9.2 Hz, 1 H), 2.83 (q , J= 8.0 Hz, 1 H), 2.74-2.62 (m, 2 H), 2.35 (s, 3 H), 2.192.06 (m, 1 H), 1.81-1.69 (m, 1 H). 3.81 Rt= 2.51 min, m / z = 570.23 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 10.75 (s, 1 H), 8.39-8.34 (m, 1 H), 8.22 (s, 1 H), 7.99-7.90 (m, 2 H), 7.76 (s, 1 H), 7.73 (d, J= 8.4 Hz, 1 H), 7.62 (d, J= 8.0 Hz, 1 H ), 7.58 (d, J= 5.2 Hz, 2 H), 4.60 (d, J= 18 Hz, 1 H), 4.43 (d, J= 18 Hz, 1 H), 2.44 (s, 3 H). 3.82 Rt= 2.52 min, m / z = 591.24 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.58 (t, J= 6.0 Hz, 1 H), 8.388.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.68-7.62 (m, 2 H), 7.36 (d, J= 8.0 Hz, 1 H), 4.56 (d, J = 18 Hz, 1 H) , 4.40 (d, J= 18 Hz, 1 H), 3.56 (d, J= 6.4 Hz, 2 H), 2.36 (s, 3 H), 0.94 (s, 4 H). 3.83 Rt= 2.30 min, m / z = 601.23 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.59 (t, J= 6.0 Hz, 1 H), 8.388.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.43 (d, J= 7.6 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H) , 4.40 (d, J= 18 Hz, 1 H), 3.81 (d, J= 6.0 Hz, 2 H), 3.10 (s, 3 H), 2.38 (s, 3 H), 1.29-1.22 (m, 2 H), 1.17-1.10 (m, 2 H). 3.84 Rt= 2.10 min, m / z = 552.16 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.76 (d, J= 6.8 Hz, 1 H), 8.388.36 (m , 1 H), 7.93-7.89 (m, 1 H) 7.68-7.61 (m, 3 H), 7.43 (d, J= 8.0 Hz, 1 H), 4.60-4.52 (m, 2 H), 4.39 (d, J= 18 Hz, 1 H), 3.59 (dd, J=10, 7.2 Hz, 1 H), 3.15 (dd, J= 10, 4.4 Hz, 1 H), 2.58-2.52 (m, 1 H ), 2.37 (s, 3 H), 2.18 (dd, J= 17, 5.2 Hz, 1 H). 3.85 Rt= 2.10 min, m / z = 552.21 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.76 (d, J= 6.5 Hz, 1 H), 8.388.36 (m , 1 H), 7.93-7.89 (m, 1 H) 7.68-7.61 (m, 3 H), 7.43 (d, J= 8.0 Hz, 1 H), 4.60-4.52 (m, 2 H), 4.39 (d, J= 18 Hz, 1 H), 3.59 (dd, J= 10, 7.2 Hz, 1 H), 3.15 (dd, J= 10, 4.4 Hz, 1 H), 2.58-2.52 (m, 1 H ), 2.37 (s, 3 H), 2.18 (dd, J= 17, 5.2 Hz, 1 H). 3.86 Rt= 2.23 min, m / z = 580.23 [M+H]+ / 1H-NMR (DMSO-d6, 400 MHz) δ 8.77 (d, J= 6.8 Hz, 1 H), 8.388.33 (m, 1 H), 7.93-7.88 (m, 1 H), 7.66 (s, 1 H), 7.64 (d, J= 8.0 Hz, 1 H), 7.42 (d, J=8.0 Hz, 1 H), 4.56 (d , J= 18 Hz, 1 H), 4.52- 7cnQcn / 77n7 / q / υιλι 104 method D 4.45 (m, 1 H), 4.39 (d, J= 18 Hz, 1 H), 3.72 (dd, J= 10, 7.2 Hz, 1 H), 3.29-3.17 (m, 3 H), 2.65 ( dd, J= 17, 8.4 Hz, 1 H), 2.37 (s, 3 H), 2.29 (dd, J= 17, 4.8 Hz, 1 H), 1.03 (t, J= 7.2 Hz, 3 H). 3.87 Rt= 2.23 min, m / z = 580.27 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.77 (d, J= 6.5 Hz, 1 H), 8.388.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.66 (s, 1 H), 7.64 (d, J= 8.3 Hz, 1 H), 7.42 (d, J=8.0 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.524.45 (m, 1 H), 4.39 (d, J= 18 Hz, 1 H), 3.72 (dd, J= 10, 7.6 Hz, 1 H), 3.29-3.17 (m, 3 H), 2.65 (dd, J= 17, 8.4 Hz, 1 H), 2.37 (s, 3 H), 2.29 (dd, J= 17, 4.8 Hz, 1 H), 1.03 ( t, J= 7.2 Hz, 3 H). 3.88 Rt= 2.91 min, m / z = 568.31 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) 5 8.80 (d, J= 6.0 Hz, 1 H), 8.388.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.66 (s, 1 H), 7.63 (d, J= 8.4, 1 H), 7.42 (d, J= 8.0 Hz, 1 H), 4.80- 4.61 (m, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.31 (d, J= 18 Hz, 1 H), 4.20-3.92 (m, 1 H), 3.76-3.56 (m, 1 H), 3.13-3.08 (m, 1 H), 2.82-2.62 (m, 3 H), 2.36 (s, 3 H), 1.05 (t, J= 4.4 Hz, 3 H). 3.89 Rt= 2.92 min, m / z = 568.23 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) 5 8.80 (d, J= 6.4 Hz, 1 H), 8.388.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.66 (s, 1 H), 7.63 (d, J= 8.4, 1 H), 7.42 (d, J= 8.0 Hz, 1 H), 4.80- 4.61 (m, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.31 (d, J= 18 Hz, 1 H), 4.21-3.91 (m, 1 H), 3.76-3.53 (m, 1 H), 3.13-3.08 (m, 1 H), 2.83-2.62 (m, 3 H), 2.36 (s, 3 H), 1.05 (t, J= 4.4 Hz, 3H). 3.90 Rt= 2.34 min, m / z = 562.25 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.41 (d, J= 7.2 Hz, 1 H), 8.398.33 (m , 1 H), 7.92-7.87 (m, 1 H), 7.67-7.60 (m, 2 H), 7.40 (d, J= 8.0 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H) , 4.43-4.32 (m, 2 H), 3.15 (quint, J= 7.6 Hz, 1 H), 2.35 (s, 3 H), 2.20-1.94 (m, 4 H), 1.841.75 (m, 1 H ), 1.66-1.57 (m, 1 H). 3.91 Rt= 2.39 min, m / z = 576.20 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.40-8.34 (m, 2 H), 7.93-7.88 (m, 1 H ), 7.67-7.60 (m, 2 H), 7.39 (d, J= 8.0 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H) , 3.85-3.75 (m, 1 H), 3.093.04 (m, 1 H), 2.36 (s, 3 H), 1.94-1.80 (m, 4 H), 1.74-1.63 (m, 2 H), 1.61 -1.49 (m, 2 H). 3.92 Rt= 2.38 min, m / z = 576.20 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.39-8.33 (m, 1 H), 8.28 (d, J= 7.6 Hz , 1 H), 7.93-7.88 (m, 1 H), 7.67-7.60 (m, 2 H), 7.36 (d, J= 8.0 Hz, 1 H), 4.55 (d, J= 18 Hz, 1 H) , 4.39 (d, J= 18 Hz, 1 H), 3.83-3.72 (m, 1 H), 2.72-2.63 (m, 1 H), 2.35 (s, 3 H), 2.08-2.00 (m, 2 H ), 1.92-1.84 (m, 2 H), 1.68-1.55 (m, 2 H), 1.39-1.25 (m, 2 7cnQcn / 77n7 / q / υιλι 105 H). 3.93 Rt= 3.05 min, m / z = 553.02 [M-H]- / method E 1H-NMR (DMSO-d6, 400 MHz) 5 8.62 (s, 1 H), 8.38-8.33 (m, 1 H), 7.93- 7.88 (m, 1 H), 7.68-7.61 (m, 2 H), 7.42 (d, J= 8.0 Hz, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 3.76 (d, J= 9.2 Hz, 2 H), 2.95 (d, J= 9.2 Hz, 2 H), 2.38 (s, 3 H), 1.73 (s, 3 H). 3.94 Rt= 2.50 min, m / z = 582.21 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) 5 9.47 (d, J= 8.4 Hz, 1 H), 8.398.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.70-7.63 (m, 2 H), 7.45 (d, J = 8.0 Hz, 1 H), 6.24-6.14 (m, 1 H), 4.57 ( d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 4.11 (q, J= 6.8 Hz, 2 H), 3.44-3.33 (m, 1 H), 2.84 (dd , J= 17, 4.0 Hz, 1 H), 2.39 (s, 3 H), 1.27 (t, J= 6.8 Hz, 3 H). 3.95 Rt= 2.50 min, m / z = 582.21 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) 5 9.47 (d, J= 8.4 Hz, 1 H), 8.398.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.70-7.63 (m, 2 H), 7.45 (d, J = 8.0 Hz, 1 H), 6.24-6.14 (m, 1 H), 4.57 ( d, J= 18 Hz, 1 H), 4.40 (d, J= 18 Hz, 1 H), 4.11 (q, J= 6.8 Hz, 2 H), 3.44-3.33 (m, 1 H), 2.84 (dd , J= 17, 4.0 Hz, 1 H), 2.39 (s, 3 H), 1.27 (t, J= 6.8 Hz, 3 H). 3.96 Rt= 2.31 min, m / z = 566.35 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.85 (d, J= 6.8 Hz, 1 H), 8.388.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.70-7.63 (m, 2 H), 7.47 (d, J= 8.0 Hz, 1 H), 4.67-4.52 (m, 2 H), 4.40 ( d, J= 18 Hz, 1 H), 3.092.85 (m, 4 H), 2.38 (s, 3 H). 3.97 Rt= 2.36 min, m / z = 634.11 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.82 (d, J= 6.0 Hz, 1 H), 8.398.33 (m , 1 H), 7.93-7.88 (m, 1 H), 7.69-7.62 (m, 2 H), 7.42 (d, J= 8.0 Hz, 1 H), 4.60-4.49 (m, 2 H), 4.40 ( d, J= 18 Hz, 1 H), 4.154.00 (m, 2 H), 3.87-3.79 (m, 1H), 3.48-3.40 (m, 1 H), 2.75 (dd, J= 17, 8.4 Hz , 1 H), 2.44-2.28 (m, 4 H). 3.98 Rt= 2.33 min, m / z = 606.14 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) δ 8.81-8.75 (m, 1 H), 8.38-8.33 (m, 1 H ), 7.93-7.88 (m, 1 H), 7.68-7.61 (m, 2 H), 7.43 (d, J= 8.0 Hz, 1 H), 4.62-4.48 (m, 2 H), 4.40 (d, J = 18 Hz, 1 H), 3.85-3.76 (m, 1 H), 3.40-3.33 (m, 1 H), 3.06 (d, J= 7.2 Hz, 2 H), 2.71-2.61 (m, 1 H) , 2.39-2.26 (m, 4 H), 0.92-0.83 (m, 1 H), 0.48-0.41 (m, 2 H), 0.25-0.17 (m, 2 H). 4.3 Rt= 2.49 min, m / z= 544.17 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.53 (d, J= 8.0 Hz, 1 H), 8.36 (d, J = 4.4 Hz, 1 H), 7.88 (d, J= 4.0 Hz, 1 H), 7.49 (s, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.45-4.34 (m, 2 H ), 3.13-3.02 (m, 1 H), 2.692.59 (m, 2 H), 2.50-2.38 (m, 5 H). 7cnQcn / 77n7 / q / υιλι 106 4.4 Rt= 2.49 min, m / z= 544.17 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.53 (d, J= 8.0 Hz, 1 H), 8.36 (d, J = 4.4 Hz, 1 H), 7.88 (d, J= 4.0 Hz, 1 H), 7.49 (s, 1 H), 4.56 (d, J= 18 Hz, 1 H), 4.45-4.35 (m, 2 H ), 3.12-3.02 (m, 1 H), 2.682.60 (m, 2 H), 2.50-2.37 (m, 5 H). 8.3 Rt= 2.23 min, m / z = 592.20 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.66-8.57 (m, 2 H), 8.30-8.23 (m, 1 H ), 7.80-7.75 (m, 1 H), 7.68-7.62 (m, 2 H), 7.49 (d, J= 8.0 Hz, 1 H), 4.59 (d, J= 18 Hz, 1 H), 4.40 ( d, J= 18 Hz, 1 H), 3.993.88 (m, 4 H), 2.40 (s, 3 H). 8.4 Rt= 2.23 min, m / z = 592.20 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 8.66-8.57 (m, 2 H), 8.30-8.23 (m, 1 H ), 7.80-7.75 (m, 1 H), 7.68-7.62 (m, 2 H), 7.49 (d, J= 8.0 Hz, 1 H), 4.59 (d, J= 18 Hz, 1 H), 4.40 ( d, J= 18 Hz, 1 H), 4.003.88 (m, 4 H), 2.40 (s, 3 H). 8.5 Rt= 2.47 min, m / z = 634.08 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) d 8.66-8.58 (m, 2 H), 8.20 (s, 1 H), 8.09 (s, 1 H), 7.89 (s, 1 H), 7.65-7.59 (m, 2 H), 7.50 (d, J= 8.4 Hz, 1 H), 4.45 (d, J= 18 Hz, 1 H ), 4.36 (d, J= 18 Hz, 1 H), 4.00-3.89 (m, 4 H), 2.40 (s, 3 H). 8.6 Rt= 2.47 min, m / z = 634.0.14 [M+H]+ / method E 1H-NMR (DMSO-d6, 400 MHz) d 8.65-8.58 (m, 2 H), 8.20 (s, 1 H ), 8.09 (s, 1 H), 7.89 (s, 1 H), 7.65-7.59 (m, 2 H), 7.50 (d, J= 8.4 Hz, 1 H), 4.45 (d, J= 18 Hz, 1 H), 4.36 (d, J= 18 Hz, 1 H), 4.00-3.88 (m, 4 H), 2.40 (s, 3 H). 9.3 Rt= 2.20 min, m / z = 618.31 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 9.03 (d, J= 6.8 Hz, 1 H), 8.278.22 (m , 1 H), 8.16-8.11 (m, 1 H), 7.70-7.64 (m, 2 H), 7.49 (d, J= 7.6 Hz, 1 H), 7.36 (t, J= 54 Hz, 1 H) , 4.71-4.60 (m, 1 H), 4.59 (d, J= 18 Hz, 1 H), 4.38 (d, J= 18 Hz, 1 H), 4.17-4.09 (m, 2 H), 3,923.84 9.4 Rt= 2.19 min, m / z = 618.27 [M+H]+ / method D 1H-NMR (DMSO-d6, 400 MHz) 5 9.03 (d, J= 6.8 Hz, 1 H), 8.278.22 (m , 1 H), 8.16-8.11 (m, 1 H), 7.70-7.64 (m, 2 H), 7.49 (d, J= 7.6 Hz, 1 H), 7.36 (t, J= 54 Hz, 1 H) , 4.71-4.60 (m, 1 H), 4.59 (d, J= 18 Hz, 1 H), 4.38 (d, J= 18 Hz, 1 H), 4.17-4.09 (m, 2 H), 3.923.84 (m, 2 H), 3.04 (s, 3 H), 2.38 (s, 3 H). 9.5 Rt= 4.73 min, m / z = 604.02 [M-H]- / method I 1H-NMR (DMSO-d6, 400 MHz) 5 8.67-8.58 (m, 2 H), 8.13-8.07 (m, 1 H), 8.07-8.01 (m, 1 H), 7.69-7.63 (m, 2 H), 7.52-7.07 (m, 3 H), 4.57 (d, J= 18 Hz, 1 H), 4.33 (d, J= 18 Hz, 1 H), 3.97-3.88 (m, 4 H), 2.40 (s, 3 H). 9.6 Rt= 4.57 min, m / z = 604.10 1H-NMR (DMSO-d6, 400 MHz) 5 8.67-8.58 (m, 2 H), 8.13-8.07 (m, 1 H), 8.07-8.01 (m, 1 H), 7.69-7.63 (m, 2 H), 7.52-7.07 (m, 3 7cnQcn / 77n7 / q / υιλι 107 [M-H]- / method E H), 4.57 (d, J= 18 Hz, 1 H), 4.33 (d, J= 18 Hz, 1 H), 3.97-3.88 (m, 4 H), 2.40 (s, 3 H). The compounds of the invention are valuable active ingredients for use in pest control. The term pests includes ectoparasites and endoparasites in and on animals and in the field of hygiene. Particular pests are fleas, ticks, mites, flies, worms and lice. Fleas and ticks are even more particular pests. In the context of the invention, animals are understood to include vertebrates. In this context, the term vertebrate is understood to include, for example, fish, amphibians, reptiles, birds and mammals, including humans. A preferred group of vertebrates according to the invention comprises warm-blooded animals, which include farm animals such as cattle, horses, pigs, sheep and goats, poultry such as chickens, turkeys, guinea fowl and geese, fur-bearing animals such as minks, foxes, chinchillas, rabbits and the like, as well as pets such as ferrets, guinea pigs, rats, hamsters, cats and dogs, and also humans. A further group of preferred vertebrates according to the invention comprises fish, including salmon. In the context of the present invention, ectoparasites are understood to be in particular insects, Acari arachnids (mites and ticks) and crustaceans (sea lice). These include insects from the following orders: Lepidoptera, Coleoptera, Homoptera, Hemiptera, Heteroptera, Diptera, Dictyoptera, Thysanoptera, Orthoptera, Anoplura, Siphonaptera, Mallophaga, Thysanura, Isoptera, Psocoptera and Hymenoptera. However, ectoparasites that can be mentioned in particular are those that bother humans or animals and carry pathogens, for example, flies such as Musca domestica, Musca vetustissima, Musca autumnalis, Fannia canicularis, Sarcophaga carnaria, Lucilia cuprina, Lucilia sericata, Hypoderma bovis, Hypoderma lineatum, Chrysomyia chloropyga, Dermatobia hominis, Cochliomyia hominivorax, Gasterophilus intestinalis, Oestrus ovis, biting flies such as Haematobia irritans irritaos, Haematobia irritaos exigua, Stomoxys calcitraos, horse flies (Tabaoids) with the subfamilies of Tabaoidae such such as Haematopota spp. (e.g. Haematopota pluvialis) and Tabaous spp, (e.g. Tabaous oigrovittatus) and Chrysopsioae such as Chrysops spp. (e.g. Chrysops caecutieos); Hippoboscids such as Melophagus ovíous (ked sheep); tsetse flies, such as Glossioia spp,; other biting insects such as mosquitoes, such as Ceratopogooidae (biting mosquitoes), Simuliidae (black flies), Psychodidae (sand flies); but also blood-sucking insects, for example, mosquitoes, such as Aoopheles spp, Aedes spp and Culex spp, fleas, such as Cteoocephalides felis and Cteoocephalides caois (cat and dog fleas), Xeoopsylla cheopis, Pulex irritaos, Ceratophyllus gallioae, Dermatophilus peoetraos, blood-sucking lice (Aooplura) such as Lioogoathus spp, Haematopious spp, Soleoopotes spp, Pediculus humaois; and also chewing lice (Mallophaga) such as Bovicola (Damalioia) ovis, Bovicola (Damalioia) bovis and other Bovicola spp. The ectoparasites 108 also include members of the order Acariña, such as mites (e.g. Choríoptes bovis, Cheyletiella spp., Dermanyssus gallinae, Ortnithonyssus spp., Demodex canis, Sarcoptes scabiei, Psoroptes ovis and Psorergates spp.) and ticks. Representative ticks are, for example, Boophilus, Amblyomma, Anocentor, Dermacentor, Haemaphysalis, Hyalomma, Ixodes, Flhipicentor, Margaropus, Rhipicephalus, Argas, Otobius and Ornithodoros and the like, which preferentially infest vertebrates, for example, warm-blooded animals, which include farm animals such as cattle, horses, pigs, sheep and goats, poultry such as chickens, turkeys, guinea fowl and geese, fur animals such as mink, foxes, chinchillas, rabbits and the like, as well as pets such such as ferrets, guinea pigs, rats, hamsters, cats and dogs, but also humans and fish. The compounds according to the invention are also active against all developmental stages or against individual developmental stages of animal pests that show normal sensitivity, as well as those that show resistance to widely used parasiticides. This is especially so in the case of resistant insects and members of the order Acariña. The insecticidal, ovicidal and / or acaricidal effect of the active substances of the invention can manifest themselves directly, that is, by killing the pests either immediately or after a certain period of time, for example, when molting occurs. , or by destroying their eggs, or indirectly, for example, by reducing the number of eggs laid and / or the hatching rate, where good efficacy corresponds to a pesticide rate (mortality) of at least 50 to 60%. The compounds of the invention can also be used against hygiene pests, especially of the order Diptera of the families Muscidae, Sarcophagidae, Anophilidae and Culicidae; the orders Orthoptera, Dictyoptera (e.g. the family Blattidae (cockroaches), such as Blatella germánica, Blatta orientalis, Períplaneta Americana) and Hymenoptera (e.g. the families Formicidae (ants) and Vespidae (wasps). The compounds of Formula (I) are also effective against fish ectoparasites, especially the subclass of Copepoda (e.g. order Siphonostomatoida (sea lice)), and are well tolerated by fish. The compounds of Formula (I) can also be used against worms of the Cestoda class, which includes the Eucestoda and Cestodaría subclasses. The compounds of the invention also have sustained efficacy against parasitic mites and plant insects. In the case of spiders of the order Acariña, they are effective against eggs, nymphs and adults of Tetranychidae (Tetranychus spp. and Panonychus spp.). They have high activity against sucking insects of the order Homoptera, especially against pests of the families Aphididae, Delphacidae, Cicadellidae, Psyllidae, Loccidae, Diaspididae and Eriophydidae (for example, citrus mites); the orders Hemiptera, Heteroptera and Thysanoptera, and in plant-eating insects of the orders Lepidoptera, Coleoptera, Diptera and Orthoptera. They are similarly suitable as a soil insecticide against pests in the soil. 7cnacn / 77n7 / zi / υιλι 109 Therefore, the compounds of Formula (I) are effective against all stages of development of sucking insects and predatory insects in crops, such as cereals, cotton, rice, corn, soybeans, potatoes, vegetables, fruit, tobacco, hops. , citrus, avocado and other crops. The compounds of Formula I are also effective against plant nematodes of the species Meloidogyne, Heterodera, Pratylenchus, Ditylenchus, Radopholus, Rizoglyphus, etc. The compounds of the invention are effective against helminths. Helminths are important in trade because they cause serious diseases in mammals and poultry, for example, sheep, pigs, goats, cattle, horses, donkeys, camels, dogs, cats, rabbits, guinea pigs, hamsters, chickens, turkeys , guinea fowl and other farm birds, as well as exotic birds. Typical nematodes are: Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostonum, Oesophagostonum, Charbertia, Trichuris, Strongylus, Trichonema, Dictyocaulus, Capillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris and Parascaris. Trematodes include, in particular, the family of Fasciolideae, especially Fasciola hepatica. The pesticidal activity of the compounds of Formula (I) according to the invention corresponds to a mortality rate of around 50-60% of the mentioned pests, more preferably to a mortality rate greater than 90%, with maximum preference to 95-100%. The compounds of Formula (I) are preferably used internally or externally in unmodified form or, preferably, together with adjuvants that are commonly used in the formulation technique. Therefore, they can be processed in any known manner to obtain, for example, liquid formulations (for example, spreadable formulations, pourable formulations, spray formulations, emulsions, suspensions, solutions, emulsifiable concentrates, solution concentrates), semi-solid formulations (for example, creams, ointments, pastes, gels, liposomal preparations) and solid preparations (for example, food additives in tablets including, for example, capsules, powders including soluble powders, granules or incorporations of the active ingredient in polymeric substances, such as implants and microparticles). Like compositions, application methods are selected in accordance with the intended goals and prevailing circumstances. The compounds of the invention can be administered alone or in the form of a composition. In practice, the compounds of the invention are generally administered in the form of compositions, that is, in admixture with at least one acceptable excipient. The proportion and nature of any acceptable excipients are determined by the properties of the selected compound of the invention, the chosen route of administration and standard practice in the veterinary and pharmaceutical fields. In one embodiment, the present invention provides compositions comprising: a compound of the invention and at least one acceptable excipient. When such treatment and / or control is carried out, a compound of the invention can be administered in any form and route that makes the compound bioavailable. The compounds of the invention 110 can be administered by a variety of routes, including orally, particularly via tablets and capsules. The compounds of the invention can be administered parenterally, more particularly by inhalation, subcutaneously, intramuscularly, intravenously, intraarterially, transdermally, intranasally, rectally, vaginally, ocularly, topically, sublingually and buccally, intraperitoneally, intraadiposally, intrathecally and by local administration, for example, with a catheter or stent. A person of mid-level skill can easily select the appropriate form and route of administration based on the particular characteristics of the selected compound, the disorder or condition to be treated, the stage of the disorder or condition, and other relevant circumstances. The pharmaceutical compositions of the invention may be administered to the subject, for example, in the form of tablets, including chewable tablets, capsules, tablets, papers, lozenges, wafers, elixirs, boluses, ointments, transdermal patches, aerosols, inhalers, suppositories, soaked products, solutions, injections and suspensions. The term "acceptable excipient" refers to those excipients that are generally used for the preparation of veterinary and pharmaceutical compositions that must be pure and non-toxic in the amounts used. They are generally a solid, semisolid, or liquid material that, in aggregate, can serve as a vehicle or medium for the active ingredient. Some examples of acceptable excipients are found in Remington's Pharmaceutical Sciences and Handbook of Pharmaceutical Excipients and include diluents, vehicles, carriers, ointment bases, binders, disintegrants, lubricants, gliding agents, sweetening agents, flavoring agents, gel bases, release matrices sustained, stabilizing agents, preservatives, solvents, suspending agents, buffers, emulsifiers, dyes, propellants, coating agents and others. In one embodiment, the composition is adapted for oral administration, such as a tablet, a capsule or a liquid formulation, for example, a solution or suspension, adapted for oral administration. In one embodiment, the composition is adapted for oral administration, such as a chewable formulation, adapted for oral administration. In yet another embodiment, the composition is a liquid or semi-solid formulation, for example, a solution, a suspension or a paste, adapted for parenteral administration. In one embodiment, the composition is adapted for administration by injection, such as a solution or suspension, adapted for administration by injection. Particular compositions for use in subjects in the treatment and / or control of nematodes / helminths comprise solutions; injectables; emulsions that include classic emulsions, microemulsions and self-emulsifying compositions, which are waterless and organic compositions, preferably oily, that form emulsions, together with body fluids, after entering the subject's body; suspensions (soaked products); pourable formulations; food additives; powder; tablets including effervescent tablets; bowling; capsules including microcapsules; and chewy treats. Forms of particular compositions are tablets, capsules, food additives or chewable treats. 111 The compositions of the present invention are prepared in a manner known in the veterinary and pharmaceutical art and include at least one of the compounds of the invention as the active ingredient. The amount of a compound of the present invention may vary depending on its particular form and may conveniently be from 1% to about 50% by weight of the unit dosage form. The present pharmaceutical compositions are preferably formulated in a unit dosage form, wherein each dose generally contains from about 0.5 mg to about 100 mg of a compound of the invention. One or more unit dosage forms may be taken for the treatment dose. In one embodiment, the present invention also provides a method of treating pests, comprising: administering to a subject in need thereof an effective amount of a compound of Formula (I) or a salt thereof, wherein the method comprises further optionally an effective amount of at least one additional active compound. In one embodiment, the present invention also provides a method of controlling pests, comprising: administering to a subject in need thereof an effective amount of a compound of Formula (I) or a salt thereof, wherein the method comprises further optionally an effective amount of at least one additional active compound. In one embodiment, the present invention also provides a method of treating or controlling pests, comprising: bringing a subject's environment into contact with an effective amount of a compound of Formula (I) or a salt thereof, in wherein the method optionally further comprises an effective amount of at least one additional active compound. Therefore, the invention provides the use of the compounds of the invention as a medicament, including for the manufacture of a medicament. In one embodiment, the invention provides for the manufacture of a medicament comprising a compound of Formula (I) or a salt thereof for treating pests. In one embodiment, the invention provides for the manufacture of a medicament comprising a compound of the invention or a salt thereof to control pests. The expressions treat, to treat, treated or treatment include, but are not limited to, slowing, stopping, reducing, improving, reversing the progression or severity of an existing symptom or preventing a disorder, condition or disease. For example, an adult Dirofilaria immitis infection could be treated by administration of a compound of the invention. A treatment can be applied or administered therapeutically. The terms control, control or controlled refer to, among others, decreasing, reducing or improving the risk of a symptom, disorder, condition or disease, and protecting an animal from a symptom, disorder, condition or an illness. Control can refer to therapeutic, prophylactic or preventive administration. For example, an immature larva or pest may be asymptomatic, but would be controlled by action on the immature larva or pest, which prevents progression of the infection to symptomatic or weakens the mature pest infection. Therefore, the use of the compounds of the invention in the treatment and / or control of pests, in 112 particularly helminths, where endoparasitic nematodes and trematodes refer to the use of the compounds of the invention to act on the various forms of the pest during its life cycle, regardless of whether a subject manifests a symptom, including morbidity or mortality, and regardless of the phases of the exhibition. As used herein, administering to a subject includes, but is not limited to, cutaneous, subcutaneous, intramuscular, mucosal, submucosal, transdermal, oral or intranasal administration. Administration could include injection or topical administration, for example, pourable or spreadable administration. The pour or spread method is especially advantageous for use in herd animals, such as cattle, horses, sheep or pigs, where it is difficult or time-consuming to treat all animals by mouth or injection. Thanks to its simplicity, this method can of course also be used for all animals, even domestic animals or individual pets, and is largely preferred by animal keepers, as it can often be carried out without the presence from the specialist veterinarian. The terms subject and patient refer to and include humans, non-human mammals and fish, the vertebrates described herein, such as dogs, cats, mice, rats, guinea pigs, rabbits, ferrets, cows, horses, sheep, goats and pigs. . Particular subjects are pets or mammalian companion animals, such as dogs, cats and also mice, guinea pigs, ferrets and rabbits. The term "effective amount" refers to an amount that gives the desired benefit to the subject and includes administration for both treatment and control. The amount will vary from individual subject to individual subject and will depend on several factors, including the general physical condition of the subject and the severity of the underlying cause of the condition to be treated, concomitant treatments, and the amount of the compound of the invention used. to maintain the desired response at a beneficial level. The diagnostician, like a mid-level professional, can easily determine an effective amount using known techniques and analysis of results obtained under analogous circumstances. When determining the effective amount, dose, the diagnostician considers several factors, including, but not limited to: the species of the patient; her size, age and general health; the specific condition, disorder, infection or disease involved; the degree, extent or severity of the condition, disorder or disease; the response of the individual patient; the particular compound administered; the route of administration; the bioavailability characteristics of the administered preparation; the selected dosage regimen; the use of concomitant medication; and other relevant circumstances. An effective amount of the present invention, the treatment dose, is expected to range from 0.5 mg to 100 mg. The mid-level trade person can determine specific amounts. Although these doses are based on a subject with a mass of about 1 kg to about 20 kg, the diagnostician will be able to determine the appropriate dose for a subject whose mass is not in this weight range. It is expected that a 113 effective amount of the present invention, the treatment dose ranges from 0.1 mg to 10 mg / kg of the subject. The dosing regimen is expected to be monthly, bimonthly, biannual, or annual administration. The compounds of the invention can be combined with one or more other active compounds or treatments against one or more disorders, diseases or conditions, including the treatment of pests, for which it is indicated. The compounds of the invention may be administered simultaneously or sequentially or separately in combination with one or more compounds or treatments to treat pests and other disorders. Therefore, it is understood that the compositions and methods of the present invention optionally include an effective amount of at least one additional active compound. Additional active compounds useful in the present invention include those used to treat fleas, ticks, flies and mosquitoes and include macrocyclic lactones, such as milbemycin oxime, imidacloprid, spinosad, pyriproxyfen, permethrin, S-methoprene, praziquantel and moxidectin. Other exemplary addition active compounds include, but are not limited to, afoxolaner, fluralaner, lotilaner, sarolaner, albendazole, cambendazole, fenbendazole, flubendazole, mebendazole, oxfendazole, parabendazole, thiabendazole, triclabendazole, amitraz, demiditraz, clorsulon, closantel, oxyclozanide, rafoxanide, cyphenothrin, flumethrin, permethrin, cyromazine, derquantel, diamfenetide, dicyclanil, dinotefuran, imidacloprid, nitenpyram, thiamethoxam, abamectin, doramectin, emamectin, eprinomectin, ivermectin, moxidectin, selamectin, milbemycin oxime, emodepside, epsiprantel, fipronil, flua pouch, fluhexafon, indoxacarb , levamisole, lufenuron, metaflumizone, methoprene, monepantel, morantel, niclosamide, nitroscanate, nitroxinil, novaluron, oxantel, praziquantel, pyrantel, pyriprole, pyriproxyfen, sisapronil, spinosad, spinetoram and triflumezopyrim, or a salt of any of the above. The activity of the compounds of the invention can be determined by various methods, including in vitro and in vivo methods. Example A In vitro evaluation of ingestion activity against fleas (Ctenocephalides felis) For flea ingestion testing, serial dilutions of the compound stock were performed using DMSO to achieve the desired range to determine ECso and EC90. An aliquot of each compound dilution was added to organic bovine blood with a final DMSO concentration of 0.5%, which was placed in an artificial feeding container. Fipronil was included as a positive control. Ten recently emerged unfed adult Ctenocephalides felis fleas, 0-7 days old, from a laboratory colony were aspirated into each vial or cage. Cages for flea ingestion assays were maintained in a temperature-controlled artificial feeding apparatus to allow continuous access to organic bovine blood containing the desired compound concentration. Fresh aliquots of compound-spiked bovine blood were provided each day of the study. Fleas were evaluated for percentage mortality at various time points between 2 h and 48 h postinfestation. Fleas that showed normal movement and / or ability to jump were considered viable, and those 114 that showed no movement after hitting the vials were classified as dead. In this test, for example, the following compounds from the preparation examples showed an EC50 <1 ppm: Examples 2.1 or 2.2; 3.1 or 3.2; 3.3 or 3.4; 3.8; 3.19 or 3.20; 3.21 or 3.22; 3.23; 3.27, 3.28, 3.29 or 3.30; 3.34 or 3.35; 3.36 or 3.37; 3.38 or 3.39; 3.40 or 3.41; 3.43 or 3.44; 3.45 or 3.46; 3.49; 3.50; 3.51; 3.52; 3.53; 3.55; 3.62; 3.65; 3.66; 3.71; 3.73; 3.74; 3.76; 3.77; 3.78 or 3.79; 3.80: 3.83; 3.84; 3.85; 3.86; 3.87; 3.90; 3.91; 3.93; 5.1; 8.1 or 8.2; 8.3 or 8.4; 8.5 or 8.6; 9.1 or 9.2; and 9.3 or 9.4; and 10.1 or 10.2. In this test, for example, the following compounds from the preparation examples showed an EC50 <3 ppm: Examples 1.1 or 1.2; 3.5 or 3.6; 3.15; 3.16 or 3.17; 3.25; 3.26; 3.47; 3.61; 3.72; and 3.75; 3.81; 3.75; 3.92; and 4.3 or 4.4. For the above data, when individual isomers are evaluated, without knowing the absolute configuration of the isomer, the data indicates that the test article is one isomer and another, for example, an individual isomer from Example 2 was evaluated and gave an ECso of < 1 ppm, so the data above indicates that the result was obtained for 2.1 or 2.2. Example B In vitro evaluation of contact activity against adult ticks (Rhipicephalus sanguineas) For tick assays, vial lids were pre-punched with a single hole in the center of each lid to allow air exchange. A filter paper (Whatman grade 540, 2.1 cm) was placed on the lid of each vial. An aliquot of each compound stock was added to an acetone / Triton solution to achieve the maximum desired doses for each study. Serial dilutions of the maximum dose were performed to achieve the desired titration range to determine ECso and EC90. The final DMSO concentration in each test vial was 0.5%. A 459 pL aliquot of each compound formulation was transferred to a vial containing a 2.1 cm Whatman grade 540 filter paper. The vials were immediately placed on an unheated roller bearing unit to allow even coating of the vial walls. Once the vials were coated, 41 pL of each compound formulation was added to the filter paper embedded in each vial cap. Each cap was dried. The vials were loosely capped and dried for a minimum of 4 h in a chemical fume hood. Ten adult ticks were added to each vial and maintained at 24°C, 80% humidity with 12-h light / dark cycles. Adult ticks were evaluated for percentage mortality at various time points between 2 h and 48 h postinfestation. The ticks were stimulated on a heated roller bearing unit and evaluated. Ticks that showed no movement, or that showed very slow or uncoordinated movement, were classified as dead. Example C Determination of PK after administration to beagle dogs The performance of a single oral or intravenous dose of the desired compound was evaluated in beagle dogs. The animals (n= 6) received the compound by oral gavage (3 or 10 mg / kg) or 115 an intravenous dose (1 or 2 mg / kg). Blood samples were collected before the dose and 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, 96, 168, 336, 504, 672, 1008, 1344, 1680, 2016, 2352, 2688, 2856 and 3024 h after the dose. A portion of each whole blood sample was processed into plasma. Concentrations of test articles in plasma and whole blood were determined by LC-MS / MS. The results for the test items are summarized in the following table: Example Structure Half-life Clearance in plasma 1.1 o 1.2 '7^ W O j,-' \ / f—y t V \ o7 Cl 36 d 0.0566 L / day / kg 2.1 o 2.2 o ZI iz I > or <j Y T QZ 45 d 0.0555 L / day / kg 3.1 or 3.2 F3C. „ r O---N O 50 d 0.0613 L / day / kg 4.1 o 4.2 ....... Cl 0 44 d 0.0566 L / day / kg Structure Half-life Clearance in plasma sarolaner ? o, / Cl---<Λ z> ° F Cl 12 d 0.173 L / day / kg 116 afoxolaner mo-n _ η κ fa \ / ζ \ 0 Cl 15.5d 0.119 L / day / kg fluralaner T ZI z^\ o 12- 15 d lotilaner F F\| O—N O f / Y-vs,A . h f zr-¿ \\ / ΝΎ,Ν / CI-ΖΛ H Ά ^VF / Λ 0 F Cl Cl 25 d 0.180 L / day / kg 7cnQcn / 77n7 / q / υιλι 117

Claims

1. A compound of Formula (I): characterized in that Ai is selected from the group consisting of CF3, CHF2, CH2F and CF2CF3; A2 is O or S; R1 is selected from the group consisting of hydrogen and halogen; R2 is selected from the group consisting of hydrogen, halogen, difluoromethyl and trifluoromethyl; Rs is selected from the group consisting of hydrogen, halogen and trifluoromethyl; R4 is selected from the group consisting of hydrogen, halogen, difluoromethyl and trifluoromethyl; Rs is selected from the group consisting of hydrogen and halogen; provided that: R1 can be hydrogen only when R2 is trifluoromethyl, difluoromethyl or bromine; Rs can be hydrogen only when R4 is trifluoromethyl or bromine; R3 can be hydrogen only when one of R2 or R4 is trifluoromethyl, difluoromethyl or bromine; R1, R3 and Rs cannot all be hydrogen when R2 and R4 are trifluoromethyl; and at most three of R1, R2, R3, R4 and Rs are hydrogen; Q is selected from the group consisting of 118 where p is 0,1 or 2; q is 0, 1, 2 or 3; r is 0 or 1; s is 0, 1 or 2; t is 0 or 1; Re, in each case, is selected independently of the group consisting of halogen; cyano; nitro; hydroxyl; -NH2; -NH(Ci-C4 alkyl); -N(Ci-C4 alkyl)2; C2-C5-alkoxycarbonyl; optionally substituted Ci-Ce-alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)?, -SCi-C4 alkyl, -S(O)Ci-C4 alkyl and -SO2Ci-C4 alkyl; Ci-Ce-alkoxy optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-C6 cycloalkyl, Ci-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(CrC4 alkyl)2, -SCi-C4 alkyl,-S(O)Ci-C4 alkyl and -SO2Ci-C4 alkyl; -NR8C(O)(Ci-C4 alkyl) optionally substituted at the Ci-C4 alkyl with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C3-C6 cycloalkyl, Ci-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)?, wherein Rs is selected independently from the group consisting of hydrogen and C1-C4 119 alkyl; -C(O)NRs(C1-C4 alkyl) optionally substituted at the C1-C4 alkyl with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl) and -N(C1-C4 alkyl)2, wherein Rs is selected independently from the group consisting of hydrogen and C1-C4 alkyl; -SCi-Ce alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, Cs-Cs cycloalkyl,C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)2; and -S(O)Ci-Cs alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl) and N(Ci-C4 alkyl^; R7, in each case, is selected independently from the group consisting of oxo, C1-C4 alkyl and C3-C6 cycloalkyl; A3 is O or S; A4 is CH or N; As is CH or N; Aβ is CH or N; A7 is CH O, S, a bond or N; As is CH O, S, a bond or N; Ag is CH or N; A10 is CH or N; An is CH or N; A12 is CH or N; A13 is CH or N; A14 is CH or N; A15 is CH or N; Ais is NR, O or S, wherein R is selected from the group consisting of hydrogen, C1-C4 alkyl and C3-Ce cycloalkyl; W1 is selected from the group consisting of -O-, -S-, -NRg-, -NC(O)Rio-, -CH2- and -C(O)-; W2 is selected from the group consisting of -O-, -S-, -NRg-, -NC(O)Rw-,-CH2- and -C(O)-; provided that: when W1 is -O-, -S-, -NRg- or -NC(O)Rio-, W2 is -CH2- or -C(O)-; and when Wz is -O-, -S-, -NRg- or -NC(O)Rio-, W1 is -CH2- or -C(O)-; W3 is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)z-, -NRg-, -CH-, -N-, -CH2 and -C(O)-; W4 is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)2-, -NRg-, -CH-, -N-, -CH2 and -C(O)-; W5 is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)2-, -NRg-, -CH-, -N-, -CH2 and -C(O)-; We is selected from the group consisting of null, -O-, -S-, -S(O)-, -S(O)2-, -NRg-, -CH-, -N-, -CH2 and -C(O)-; wherein the bonds between Wi, W2, W3 and W4 can be single or double bonds; provided that: (i) no more than two of W1, W2, W3 and W4 are null; (ii) no more than two of W1, W2, W3 and W4 are -O-, -S-, -S(O)-, -S(O)2-, -NRg- or -C(O)-; (iii) if two of W1, W2, W3 and W4 are -O- and / or -S-, at least one carbon atom is present between them; and (iv) when W1, W2, W3 or W4 is -CH- and / or -NR9-,a double bond is formed within the ring formed by W1, W2, W3 and W4; Rg, in each case, is independently selected from the group consisting of hydrogen and C1Ce-alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-Ce cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl and -SO2C1-C4 alkyl; R10, in each case, is independently selected from the group consisting of oxo, C1-C4 alkyl and C3-Ce cycloalkyl; X is a 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the O, S, and N group, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2, or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl,C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C3-C6 cycloalkyl, -C6-C6 alkyl and -C6-C6 haloalkyl, C3-Ce cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -C3-C6 cycloalkyl, -C(O)NH-C6 alkyl and -C(O)NH-C6 haloalkyl, wherein any N in the heteroaryl, if valency permits, is optionally substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl,-S(O)C3-C4 alkyl, SO2C4-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl and -C(O)NH-C6-C6 haloalkyl, and C3-Cs cycloalkyl; or 121 X is selected from the group consisting of R11 N.. WY and O wherein R11 is selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C2-C7 alkylcarbonyl, C2-C5 alkoxycarbonyl,C2-C6 alkenyl and C2-C6 alkynyl; W is selected from the group consisting of (i) hydrogen; (ii) C1-C6 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen; cyano; hydroxyl; oxo; C1-C4 alkoxy; C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents selected independently from the halogen and cyano group; acetylenel; -NH2; C2-C7 aminocarbonyl; -NH(C1-C4 alkyl); -N(C1-C4 alkyl)2; -SC1-C4 alkyl; -S(O)C1-C4 alkyl; -SO2C1-C4 alkyl; -C(O)NH-C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, hydroxyl, cyano and C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy,C3Ce cycloalkyl and -NH2; -C(O)NH-Ci-C6 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, C3Oβ cycloalkyl and -NH2; -C(O)NH-Ci-C6 cyanoalkyl optionally substituted with 1 to 3 halogens; C(O)NH-Ci-C6 haloalkyl; -C(O)-4- to 7-membered heterocycloalkyl linked by a nitrogen and optionally having 1 or 2 further heteroatoms selected from the group of O, S, and N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, -NH2, C1-C7 aminocarbonyl, C1-C4 alkyl, optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl,-S(O)C3-C4 alkyl, SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C6-C6 alkyl, and C3-Ce cycloalkyl, wherein any other N in the 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1C4 alkyl, -SO2C1-C4 haloalkyl and C1-C4 alkyl optionally substituted with 1 to 5 substituents 122 independently selected from the group consisting of halogen, cyano, hydroxyl, acetylene, C4 alkoxy, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C3-C4 alkyl, -SO2C1-C4 alkyl, C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl and -C(O)NH-C6-C6 haloalkyl; 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1,2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C4-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C4-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -SCi-C4 alkyl, -S(O)C4-C4 alkyl, -SO2C4-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl and -C(O)NH-C6-C6 haloalkyl, Cs-Ce cycloalkyl, C4-C4 haloalkyl, C4-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2 and -C(O)NH-C3-C6 cycloalkyl, wherein any N in the heteroaryl, if valency permits, is optionally substituted with a substituent selected from the group consisting of hydrogen, Ci-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylene, oxo, Ca-Ce cycloalkyl,Ci-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SCi-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2Ci-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NHCi-Ce alkyl, and Cs-Ce cycloalkyl, wherein any S in the heteroaryl is optionally substituted with 1 or 2 oxygen atoms; phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, Ci-C4 alkyl, cyano and hydroxyl; C3-C6 cycloalkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C4-C4 alkoxy, C4-C4 alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C4-C4 haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -C4-C4 alkyl, -S(O)C4-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl, -C(O)NH-C6-C6 haloalkyl,C2-C6 alkenyl and C2-C6 alkynyl; and a 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S, B, and N, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, and C3-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C3-C6 cycloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -C4-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2Ci-C4 alkyl, -CfOjNH-Cs-Ce cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl,wherein any B in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with hydroxyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2Ci-C4 alkyl, -SO2Ci-C4 haloalkyl, -C(O)-NH2, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenel, C1-C4 alkoxy, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2Ci-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NHCi-Ce haloalkyl, C3-C6 cycloalkyl,5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; (iii) Cs-Ce cycloalkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, C1-C4 alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C1-C4 haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C1-C6 alkyl, -C(O)NH-C1-C6 haloalkyl,Cg-Ce alkenyl optionally substituted with 1 to 3 halogens and C2-Cs alkynyl; (iv) a 6-membered aryl or 5- to 10-membered heteroaryl having 1, 2, or 3 heteroatoms selected from the group of O, S, and N, wherein the carbons of the 6-membered aryl and the 5- to 10-membered heteroaryl are optionally substituted with 1, 2, or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl, optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SCi-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and C(O)NH-Ci-C6 alkyl, C3-Ce cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(Ci-C4 alkyl), -N(CiC4 alkyl)2 and -C(O)NH-C3-C6 cycloalkyl, wherein any N in the heteroaryl, if valency permits,is optionally substituted with a substituent selected from the group consisting of hydrogen and C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C3-C6 cycloalkyl and -C6-C1-C6 alkyl; (v) 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the O, S and N group, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C1-C4 alkoxy,C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, C3-Ce cycloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2Ci-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -SO2NH(C1-C4 alkyl), -SO2N(C1-C4 alkyl)z, -C(O)-NHz, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenel, oxo, C1-C4 alkoxy, C1-C2 cycloalkyl,-NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NHC1-C6 haloalkyl, C3-C6 cycloalkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; and (V¡) -NR12R13 wherein R12 is selected from the group consisting of hydrogen, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C1-C7 alkylcarbonyl, C1-C7 aminocarbonyl, and C2-C5 alkoxycarbonyl; R13 is selected from the group consisting of hydrogen, C2-C6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano,nitro, hydroxyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl and -SO2C1-C4 alkyl, C3-C6 cycloalkyl, -C(O)C1-C2 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C1-C4 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)z, -SC1-C4 alkyl, -S(O)C1-C4 alkyl and -SO2C1-C4 alkyl, 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the O, S, and N group, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo,C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NHh, C1-C7 aminocarbonyl, -NH(CiC4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-Cs cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, and Cs-Ce cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group that consists of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylene, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1C4 alkyl,-C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, C3-Ce cycloalkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; and a 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2, or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl),-N(C4-C1 alkyl)2, -SC1-C4 alkyl, -S(O)C4-C1 alkyl, -SO2C4-C1 alkyl, -C(O)NH-C3-C6 cycloalkyl and C(O)NH-C6-C1 alkyl, C3-C6 cycloalkyl, C4-C1 haloalkyl, C4-C1 alkoxy, -NH2, -NH(C4-C1 alkyl), -N(C4-C1 alkyl)2, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C6-C1 alkyl, wherein any N in the heteroaryl, if valency permits, is optionally substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SCi-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl,and C3-C6 cycloalkyl; or Rn and W are taken together with the nitrogen to which they are attached to form a 4- to 7-membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S, and O, wherein the ring carbons are optionally substituted with 1 to 4 substituents independently selected from cyano, hydroxyl, oxo, halogen, C1-C2 alkoxy, N,N-di-C1-C4 alkylaminocarboxyl, N-C1-C4 alkylaminocarboxyl, C1-C7 aminocarboxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C3-C1-C2 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2 and -C(O)NH-C3-C6 cycloalkyl, C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, cyano, hydroxyl and C1-C4 alkoxy, C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl, -C(O)NH-Ci-C6 haloalkyl,5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C4-alkyl, cyano, hydroxyl, C1-C2 alkoxy, N,N-di-C4-alkylaminocarboxyl, N-C4-alkylaminocarboxyl and C1-C7 aminocarboxyl, wherein any N in the 4- to 7-membered ring is substituted with a substituent selected from the group consisting of hydrogen, C4-alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C3-C4 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C4-alkyl), -N(C4-alkyl)2 and -C(O)NH-C3-C6 cycloalkyl, C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-CiCe alkyl,5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered ring is optionally substituted with 1 or 2 oxygen atoms; and Y is optionally substituted C3-C6 alkyl with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, acetylenel, -NH2, C1-C7 aminocarbonyl, -NH(C3-C4 alkyl), -N(C3-C4 alkyl)2, -SC1-C4 alkyl, S(O)C3-C4 alkyl, -SO2C3-C4 alkyl, -SO2NH(C3-C4 alkyl), -SO2N(C3-C4 alkyl)2, -SO2NH(C3-C4 haloalkyl), -C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, hydroxyl,cyano and C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy and -NH2, -C(O)NH-Ci-C6 alkyl, -C(O)NH-Ci-C6 cyanoalkyl optionally substituted with 1 to 3 halogens, -C(O)NH-Ci-C6 haloalkyl, phenyl optionally substituted with 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(Ci-C4 alkyl), -N(C1-C4 alkyl)2 and -C(O)NHC3-C6 cycloalkyl, and C3-C6 cycloalkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2,-SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C1-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl, 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C4-C1 alkyl), -N(C4-C1 alkyl)2, -SC1-C4 alkyl, -S(O)C4-C1 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C6-C1 alkyl, C3-Ce cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C4-C1 alkyl), -N(C4-C1 alkyl)z, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C6-C1 alkyl,wherein any N in the heteroaryl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C1-C6 alkyl and Cs-Ce cycloalkyl, and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the The heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl,oxo, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C1-C6 alkyl, and C3-C6 cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C1-C6 alkyl,C3-Ce cycloalkyl and 5- to 6-membered heteroaryl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; or a salt thereof.

2. A compound according to claim 1, characterized in that W is selected from the group consisting of (i) hydrogen; (ii) C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen; cyano; hydroxyl; oxo; C1-C4 alkoxy; C1-C4 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the halogen and cyano group; acetylenel; -NH2; C1-C4 aminocarbonyl; -NH(C1-C4 alkyl); -N(C1-C4 alkyl; -SC1-C4 alkyl; -S(O)C1-C4 alkyl; -SO2C1-C4 alkyl; -C(O)NH-C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, hydroxyl, cyano and C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy,CsCe cycloalkyl and -NH2; -C(O)NH-Ci-Ce alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, CsCe cycloalkyl and -NH2; -C(O)NH-Ci-Ce cyanoalkyl optionally substituted with 1 to 3 halogens; C(O)NH-Ci-Ce haloalkyl; -C(O)-4- to 7-membered heterocycloalkyl linked by a nitrogen and optionally having 1 or 2 further heteroatoms selected from the group of O, S and N, wherein the carbons of the 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, -NH2, C1-C7 aminocarbonyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2,-SCi-C4 alkyl, -S(O)Ci-C4 alkyl, SO2Ci-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, and Cs-Ce cycloalkyl, wherein any other N in the 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1C4 alkyl, -SO2Ci-C4 haloalkyl and Ci-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylene, C1C4 alkoxy, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SCi-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, C(O)NH-C3-Ce cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl; 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1,2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C4-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C4-C4 alkyl, -SO2C4-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl and -C(O)NH-C6-C6 haloalkyl, Ca-Ce cycloalkyl, C1-C4 haloalkyl, C4-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(C3-C4 alkyl), -N(C3-C4 alkyl)? and -C(O)NH-C3-C6 cycloalkyl, wherein any N in the heteroaryl, if valency permits, is optionally substituted with a substituent selected from the group consisting of hydrogen, C3-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylene, oxo, C3-C6 cycloalkyl,C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SCi-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NHC1-C6 alkyl, and C3-C6 cycloalkyl, wherein any S in the heteroaryl is optionally substituted with 1 or 2 oxygen atoms; phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl; C3-C6 cycloalkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C4-C4 alkoxy, C1-C4 alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C4-C4 haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C4-C4 alkyl, -SO2C4-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl, -C(O)NH-C6-C6 haloalkyl,C2-C6 alkenyl and C2-Ce alkynyl; and a 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S, B, and N, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, and C3-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C3-C6 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C3-C4 alkyl), -N(C3-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl,wherein any B in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with hydroxyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -C(O)-NH2, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenel, C1-C4 alkoxy, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2Ci-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NHCi-Ce haloalkyl, C3-Ce cycloalkyl,5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; (iii) C3-Ce cycloalkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, C1-C4 alkyl optionally substituted with 1 to 3 groups selected from the group consisting of halogen and cyano, C1-C4 haloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C1-C6 alkyl, -C(O)NH-C1-C6 haloalkyl,C2-C6 alkenyl optionally substituted with 1 to 3 halogens and C2-C6 alkynyl; (iv) a 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2, or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl, optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, and -C(O)NH-C1-C6 alkyl, Cs-Ce cycloalkyl, C1-C4 haloalkyl, Ci-C4 alkoxy, -NH2, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2 and -C(O)NH-C3-C6 cycloalkyl, wherein any N in the heteroaryl, if valency permits,is optionally substituted with a substituent selected from the group consisting of hydrogen and C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C1-C6 alkyl; (v) a 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the O, S, and N group, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo,C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C3-C6 cycloalkyl, -NH2, C1-C7 aminocarbonyl, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C4-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl and C(O)NH-C6-C6 haloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, -NH2, C1-C7 aminocarbonyl, -SO2C1-C4 alkyl, -SO2C1-C4 haloalkyl, -C(O)-NH2, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylene, C1-C4 alkoxy, C3-C6 cycloalkyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl,-S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 haloalkyl, Cs-Cs cycloalkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; and (vi) -NR12R13 wherein R12 is selected from the group consisting of hydrogen, C2-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C1-C7 alkylcarbonyl, C1-C7 aminocarbonyl, and C2-C5 alkoxycarbonyl; R13 is selected from the group consisting of hydrogen, C2-C6 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy,-NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl and -SO2C1-C4 alkyl, C3-C6 cycloalkyl, -C(O)-C1-C6 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl and -SO2C1-C4 alkyl, 4 to 7 membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the heterocycloalkyl is optionally benzofused, wherein the carbons of the 4 to 7-membered heterocycloalkyl or the optionally benzofused 4 to 7-membered heterocycloalkyl are optionally substituted with 1 to 4 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo,C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(CiC4 alkyl), -N(Ci-C4 alkyl)2, -SCi-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-Q alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-C6 alkyl and -C(O)NH-Ci-C6 haloalkyl, and C3-C6 cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected of the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently of the group consisting of halogen, cyano, hydroxyl, acetylene, C1-C4 alkoxy, -NH2, C1-C4 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)?, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1C4 alkyl,-C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, C3-Ce cycloalkyl, 5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofused 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; and a 5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2, or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl),-N(C1-C4 alkyl)?, -SCi-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and C(O)NH-C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C1-C6 alkyl, wherein any N in the heteroaryl, if valency permits, is optionally substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)?, -SC1-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl,and C3-C6 cycloalkyl; or R11 and W are taken together with the nitrogen to which they are attached to form a 4- to 7-membered ring optionally containing 1 to 2 heteroatoms selected from the group consisting of N, S, and O, wherein the ring carbons are optionally substituted with 1 to 4 substituents independently selected from cyano, hydroxyl, oxo, halogen, C1-C2 alkoxy, N,N-di-C1-C4 alkylaminocarboxyl, N-C1-C4 alkylaminocarboxyl, C1-C7 aminocarboxyl, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C3-C3 cycloalkyl, C1-C4 alkoxy, -NH₂, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)₂ and -C(O)NH-C3-Cs cycloalkyl, C3-Cs cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, cyano, hydroxyl and C1-C4 alkoxy, C(O)NH-C3-C6 cycloalkyl, -C(O)NH-Ci-Ce alkyl, -C(O)NH-Ci-Cs haloalkyl,5- to 6-membered heteroaryl and optionally substituted phenyl with 1 to 3 substituents selected independently from the group consisting of halogen, C1-C4 alkyl, cyano, hydroxyl, C1-C? alkoxy, N,N-di-C1-C4 alkylaminocarboxyl, N-C1-C4 alkylaminocarboxyl and C1-C7 aminocarboxyl, wherein any N in the 4- to 7-membered ring is substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C3-C6 cycloalkyl, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2 and -C(O)NH-C3-C6 cycloalkyl, C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, C1-C4 alkoxy, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-CiCe alkyl,5- to 6-membered heteroaryl and phenyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, C1-C4 alkyl, cyano and hydroxyl, wherein any S in the 4- to 7-membered ring is optionally substituted with 1 or 2 oxygen atoms; and Y is optionally substituted Ci-Cs alkyl with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, Cs-Ce cycloalkyl, C1-C4 alkoxy, acetylenyl, -NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SC1-C4 alkyl, S(O)Ci-C4 alkyl, -SO2Ci-C4 alkyl, -C(O)C3-C6 cycloalkyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, hydroxyl, cyano and Ci-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, Ci-C4 alkoxy and -NH2,-C(O)NH-C6 alkyl, -C(O)NHC6 cyanoalkyl optionally substituted with 1 to 3 halogens, -C(O)NH-C6 haloalkyl, phenyl optionally substituted with 1, 2 or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, C1-C4 alkyl optionally substituted with 1 to 3 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, Cs-C4 cycloalkyl, C1-C4 haloalkyl, C1-C4 alkoxy, -NH2, -NH(C3-C4 alkyl), -N(C3-C4 alkyl)2 and -C(O)NHC3-C4 cycloalkyl, and C3-C4 cycloalkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting in halogen, cyano, hydroxyl, oxo, C4-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C4-C4 alkyl), -N(C4-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C4-C4 alkyl, -SO2C4-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, -C(O)NH-C6-C6 alkyl, C2-C6 alkenyl and C2-C6 alkynyl,5- to 10-membered heteroaryl having 1 or 2 heteroatoms selected from the group of O, S, and N, wherein the carbons of the 5- to 10-membered heteroaryl are optionally substituted with 1, 2, or 3 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, Ci-C4 alkyl, optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano, hydroxyl, oxo, Ci-C4 alkoxy, -NH2, Ci-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -SCi-C4 alkyl, -S(O)Ci-C4 alkyl, -SO2Ci-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl, and -C(O)NH-Ci-C6 alkyl. C3-Cs cycloalkyl, C1-C4 haloalkyl, Ci-C4 alkoxy,-NH2, C1-C7 aminocarbonyl, -NH(Ci-C4 alkyl), -N(Ci-C4 alkyl)2, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-Ci-C6 alkyl, wherein any N in the heteroaryl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen,C1-C4 optionally substituted 133 alkyl with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylenyl, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SCi-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C1-Ce alkyl and C1-Ce cycloalkyl, and 4- to 7-membered heterocycloalkyl having 1 or 2 heteroatoms selected from the group of O, S and N, wherein the heterocycloalkyl is optionally benzofuslonated, wherein the carbons of the 4- to 7-membered heterocycloalkyl or The optionally benzofuslonated 4- to 7-membered heterocycloalkyl is optionally substituted with 1 to 4 substituents selected independently from the group consisting of halogen, cyano, nitro, hydroxyl, oxo, Ci-C4 alkyl optionally substituted with 1 to 5 substituents selected independently from the group consisting of halogen, cyano,hydroxyl, acetylene, oxo, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-C6 cycloalkyl and -C(O)NH-C1-C6 alkyl, and C1-C1-C2 cycloalkyl, wherein any N in the 4- to 7-membered heterocycloalkyl or the optionally benzofuslonated 4- to 7-membered heterocycloalkyl, if valency permits, is substituted with a substituent selected from the group consisting of hydrogen, C1-C4 alkyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, acetylene, C1-C4 alkoxy, -NH2, C1-C7 aminocarbonyl, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -SC1-C4 alkyl, -S(O)C1-C4 alkyl, -SO2C1-C4 alkyl, -C(O)NH-C3-Ce cycloalkyl and -C(O)NH-C1-C6 alkyl, Cs-Cs cycloalkyl and 5- to 6-membered heteroaryl,wherein any S in the 4- to 7-membered heterocycloalkyl or the optionally benzofuslonated 4- to 7-membered heterocycloalkyl is optionally substituted with 1 or 2 oxygen atoms; or a salt thereof.

3. A compound according to claim 1, characterized in that R1 is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is trifluoromethyl and Rs is a halogen; or a salt thereof.

4. A compound according to claim 1, characterized in that R1 is trifluoromethyl, R3 is hydrogen, R4 is halogen and Rs is halogen; or a salt thereof.

5. A compound according to claim 1, characterized in that R1 is trifluoromethyl, R3 is hydrogen, R4 is chlorine and Rs is a halogen; or a salt thereof.

6. A compound according to claim 1, characterized in that R1 is trifluoromethyl, R3 is hydrogen, R4 is halogen and Rs is chlorine; or a salt thereof.

7. A compound according to claim 1, characterized in that R1 is trifluoromethyl, R3 is hydrogen, R4 is halogen and Rs is fluoro; or a salt thereof.

8. A compound according to claim 1, characterized in that R1 is trifluoromethyl, Rs is hydrogen, R4 is chlorine and Rs is fluoro; or a salt thereof.

9. A compound according to claim 1, characterized in that R1 is hydrogen, R2 is hydrogen, R2 is hydrogen, R2 is hydrogen, R2 is hydrogen, R2 is hydrogen, R2 is hydrogen, R2 is trifluoromethyl, R3 is hydrogen, R4 is bromine and Rs is fluoro; or a salt thereof.

10. A compound according to any one of claims 1 to 9, characterized in that Ai is CF3; or a salt thereof. 134 11. A compound according to any one of claims 1 to 9, characterized in that Ai is CHF2; or a salt thereof.

12. A compound according to claim 1, characterized in that it is selected from the group consisting of: 5 Example Compound 1.1 2-methylsulfonyl-1-[6-[(5S 0 R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)4H-isoxazol-3-yl]spiro[1 H-isobenzofuran-3,3'-azetidin]-1'-yl]ethanone; 10 1.2 2-methylsulfonyl-1-[6-[(5R 0 S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)4H-isoxazol-3-yl]spiro[1 H-isobenzofuran-3,3'-azetidin]-1'-yl]ethanone; 2.1 N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S 0 R)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]naphthalen-1-carboxamide; 2.2 N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R 0 S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]naphthalen-1-carboxamide; 15 3.1 2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S 0 R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-soxazol-3-l]benzamide; 3.2 2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R 0 S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-oxaxazol-3-yl]benzamide; 20 3.3 4-[(5S 0 R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-¡l]2-methyl-N-[(4R)-3-oxo-2-(2,2,2-trifluoroethyl)isoxazolidin-4-¡l]benzamide; 3.4 4-[(5S 0 R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]2-methylN-[(4S)-3-oxo-2-(2,2,2-trifluoroethyl)isoxazoldan-4-yl]benzamide; 3.5 4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-oxazol-3-yl]-2methylN-[(3S)-2-oxo-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]benzamide; 25 3.6 4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-oxazo1-3-yl]-2methyl-N-[(3R)-2-oxo-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl]benzamide; 3.7 4-[(5RS)-5-[3-cloro-2-fluoro-5-(tr¡fluoromet¡l)fenil]-5-(tr¡fluorometil)-4H-¡soxazol-3-¡l]-2met¡l-N-[(4S)-3-oxo-2-(2,2,2-tr¡fluoroet¡l)¡soxazol¡d¡n-4-¡l]benzam¡da; 30 3.8 N-[2-(c¡cloprop¡lmet¡lam¡no)-2-oxo-et¡l]-2-metil-4-[(5RS)-5-[3-cloro-2-fluoro-5(tr¡fluoromet¡l)fen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-¡l]benzam¡da; 3.9 3-metil-N-[2-oxo-2-(2,2,2-tr¡fluoroet¡lam¡no)etil]-5-[(5RS)-5-(tr¡fluorometil)-5-(2,4,6tr¡fluorofen¡l)-4H-¡soxazol-3-¡l]tiofen-2-carboxam¡da; 3.10 (2R)-1 -[5-[(5RS)-5-[3-cloro-2-fluoro-5-(tr¡fluorometil)fenil]-5-(tr¡fluorometil)-4H-¡soxazol3-il]-3-metil-tiofen-2-carbonil]-N-(2,2,2-trifluoroetil)pirrolidin-2-carboxamida; 35 3.11 (2S)-1 -[5-[(5RS)-5-[3-cloro-2-fluoro-5-(tr¡fluorometil)fen¡l]-5-(tr¡fluoromet¡l)-4H-isoxazol3-¡l]-3-met¡l-t¡ofen-2-carbon¡l]-N-(2,2,2-trifluoroet¡l)p¡rrol¡d¡n-2-carboxam¡da; 3.12 3-methyl-5-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-¡soxazol- 135 3-¡l]-N-[(3RS)-2-oxo-1-(2,2,2-tr¡fluoroethyl¡l)p¡rrol¡d¡n-3-¡l]t¡ofen-2-carboxamide; 3.13 3-methyl-N-(4-pyridyl)-5-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)4H-isoxazol-3-yl]thiofen-2-carboxamide; 3.14 [2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4H-isoxazol3-¡l]phenyl]-[(3RS)-3-hydrox¡p¡rrol¡d¡n-1-yl]methanone; 3.15 2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-oxaxazol3-yl]-N-[(3RS)-1-cyclopropyl-2-oxo-pyrrolidine-3-yl]benzamide; 3.16 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-oxaxazol-3-yl]N-(trans-3-cyanochlorobutyl)-2-methyl-benzamide; 3.17 4-[(5S o R)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phenyl]-5-(tr¡fluoromethyl)-4H-isoxazol-3-¡l]N-(trans-3-cyanoclobutyl)-2-methyl-benzam¡da; 3.18 2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[[4-(trifluoromethyl)thiazol-2-yl]methyl]benzamide; 3.19 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]N-(cis-3-cyanocyclobutyl)-2-methylbenzamide; 3.20 4-[(5S o R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-oxaxazol-3-yl]N-(cis-3-cyanocyclobutyl)-2-methylbenzamide; 3.21 4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2methyl-N-[(3R)-2-oxopyrrolidin-3-yl]benzamide; 3.22 4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2methyl-N-[(3S)-2-oxopyrrolidin-3-yl]benzamide; 3.23 N-[(4-cyanothiazol-2-yl)methyl]-2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.24 2-methyl-N'-(2-met¡lsulfon¡lacet¡l)-4-[(5RS)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phen¡l]-5(tr¡fluorometh¡l)-4H-¡soxazol-3-hydrazone]; 3.25 2-methyl-N-(2-oxo¡midazolidine-1-¡l)-4-[(5RS)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phen¡l]-5(tr¡fluorometh¡l)-4H-¡soxazol-3-benzamida]; 3.26 2-met¡lN-[2-oxo-3-(2,2,2-tr¡fluoroet¡l)¡m¡dazol¡din-1-¡l]-4-[(5RS)-5-[3-chloro- 2-fluoro-5(tr¡fluorometh¡l)phen¡l]-5-(tr¡fluoromethl)-4H-¡soxazole-3-¡l]benzamide; 3.27 4-[(5S o R)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-isoxazole-3-¡l]N-[(3S)-1-(cyanomethyl)-2-oxo-p¡rrol¡d¡n-3-b¡l-b¡l-menzamida]; 3.28 4-[(5S o R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]N-[(3R)-1 -(c¡anomet¡l)-2-oxo-pyrrol¡d¡n-3-¡l]-2-methyl-benzamide; 3.29 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5-(trifluoromethyl)-4H-¡soxazol-3-yl]N-[(3S)-1-(cyanomet¡l)-2-oxo-pyrrol¡d¡n-3-¡l]-2-meth-l-benzamide; 3.30 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-¡l]-7cnQcn / 77n7 / q / υili 136 N-[(3R)-1 -(cyanomethyl)-2-oxo-pyrrol¡d¡n-3-¡l]-2-methyl-benzamide; 3.31 3-methyl-5-[(5RS)-5-[3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluoromethyl)-4H-¡soxazol3-¡l]-N-[[4-(trifluoromethyl)thiazol-2-yl]methyl]thiophene-2-carboxamide; 3.32 N-[(4-cyanothiazol-2-yl)methyl]-3-methyl-5-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]thiophene-2-carboxamide; 3.33 2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[(3RS)-1-ethyl-2-oxo-pyrrolidin-3-yl]benzamide; 3.34 2-methyl-N-(1-methyl-azetidin-3-yl)-4-[(5 R o S)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.35 2-methyl-N-(1-methylsulfonylazetidin-3-yl)-4-[(5 S o R)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.36 N-[1 -(ciclopropancarbonil)azetid in-3-¡ l]-2-metil-4-[(5R o S)-5-[3-cloro-2-fluoro-5- (trifluoromet¡l)fen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-il]benzam¡da; 3.37 N-[1 -(c¡clopropancarbon¡l)azet¡din-3-¡l]-2-met¡l-4-[(5S o R)-5-[3-cloro-2-fluoro-5(tr¡fluoromet¡l)fen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-¡l]benzam¡da; 3.38 2-metil-4-[(5R o S)-5-[3-cloro-2-fluoro-5-(tr¡fluoromet¡l)fen¡l]-5-(tr¡fluoromet¡l)-4Hisoxazol-3-¡l]-N-[3-(tr¡fluoromet¡l)c¡clobut¡l]benzamida; 3.39 2-metil-4-[(5S o R)-5-[3-cloro-2-fluoro-5-(trifluorometil)fenil]-5-(trifluorometil)-4Hisoxazol-3-il]-N-[3-(trifluorometil)c¡clobut¡l]benzamida; 3.40 2-metil-4-[(5S o R)-5-[3-cloro-2-fluoro-5-(tr¡fluorometil)fenil]-5-(tr¡fluorometil)-4Hisoxazol-3-il]-N-[1 -(2,2,2-trifluoroetil)azetidin-3-¡l]benzamida; 3.41 2-metil-4-[(5R o S)-5-[3-cloro-2-fluoro-5-(tr¡fluorometil)fenil]-5-(tr¡fluorometil)-4Hisoxazol-3-¡l]-N-[1-(2,2,2-trifluoroet¡l)azet¡d¡n-3-il]benzam¡da; 3.42 2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-¡soxazol3-¡l]-N-[1 -(2,2,2-trifluoroethyl)pyrazol-4-yl]benzamida; 3.43 2-methyl-N-(oxethan-3-yl)-4-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-¡l]benzamida; 3.44 2-Methyl-N-(oxetan-3-yl)-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-soxazol-3-yl]benzam¡da; 3.45 2-Methyl-4-[(5S or R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-N-[1-(1,3,4-thiadiazol-2-yl)azetidin-3-yl]benzam¡da; 3.46 2-methyl-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(tnfluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-N-[1-(1,3,4-thiadiazol-2-yl)azet¡d¡n-3-¡l]benzam¡da; 3.47 4-[(5RS)-5-[3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluoromethyl)-4H-¡soxazol-3-¡l]-N(c¡s-3-methox¡cyclobutyl)-2-met¡l-benzam¡da; 3.48 N-(3-cyano-1-bicyclo[1.1.1]pentanyl)-2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5- 7cnQcn / 77n7 / q / υιλι 137 (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.49 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]2-methylN-((cis)3-methylsulfonylcyclobutyl)benzamide; 3.50 N-(3-fluorocyclobutyl)-2-methyl-4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.51 2-methyl-4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-N-(t¡etan-3-yl)benzam¡da; 3.52 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-¡soxazol-3-yl]N-(1,1-d¡oxotietan-3-yl)-2-methyl-benzam¡da; 3.53 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-isoxazol-3-¡l]2-methyl-N-[(3R)-2-oxoazet¡din-3-¡l]benzamide; 3.54 4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]2-methyl-N-[(3S)-2-oxoazetidine-3-yl]benzamide; 3.55 N-cyclobutyl-2-methyl-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.56 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5RS)-5-[2,4-difluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]thiophene-2-carboxamide; 3.59 2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-oxaxazol3-yl]-N-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]benzamide; 3.60 2-methyl-4-[(5RS)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5-(trifluoromethyl)-4H-¡soxazol3-¡l]-N-[1-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-¡l]benzam¡da; 3.61 2-methyl-4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[1-(trifluoromethylsulfonyl)azetidin-3-yl]benzamide; 3.62 2-methyl-N-(2-oxaespiro[3.3]heptan-6-yl)-4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.63 N-(1 -cyanoc¡cloprop¡l)-2-methyl-4-[(5R or S)-5-[3-chlo ro-2-f I uoro-5-(trif luoromethi l)fe nil]-5(tr¡fluoromet¡l)-4H-¡soxazol-3-¡l]benzamide; 3.64 N-(azetidin-3-¡l)-2-methyl-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5(tr¡fluoromethyl)-4H-¡soxazol-3-yl]benzam¡da; 3.65 2-methyl-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H¡soxazole-3-¡l]-N-[trans-3-(tr¡fluorometh¡l)c¡lbenzamide; 3.66 N-[1 -(dimethy Isu If amoi l)azetidine-3-¡ l]-2-meth¡ l-4-[(5 R o S)-5-[3-chloro-2-fluoro-5- (trifluoromet¡l)phen¡l]-5-(tr¡fluorometh¡l)-4H-xazol-3-3-ml]; 3.71 3-[[2-methyl-4-[(5S or R)-5¿3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4Hysoxazol-3-¡l]benzo¡l]azetyl-carmine-1; 3.72 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-isoxazole-3-¡l]- 7cnQcn / 77n7 / q / υιλ138λ 2-met¡lN-[(3S)-2-oxo-1-(2,2,2-tr¡fluoroeth¡l)azet¡d¡n-3-¡l]benzamide; 3.73 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-¡soxaz ol-3-¡l]2-met¡lN-[(3R)-2-oxo-1-(2,2,2-tr¡fluoroeth¡l)azetid¡n-3-¡l]benzamide; 3.74 2-methyl-4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H¡soxazol-3-¡l]-N-[c¡s-3-(tr¡fluorometh¡l)c¡s-3-(tr¡fluorometh¡l)clobutylbenzal¡amda]; 3.75 N-[1 -(cyanomethyl)p¡razol-4-yl]-2-met¡l-4-[(5S or R)-5-[3-chloro-2-fluoro-5- (trifluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazole-3-benzade]; 3.76 4-[(5S or R)-5-[3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluoiOmethyl)-4H-¡soxazol-3-¡l]N-[(3R)-1 -(c¡anomethyl)p¡rrol¡n-3-l]-2-met¡l-benzamide; 3.77 N-[(1 -cyanocycloprop¡l)met¡l]-2-met¡l-4-[(5R or S)-5-[3-chloro-2-fluoro-5- (trifluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-isoxazole-3-ylbenzamide]]; 3.78 2-methyl-4-[(5S o R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromet¡l)-4Hysoxazol-3-yl]-N-[(4R o S)-2-methylsulfonyl¡soxazolidine-4-benzam¡m¡]; 3.79 2-methyl-4-[(5S o R)-5-[3-chloro-2-fluoro-5-(tnfluoromethyl)phen¡l]-5-(tnfluoromet¡l)-4Hisoxazol-3-yl]-N-[(4S o R)-2-methylsulfon¡l¡soxazol¡d¡n-4-¡l]benzamide; 3.80 4-[(5S o R)-5-[3-chloro-2-fluoro-5-(tr¡fluorometh¡l)phen¡l]-5-(tr¡fluorometh¡l)-4H-¡sox azole-3-¡l]2-met¡lN-[(3R)-1-(2,2,2-trifluoroethyl)p¡rrol¡n-3-¡l]benzamide; 3.81 N-(3-cyanophen¡l)-2-methyl-4-[(5S o R)-5-[3-chloro-2-fluoro-5-(trifluoromet¡l)phen¡l]-5- (trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3.82 2-methyl-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phenyl]-5-(tr¡fluoromethyl)-4Hysoxazole-3-¡l]-N-[[1-(tr¡fluorometh¡l)clp¡lb); 3.83 2-methyl-N-[(1 -methi Isu Iphonylcyclopropy I) methi l]-4-[(5 R or S)-5-[3-chloro-2-fluoro-5- (tr¡fluoromethl)phen¡l]-5-(tr¡fluoromethl)-4H-soxazol-3-l]benzamide; 3.84 4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazole-3-¡l]2-methyl-N-[(3S)-5-oxopyrrolidin-3ylbenzamida]; 3.85 4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]2-met¡lN-[(3R)-5-oxop¡rroldin-3-¡benzam¡]; 3.86 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-¡soxazol-3-¡l]N-[(3S)-1-ethyl-5-oxo-pyrrol¡d¡n-3-¡l]-meth-benzamida; 3.87 4-[(5R or S)-5-[3-chloro-2-fluoro-5-(tr¡fluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-isoxazole-3-¡l]N-[(3R)-1 -ethyl-5-oxo-p¡rrol¡n-3-¡l]-2-methyl-benzamide; 3.88 2-methyl-4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromet¡l)phen¡l]-5-(trifluorometh¡l)-4Hisoxazol-3-yl]-N-[(4S o R)-2-ethylsoxazolide-4-benzalida]; 3.89 2-methyl-4-[(5R o S)-5¿3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4Hysoxazol-3-yl]-N-[(4R o S)-2-ethyl¡soxazol¡d¡n-4-yl]benzamide; 3.90 4-[(5S o R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5-(tr¡fluoromethyl)-4H-isoxazole-3-¡l]- 7cnQcn / 77n7 / q / υιλ139ι N-[cis-3-c¡anoc¡chlopentyl]-2-methyl-benzamide; 3.91 N-(cis-4-cyanoc¡chlohex¡l)-2-meth¡l-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]-5(tr¡fluoromethyl)-4H-¡soxazol-3-benzalda]; 3.92 N-(trans-4-cyanocyclohexyl)-2-met¡l-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phen¡l]5-(tr¡fluoromet¡l)-4H-¡soxazol-3-yl]benzamide; 3.93 2-methyl-N-(3-methylot¡ethane-3-yl)-4-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluorometh¡l)-4H-¡soxazol-3-yl]benzamide; 3.94 2-methyl-4-[(5S o R)-5¿3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4Hysoxazol-3-yl]-N-[(5S o R)-3-ethoxy-4,5-d¡h¡droisoxazole-5-¡l]benzamide; 3.95 2-methyl-4-[(5S o R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4Hisoxazol-3-yl]-N-[(5R o S)-3-ethoxy-4,5-d¡h¡h¡¡so¡xal-b¡mizol-5¡]; 3.96 N-(trans-3-cyano-3-fluoro-cyclobut¡l)-2-met¡l-4-[(5R or S)-5-[3-chloro-2-fluoro-5- (trifluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4H-¡zoxail-menzab¡l]; 3.97 4-[(5R o S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]2-met¡lN-[(3SR)-5-oxo-1-(2,2,2-tr¡fluoroeth¡l)p¡rrol-benza-3m¡m¡n]; 3.98 4-[(5R or S)-5-[3-chloro-2-fluoro-5-(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluorometh¡l)-4H-¡soxazol-3-¡l]N-[(3SR)-1 -(cycloprop¡lmethl)-5-oxo-p¡rrol¡n-3-¡l]-2-methl-benzamide; 4.1 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylam¡no)et¡l]-5-[(5S o R)-5-[3-chloro-2-fluoro-5(trifluoromethyl)phen¡l]-5-(tr¡fluorometh¡l)-4l-l-¡soxazol-3-yl]t¡ophen-2-carboxamide; 4.2 3-met¡lN-[2-oxo-2-(2,2,2-tr¡fluoroethylamine)et¡l]-5-[(5R o S)-5-[3-chloro-2-fluoro-5(tr¡fluoromet¡l)phen¡l]-5-(tr¡fluorometh¡l)-4H-¡soxazol-3-¡l]t¡ophen-2-carboxam¡da; 4.3 N-(c¡s-3-cyanoc¡clobutyl)-3-met¡l-5-[(5R or S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(tr¡fluorometh¡l)-4H-¡soxazol-3-yl]t-boxofenda-2; 4.4 N-(cis-3-cyanoc¡clobut¡l)-3-met¡l-5-[(5S o R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(tnfluorometh¡l)-4H-¡soxazol-3-¡l]thioboxam-2-carphenyl; 5.1 (RS)-4-[5-[3-cloro-2-fluoro-5-(tr¡fluoromet¡l)fenil]-5-(difluorometil)-4H-isoxazol-3-¡l]-2met¡l-N-[2-oxo-2-(2,2,2-tnfluoroet¡lam¡no)et¡l]benzam¡da; 6.1 4-metil-N-[2-oxo-2-(2,2,2-tr¡fluoroet¡lam¡no)etil]-6-[(5R o S)-5-[3-cloro-2-fluoro-5(tr¡fluorometil)fen¡l]-5-(trifluorometil)-4H-isoxazol-3-il]p¡r¡dazin-3-carboxamida; 6.2 4-metil-N-[2-oxo-2-(2,2,2-tr¡fluoroetilam¡no)etil]-6-[(5S o R)-5-[3-cloro-2-fluoro-5(trifluorometil)fen¡l]-5-(tr¡fluorometil)-4H-¡soxazol-3-il]pir¡dazin-3-carboxamida; 7.1 3-metil-N-[2-oxo-2-(2,2,2-trifluoroet¡lam¡no)etil]-5-[(5R o S)-5-[3-cloro-2-fluoro-5(trifluoromet¡l)fen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-il]piraz¡n-2-carboxamida; 7.2 3-metil-N-[2-oxo-2-(2,2,2-tr¡fluoroet¡lam¡no)et¡l]-5-[(5S o R)-5-[3-cloro-2-fluoro-5(tr¡fluoromet¡l)fen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-¡l]p¡raz¡n-2-carboxam¡da; 8.1 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-bromo-2-fluoro-5- (trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 8.2 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3-bromo-2-fluoro-5(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 8.3 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S o R)-5-[2,3-difluoro-5-(tnfluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 8.4 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R o S)-5-[2,3-difluoro-5-(trifluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-yl]benzam¡da; 8.5 2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R or S)-5-[3-bromo-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 8.6 2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S or R)-5-[3-bromo-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 9.1 2-meth¡lN-[2-oxo-2-(2,2,2-tr¡fluoroethylamino)et¡l]-4-[(5R or S)-5-[3-(difluoromethyl)-2-fluoro5-(trifluoromethyl)phen¡l]-5-(trifluoromethyl)-4H-so-3-ml; 9.2 2-methyl-N-[2-oxo-2-(2,2,2-tnfluoroet¡lamino)et¡l]-4-[(5S o R)-5-[3-(difluoromethyl)-2-fluoro5-(tr¡fluorometh¡l)phen¡l]-5-(tr¡fluorometh¡l)-4H-¡soxazol-3-¡l]benzam¡da; 9.3 2-methyl-N-(1 -methi Isu Ifoni lazetidin-3-yl)-4-[(5 R o S)-5-[3-(difluoromethyl)-2-fluoro-5- (tnfluoromet¡l)phen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-benzamida]; 9.4 2-methyl-N-(1 -methyl Isu Ifoni lazetidin-3-yl)-4-[(5S o R)-5-[3-(difluoromethyl)-2-fluoro-5- (trifluorometh¡l)phen¡l]-5-(tr¡fluoromet¡l)-4H-¡soxazol-3-menzada]; 9.5 2-met¡lN-[2-oxo-2-(2,2,2-tr¡fluoroethylam¡no)et¡l]-4-[(5R o S)-5-[3,5-bis(difluoromet¡l)-2fluoro-phenyl]-5-(tr¡fluorometh¡l)-4H-isoxazole-3-¡l]benzamide; and 9.6 2-methyl-N-[2-oxo-2-(2,2,2-tr¡fluoroeth¡no)ethyl]-4-[(5S or R)-5-[3,5-bis(difluorometh¡l)-2fluoro-phenyl]-5-(tr¡fluorometh¡l;xa]-zolH-3-so or a salt of any of the above.

13. A compound according to claim 1, characterized in that it is selected from the group consisting of: 2-methylsulfonyl-1-[6-[(5S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3yl]spiro[1H-isobenzofuran-3,3'-azetidin]-1'-1]ethanone; 2-methylsulfonyl-1-[6-[(5R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3yl]spiro[1H-isobenzofuran-3,3'-azetidin]-1'-1]ethanone; N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]naphthalene-1-carboxamide; N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-soxazol-3-yl]naphthalen-1-carboxamide; 2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-soxazol-3-l]benzamide;2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5141 (trifluoromethyl)-4H-isoxazol-3-yl]benzamide; 3-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5S)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]thiophene-2-carboxamide; 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5R)-5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5(tr¡fluoromethyl)-4H-isoxazol-3-¡l]t¡ofen-2-carboxam¡da; 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R)-5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; y 2-met¡lN-[2-oxo-2-(2,2,2-tr¡fluoroet¡lam¡no)et¡l]-4-[(5S)-5-[3-bromo-2-fluoro-5-(tr¡fluorometil)phen¡l]-5(tr¡fluoromet¡l)-4H-¡soxazol-3-¡l]benzam¡da; o una sal de cualquiera de los anteriores.; 14. A compound characterized in that it is 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S)5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-1]benzamide or a salt thereof.

15. A compound characterized in that it is 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S)5-[3-chloro-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-1]benzamide.

16. A compound characterized in that it is selected from the group consisting of: 2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R)-5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; and 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S)-5-[3-bromo-2-fluoro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-yl]benzamide; or a salt of any of the foregoing.

17. A compound characterized in that it is selected from the group consisting of: 2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5R)-5-[3,5-bis(difluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-1]benzamide; and 2-methylN-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-4-[(5S)-5-[3,5-bis(difluoromethyl)phenyl]-5-(trifluoromethyl)-4H-isoxazol-3-1]benzamide; or a salt of any of the foregoing.

18. A composition characterized in that it comprises a compound according to any one of claims 1 to 17, or a salt thereof, and at least one acceptable carrier.

19. The use of a compound according to any of claims 1 to 17, or a salt thereof, as a medicament.

20. The use of a compound according to any of claims 1 to 17, or a salt thereof, in the preparation of a medicament for treating pests.

21. The use of a compound according to any of claims 1 to 17, or a salt thereof, in the preparation of a flea treatment medicament.

22. The use of a compound according to any of claims 1 to 17, or a salt thereof, in the manufacture of a medicament for controlling ticks.